CA2065985A1 - Quinoxalines, processes for their preparation, and their use - Google Patents

Quinoxalines, processes for their preparation, and their use

Info

Publication number
CA2065985A1
CA2065985A1 CA002065985A CA2065985A CA2065985A1 CA 2065985 A1 CA2065985 A1 CA 2065985A1 CA 002065985 A CA002065985 A CA 002065985A CA 2065985 A CA2065985 A CA 2065985A CA 2065985 A1 CA2065985 A1 CA 2065985A1
Authority
CA
Canada
Prior art keywords
alkyl
alkoxy
amino
fluorine
hydroxyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002065985A
Other languages
French (fr)
Inventor
Uta-Maria Billhardt
Manfred Rosner
Gunther Riess
Irvin Winkler
Rudolf Bender
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis Deutschland GmbH
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19914142322 external-priority patent/DE4142322A1/en
Application filed by Individual filed Critical Individual
Publication of CA2065985A1 publication Critical patent/CA2065985A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D241/00Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D241/00Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40Benzopyrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D241/00Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40Benzopyrazines
    • C07D241/44Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Medicinal Preparation (AREA)

Abstract

Abstract:

Quinoxalinones, processes for their preparation, and their use Compounds of the formula I or Ia (I)

Description

.~ECHST AKrlENGESELLSCHAFT HOE 91/F 11~K Dr. WN/fe 2 ~ 8 ~
Description 5 Quinoxalines, processes for their preparation, and their use The present invention relates to quinoxalines, to processes for their preparation, and to their use.
Quinoxalines are a well-known class of compound (O. Hinsberg, J. Liebi~s Ann.
Chem. 237, 327 (1986)).
Quinoxaline derivatives have been described in the patent literature for use in various applications in medicine.
Austrian Patent 284,848 (19.12.67) mentions 1-N-dialkylaminoalkyl-3,4-dihydroquinoxalin-2(1H)-ones as spasmolytic agents. A series of patent applications by the Japanese company Sumitomo Chem. Co. Ltd. describe 4-N-aroyl-, arylacyl- and arylsulfonyl-3,4-dihydroquinoxalin-2(1H)-ones which have an antiinflammatory action (JA 17,137t69 (11.4.66), JA 17,136/69 (8.4.66), ~IA 7,008/422 (9.8.66), BE 706,623 (16.11.66)). 3,4-Dihydroquinoxalin-2(1H)-one-3-carboxamides ars contained in US Patent US 3,654,275 (4.4.72). They, too, have an antiinflamma~ory action. In US Applications US 4,203,987 (21.5.79) and 4,032,639 (22.3.76), pyridinyl-alkyltetrahydropyrazino[1,2-a]quinoxalinone derivatives are described by Am0rican Horne Prod. Corp. as antihypertensive and antisecretory reagents. A European Patent Application by Pfizer Inc. (EP 266,102 A (30.10.86)) includes 4-N-benzenesulfonyl-3,4-dihydroquinoxalin-2(1H)-one-1-alkylcarboxylic acids as aldose reductase inhibitors.
However, an antiviral activity has not been demonstrated to date.

Surprisingly, it has now been found that quinoxalines of the formulae I and la 2 2 ~ 8 ~

I

R 1 ~N~R 3 ( I ) and their tautomeric forms of the formula la N X

R ~ R 2 ( I a ) ~N/~

R
and physiologically acceptable salts or prodrugs thereof have an antiviral action, in particular against retroviruses, for example against the human immunodeficiency virus (H IV) .

20 In the compounds of the formula I or la according to the invention, 1) n is ~ero, one, twl three or four, the individual substituents R' independently of ons another are fluorine, chlorine, bromine, iodine, trifluoromethyl, trifluoromethoxy~ hydroxyl, C1-C8-alkyl, C5-C8-cycloalkyl, C1-C~-alkoxy, (C:1-C6-alkoxy)-(C1-C4-alkoxy3, 2~g8~

C,-C6-alkylthio, C,-C6-alkylsulfinyl, C,-C6-alkylsulfonyl, ni~ro, amino, azido, C,-C6-alkylamino, di(C,-C6-alkyl)amino, piperidino, morpholino, 1-pyrrolidinyl, 4-methylpiperazinyl, thiomorpholino, irnidazolyl, triazolyl, tetrazolyl, C,-C6-acyl, C,-C6-acyloxy, C,-C6-acylamino, cyano, carbamoyl, carbo~
(C,-C6-alkyl)oxycarbonyl, hydroxysulfonyl, sulfamoyl or a phenyl, phenoxy, phenoxycarbonyl, phenylthio, phenylsulfinyl, phenylsulfonyl, phenoxysulfonyl, phenylsulfonyloxy, anilinosulfonyl, phenylsulfonylamino, benzoyl, 2-pyridyl, 3-pyridyl or 4-pyridyl radical which is substituted by up to five radicals R6 which are independent o~ one another, where R6 can be t5 fluorine, chlorine, bromine, iodine, cyano, trifluoromethyl, trifluoromethoxy, nitro, amino, azido, C1-C6-alkyl, C3-C9-cycloalkyl, C1-C6-alkoxy, C,-C6-alkylthio, C1-C6-alkylsulfinyl, C1-C6-alkylsulfonyl, C1-C6-alkylamino, di(C,-C6-alkyl)amino, (C1-C6-alkyl)oxycarbonyl, phenyl, phenoxy, 2-, 3- or 4-pyridyl, R2 is hydrogen, C,-C6-alkoxy, hydroxyl, picolyl, cyclopropyl or isopropenyloxycarbonyl and R5 is hydrogen, hydroxyl, C1-C6-alkoxy, aryloxy, C,-C6-acyloxy, cyano, amino, 2~ C,-C6-alkylamino, di(C,-C6-alkyl~amino, arylamino, Ct-C6-acylamino, I:~,-C8-alkyl, optionally substituted by fluorine, chlorine, bromine, iodine, cyano, amino, mercapto, hydroxyl, C1-C6-acyloxy, benzoyloxy, benzyloxy, phenoxy, C,-C6-alkoxy, C,-C6-alkylamino, di(C1-(::6-alkyl~amino, C,-C6-alkylthio, C,-C:6-alkylsulfonyl, phenylsulfonyl, oxo, thioxo, carboxyl or carbamoyl;

2~9~

C2-C~-alkenyl, optionally substituted by fluorine, chlorine, bromine, iodine, cyano, amino, mercapto, hydroxyl, C,-C6-acyloxy, benzoyloxy, benzyloxy, phenoxy, C,-C6-alkoxy, C1-C6-alkylamino, di~Cl-C8-alkyl)amino, C1-C6-alkylthio, C1-C6-alkylsulfonyl, phenylsulfonyl, oxo,thioxo, carboxyl and carbamoyl;

C3-Ca-allenyl, optionally substituted by fluorine, chlorine or hydroxyl, C1-C4-alkoxy, oxo, phenyl;
C3-CB-alkynyl, optionally substituted by fluorine, chlorine, bromine, iodine, cyano, amino, mercapto, hydroxyl, Cl-C6-acyloxy, benzoyloxy, benzyloxy, phenoxy, C1-C8-alkoxy, C,-C6-alkylamino, di(C1-C6-alkyl)amino, C1-C6-alkylthio, Cl-C6-alkylsulfonyl, phenylsulfonyl, oxo,thioxo, carboxyl or carbamoyl;

C3-C8-cycloalkyl, optionally substituted by fluorine, chlorine, bromine, iodine, cyano, amino, mercapto, hydroxyl, C1-C6-acyloxy, benzoyloxy, benzyloxy, phenoxy, C1-G6-alkoxy, C1-C6-alkylamino, di(C1-C6-alkyl)amino, C,-C6-alkylthio, C,-C6-alkylsulfonyl, phenylsulfonyl, oxo,thioxo, carboxyl or carbarnoyl;

C3-CB-cycloalkenyl, 2~ optionally ~ubstituted by fluorine, chlorine, bromine, iodine, cyano, amino, mercapto, hydroxyl, C1-C6-acyloxy, benzoyloxy, benzyloxy, phenoxy, Cl-C6-alkoxy, C,-C6-alkylamino, di~Cl-C6-alkyl)amino, Cl-C6-alkylthio, C,-S:~6-alkylsulfonyl, phenylsulfonyl, oxo, thioxo, carboxyl or carbamoyl;

2 ~ 8 ~

(C3-C8-cycloalkyl~-(C,-C4-alkyl), optionally substituted by fluorine, chlorine, bromine, iodine, cyano, amino, mercapto, hydroxyl, C1-C6-acyloxy, benzoyloxy, benzyloxy, phenoxy, Cl-C6-alkoxy, C1-C6-alkylamino, di(C1-C6-alkyl)amino, C1-C6-alkylthio, Cl-C6-alkylsulfonyl, phenylsulfonyl, oxo,thioxo, carboxyl or carbamoyl;

(C3-C8-cycloalkenyl)-(C, -C4-alkyl), optionally substituted by fluorine, chlorine, bromine, iodine, cyano, amino, rnercapto, hydroxyl, C,-C6-acyloxy, benzoyloxy, benzyloxy, phenoxy, C1-C6-alkoxy, C,-C6-alkylamino, di(C1-C6-alkyl)amino, C,-C6-alkylthio, C,-C6 alkylsulfonyl, phenylsulfonyl, oxo,thioxo, carboxyl or carbamoyl;

1 5 C,-C6-alkylcarbonyl, optionally substituted by fluorine, chlorine, bromine, iodine, cyano, amino, mercapto, hydroxyl, C1-C6-acyloxy, benzoyloxy, benzyloxy, phenoxy, C,-C6-alkoxy, C,-C6-alkylamino, di(C1-C6-alkyl)amino, C,-C6-alkylthio, C,-C6-alkylsulfonyl, phenylsulfonyl, oxo,thioxo, carboxyl or carbamoyl;

C2-C8-alkenylcarbonyl, optionally substituted by fluorine, chlorine or hydroxyl,C1-C4-alkoxy, oxo, phenyl;

2~ (C3-C6-cycloalkyl)carbonyl, optionally substituted by fluorine, chlorine or hya'roxyl, C,-C4-alkoxy, oxo, phenyl;

(C5-C~-cycloalkenyl)carbonyl, optionally substituted by fluorine, chlorine or hydroxyl, C,-C4-alkoxy, oxo, phenyl;

- :

2~6~

(C3-C~-cycloalkyl)-(C1-C~-alkyl)carbonyl, optionally substituted by fluorine, chlorine or hydroxyl, C1-C4-aikoxy, oxo, phenyl;

(C5-C6-cycloalkenyl)-(Cl-c3-alkyl)carbonyl~ optionally substituted by fluorine, chlorine or hydroxyl, C1-C4-alkoxy, oxo, phenyl;

C,-C8-alkyloxycarbonyl, optionally substituted by fluorine, chlorine, bromine, hydroxyl, C1-C4-alkoxy, Cl-C4-alkylarnino, di(Cl-C4-alkyl)amino, C1-C4-alkylthio;

C2-C8-alkenyloxycarbonyl, optionally substituted by fluorine, chlorine, hydroxyl, C1-C4-alkoxy, oxo, ph~nyl;

C2-C5-alkynyloxycarbonyl, optionally substituted by fluorine, chlorine, hydroxyl, C1-C4-alkoxy, oxo, phenyl;
C1-CB-alkylthiocarbonyl, optionally substituted by fluorine, chlorine, hydroxyl,Cl-C4-alkoxy, oxo, phenyl;

C2-C~-alkenylthiocarbonyl, optionally substituted by fluorine, chlorine, hydroxyl, C1-C4-alkoxy, oxo, phenyl;

C1-CB-alkylamino- and di(C1-C5-alkyl)aminocarbonyl, in each case optionally substituted by fluorine, chlorine, hydro)~yl, Cl-C4-alkoxy, oxo, phenyl;

pyrrolidin-1-yl, morpholino-, piperidino-, piperæinyl-, w 4-methylpiperazin-1-ylcarbonyl, in each case optionally substituted by ~1-C4-alkyl, C2-C6-alkenyl,C1-C4-acyl, oxo, thioxo, carboxyi, or phenyl;

C2-C5-alkenylamino- and di(C,-C6-alkenyl)aminocarbonyl, in each case optionally substituted by fluorine, chlorine, hydroxyl, C1-C4-alkoxy, oxo, phenyl;

2 ~ 8 5 C1-C6-alkylsulfonyl, optionally substituted by fluorine, chlorine, hydroxyl, C:1-C4-alkoxy, oxo, phenyl;

C1-C6-alkenylsulfonyl, optionally substituted by fluorine, chlorine, hydroxyl, C1-C4-alkoxy, oxo, phenyl;

or aryl, arylcarbonyl, aryl(thiocarbonyl), (arylthio)carbonyl, (arylthio~thiocarbonyl, aryloxycarbonyl, arylaminocarbonyl, ~arylamino)thiocarbonyl, arylalkylaminocarbonyl, arylsulfonyl, arylalkyl, arylalk~nyl, arylalkynyl, arylalkyl-carbonyl, arylalkenylcarbonyl, arylalkoxycarbonyl or aryl(alkylthio)carbonyl, each of which is substituted by up to five radicals R5 which are independent of one another, it being possible for the alkyl radical to contain in each case 1 to 5 carbon atoms, and R6 being as defined above, or heteroaryl, heteroarylalkyl, heteroarylalkenyl, heteroarylalkylcarbonyl or heteroarylalkenylcarbonyl, heteroaryloxycarbonyl, (heteroarylthio)carbonyl, heteroarylaminocarbonyl, heteroarylalkyloxycarbonyl, heteroaryl(alkylthio)carbonyl or heteroarylalkylaminocarbonyl, each of which is substituted by up to three radicals R6 which are independent of one another, it being possible for the alkyl raclical to contain in each case 1 to 3 carbon atoms, R3 and R4 are identical or different and, independently of one another, are hydrogen, C1-C8-alkyl which is optionally substituted by fluorine, chlorine, hydroxyl, amino, mercapto, Cl-C:4-acyloxy, b~nzoyloxy, benzyloxy, phenoxy, G1-C4-alkoxy, C1-C4-alkylamino, di(C1-C4-alkyl~amino, C1-C4-alkylthio, C1-C4-alkylsulFonyl, Cl-C4-alkylsulfinyl, carboxyl or carbamoyl;

C2-C8-alkenyl, optionally substituted by fluorine or chlorine, hydroxyl, amino, mercapto, C,-C4-acyloxy, benzoyloxy, benzyloxy, phenoxy, Gl-C"-alkoxy, C1-C4-.

2 ~ 9 3 ~

alkylamino, di(C1-C4-alkyl)amino, C1-C4 alkylthio, C,-C4-alkylsulfonyl, C;1-C4-alkylsulfinyl, carboxyi or carbamoyl;

C3-CE,-cycloalkyl, optionally substituted by fluorine, chlorine, hydroxyl, amino, mercapto, C,-C4-acyloxy, benzoyloxy, benzyloxy, phenoxy, C,-C"-alkoxy, C,-C4-alkylamino, di(C1-C4-alkyl)amino, C,-C,-alkylthio, C1-C4-alkyisulfonyl, C,-C4-alkylsulfinyl, carboxyl or carbamoyl;

C3-C8-cycloalkenyl, optionally substituted by fluorine or chlorine, hydroxyl, amino, mercapto, C,-C4-acyloxy, benzoyloxy, benzyloxy, phenoxy, C1-~4-alkoxy, C1-C4-alkylamino, di(C,-C4-alkyl)amino, C,-C4-alkylthio, C,-C4-alkylsulfonyl, C1-C4-alkylsulfinyl, carboxyl or carbamoyl;

aryl, arylalkyl, heteroaryl or heteroarylalkyl, each of which is substituted by up to five radicals R6 which are independent of one another, it being possible for thealkyl radical to contain 1 to 3 carbon atoms in each case, and R6 being as defined above, R3 and R4 can furthermore also be part of a saturated or unsaturated carbo- or heterocyclic ring which has 3 to 8 carbon atoms and which can optionally be substituted by fluorine, chlorine, hydroxyl, amino, C,-C6-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, C1-C6-acyloxy, benzoyloxy, C1-C6-alkoxy, oxo, thioxo, carboxyl, carbamoyl or phenyl, ?5 X is oxygen, sulfur~ selenium or substituted nitrogen N-R2, it being possible for R2 to have the abovementioned meanings, with the exception of those compounds in which R3 and R4 are both hydrogen, and compounds in wnich R2 and R5 are hydrogen and R3 and/or R4 are/is arylalkyl, andcompounds in which X is oxygen and R2 and Rs are hydrogen.

2 ~

In a preferred group of compounds of the formula I or la, 2) n is zero, one, two or three, the individual substituents R1 independently of one another are fluorine, chlorine, bromine, trifluoromethyl, trifluoromethoxy, hydroxyl, Cl-C4-alkyl, C5-C6-cycloalkyl, C1-C4-alkoxy, (C1-C4-alkoxy)-(C1-C4-ali~o~ C~ 4-alkylthio, C1-C4-alkylsulfinyl, C1-C4-alkylsulfonyl, nitro, amino, C1-C4-alkylamino, di(C1-C4-alkyl)amino, piperidino, morpholino, 1-pyrrolidinyl, 4-methylpip~razinyl, thiomorpholino, imidazolyl, C1-C4-acyl, C,-C4-acyloxy, C1-C4-acylamino, cyano, carbamoyl, carboxyl, (C1-C4-alkyl)oxycarbonyl, hydroxysulfonyl or sulfamoyl or a phenyl, phenoxy, phenoxycarbonyl, phenylthio, phenylsulfinyl, phenylsulfonyl, phenoxysulfonyl, phenylsulfonyloxy, anilinosulfonyl, phenylsulfonylamino, benzoyl, 2-pyridyl, 3-pyridyl or 4-pyridyl radical which is substituted by up to two radicals R6 which are independent of one another, where R6 can be fluorine, chlorine, bromine, cyano, trifluoromethyl, nltro, amino, C1-C4-alkyl, C3-C7-cycloalkyi, Cl-C4-alkoxy, C,-C4-alkylthio, Cl-C4-alkylsulfinyl, C,-C4-alkylsulfonyl, C,-C4-alkylamino, di(C,-C4-alkyl)amino, ~C:l-C4-alkyl)oxycarbonyl, phenyl or phenoxy, 2~9~ ~

R2 is hydrogen and R5 is hydrogen, hydroxyl, cyano, amino, C,-C6-alkyl, optionally substituted by fluorine, chlorine, bromine, iodine, cyano, amino, rnercapto, hydroxyl, C:l-C4 acyloxy, benzoyloxy, benzyloxy, phenoxy, C1-C~-alkoxy, C,-C4-alkylamino, di(C,-C4-alkyl)amino, C,-C4-alkylthio, oxo, thioxo, oarboxyl or carbamoyl;

C2-C8-alkenyl, optionally substituted by fluorine, chlorine, bromine, iodine, cyano, amino, mercapto, hydroxyl, C,-C4-acyloxy, benzoyloxy, benzyloxy, phenoxy, C,-C4-alkoxy, C1-C4-alkylamino, di(C1-C4-alkyl)amino, C,-C4-alkylthio, oxo, thioxo, carboxyl or carbamoyl;
t5 C3-Ca-allenyl, C3-C8-alkynyl, optionally substituted by fluorine, chlorine, bromine, iodine, cyano, amino, mercapto, hydroxyl, C1-C4-acyloxy, benzoyloxy, benzyloxy, phenoxy, C,-C4-alkoxy, C,-C4-alkylamino, di(C,-C4-alkyl)amino, C1-C4-alkylthio, oxo, thioxo, carboxyl or carbamoyl;

C3-CB-cycloalkyl, optiorlally subs~ituted by fluorine, chlorine, bromine, iodine, cyano, amino, mercapto, hydroxyl, C,-C4-acyloxy, benzoyloxy, benzyloxy, phenoxy, C1-C4-alkoxy, C,-C4-alkylamino, di(C,-C4-alkyl)amino, C1-C4-alkylthio, oxo, thioxo, carboxyl or carbamoyl;

C3-C8-cycloalkenyl, optionally substituted by fluorine, chlorine, bromine, iodine, ~yano, amino, mercapto, hydroxyl, C1-C4-acyloxy, benzoyloxy, benzyloxy, phenoxy, C1-C4-alkoxy, C1-C4-alkylamino, di(C1-C4-alkyl)amino, C1-C4-alkylthio, oxo, thioxo, carboxyl or carbamoyl;

(C3-C~-cycloalkyl)-(C1-C2-alkyl) optionaliy substituted by fluorine, chlorine, bromine, iodine, cyano, amino, mercapto, hydroxyl, C1-C4-acyloxy, benzoyloxy, benzyloxy, phenoxy, C1~C4-alkoxy, Cl-C4-alkylamino, di(C1-C4-alkyl)amino, C1-C4-alkylthio, oxo, thioxo, carboxyl or carbamoyl;

(C3-C~-cycloalkenyl)-(C,-C2-alkyl), optionally substituted by fiuorine, chlor;ne, bromine, iodine, cyano, amino, mercapto, hydroxyl, C1-C4-acyloxy, benzoyloxy, benzyloxy, phenoxy, C,-C4-alkoxy, C~-C4-alkylamino, di(C,-C4-alkyl)amino, C1-C4-alkylthio, oxo, thioxo, carboxyl or carbamoyl;

C1-C6-alkylcarbonyl, optionally substituted by fluorine, chlorine, bromine, iodine, cyano, amino, mercapto, hydroxyl, C1-C4-acyloxy, benzoyloxy, benzyloxy, phenoxy, C1-C~,-alkoxy, C1-C4-alkylamino, di(C1-C4-alkyl)amino, C1-C4-alkylthio, oxo, thioxo, carboxyl or carbamoyl;

C2-C6^alkenylcarbonyl, optionally substituted by fluorine, chlorine or hydroxyl,C,-C4-alkoxy, oxo, phenyl;
~C3-C6-cycloalkyl)carbonyl, optionally substituted by fluorine, chlorine or hydroxyl, C1-C4-alkoxy, oxo, phenyl;

(C5-C6-cycloalkenyl)carbonyl, optionally substituted by fluorine, chlorine or hydroxyl, C1-C4-alkoxy, oxo, phenyl;

g ~ 5 ~C3-C6-cycloalkyl)-(C,-C2-alkyl)carbonyl, optionally substituted by fiuorine, chlorine or hydroxyl, Cl-C4-alkoxy, oxo, phenyl;

(C5-C6-cycloalkenyl)-(C,-C2-alkyl)carbonyl, optionally substituted by fluorine, chlorine or hydroxyl, C1-C4-alkoxy, oxo, phenyl;

C1-C6-alkyloxycarbonyl, optionally substituted by fluorine, chlorin~, bromine, hydroxyl, C1 C4-alkoxy, C1-C~,-alkylamino, di(Cl-C4-alkyl)amino, C,-C4-alkylthio;

C2-C6-alkenyloxycarbonyl, optionally substituted by fluorine, chlorine, hydroxyl, C1-C4-alkoxy, oxo, phenyl;

C2-C6-alkynyloxycarbonyl, optionally substituted by fluorine, chlorine, hydroxyl, C1-C4-alkoxy, oxo, phenyl;
~5 C1-C6-alkylthiocarbonyl, optionally substituted by fluorine, chlorine, hydroxyl,C1-C4-alkoxy, oxo, phenyl;

C2-C6-alkenylthiocarbonyl, optionally substituted by fluorine, chlorine, hydroxyl, C1-C4-alkoxy, oxo, phenyl;

C1-C6-alkylamino- and di(C1-C6-alkyl)aminocarbonyl, in each case optionally substituted by fluorine, chlorine, hydroxyl, C1-C4-alkoxy, oxo, phenyl;

pyrrolidin-1-yl, morpholino-, piperidino-, piperazinyl-, or 4-methylpiperazin-1-ylcarbonyl;

C2-C6-alkenylamino- and di(C1-C5-alkenyl)aminocarbonyl, in each case optionally substituted by fluorine, chlorine, hydroxyl, C1-C4-alkoxy, oxo, phenyl;

~ ~ 6 ~

C1-C4-alkylsulfonyl, optionally substituted by fluorine, chlorine, hydroxyl, C,-C4-alkoxy, oxo, phenyl;

C1-C4-alkenylsulfonyl, optionally substituted by fluorine, chlorine, hydroxyl, C,-C4-alkoxy, oxo, phenyl;

or aryl, arylcarbonyl, aryl(thiocarbonyl), (arylthio)carbonyl, (arylthio)thiocarbonyl, aryloxycarbonyl, arylaminocarbonyl, (arylamino)thiocarbonyl, arylalkylaminocarbonyl, arylsulfonyl, arylalkyl, arylalkenyl, arylalkynyl, arylalkyl-carbonyl, arylalkenylcarbonyl, aryl(alkyl~hio)carbonyl or arylalkoxycarbonyl, each of which îs substituted by up to three radicals R6 which are independsnt of one another, it being possible for the alkyl radical to contain in each case 1 to 5 carbon atoms and R6 being as defined above, or 1- or 2-naphthylmethyl, 2-, 3- or 4-picolyl, 2- or 3-furylmethyl, 2- or 3-thienylmethyl, 2- or 3-pyrrolylmethyl, 2-, 3- or 4-pyridylcarbonyl, 2- or 3-furylcarbonyl, 2- or 3-thienylcarbonyl, 2- or 3-thienylacetyl, 2-, 3- or 4-picolyloxycarbonyl, 2- or 3-furylmethyloxycarbonyl, 2- or 3-thienylrnethyl-oxycarbonyl, each of which is substituted by up to two radicals R6 which are independent of one another, and R3 and R4 are identical or different and independently of 2~ one another are hydrogen, C1-C6-alkyl, optionally substituted by fluorine, chlorine, hydroxyl, amino, mercapto, C1-C4-acyloxy, benzoyloxy, ben7yloxy, phenoxy, C1-C4-aikoxy, C,-C4-~lkylamino, 2 ~

di(C1-C4-alkyl)amino, C,-54-alkylthio, C1-C4-alkylsulfonyl, C,-C4-alkylsulfinyl,carboxyl or carbamoyl;

C2-Ca-alkenyl, optionally substituted by fluorine or chlorine, hydroxyl, amino, mercapto, C,-C4-acyloxy, benzoyloxy, benzyloxy, phenoxy, C1-C4-alkoxy, C,-C4-alkylamino, di(C1-C4-alkyl~amino, Cl-C4-alkylthio, C,-C4-alkylsulfonyl, C,-C4-alkylsulfinyl, carboxyl or carbamoyl;
C3-Ca-cycloalkyl, optionally substituted by fluorine, ch!orine, hydroxyl, arnino, mercapto, Cl-C4-acyloxy, benzoyloxy, benzyloxy, phenoxy, C,-C4-alkoxy, C1-C4-alkylamino, di(C,-C4-alkyl)amino, C,-C4-alkylthio, C,-C4-alkylsulfonyl, C l-C4-alkylsulfinyl, carboxyl or carbamoyl;

C3-Ca-cycloalkenyl, optionally substituted by fluorine or chlorine, hydroxyl, amino, mercapto, Cl-C4-acyloxy, benzoyloxy, benzyloxy, phenoxy, C1-C4-alkoxy, C1-C4-alkylamino, di(C1-C4-alkyl)amino, C,-C4-alkylthio, C,-C4-alkylsulfonyl, C,-C4-alkylsulfinyl, carboxyl or carbamoyl;
aryl, arylalkyl, heteroaryl or heteroarylalkyl, each of which is substituted by up to three radicals R~ which are independent o~ one another, it being possible for the alkyl radical to contain in each case 1 to 3 carbon atoms and R6 being as defined above, R3 and R4 can furthermore also be par~ of a saturated or unsaturated carbo- or heterocyclic ring which has 3 tQ 7 carbon atoms and which can optionally be substitut~d by fluorine, chlorine, hydroxyl, amino, C1-C4-alkyl, C2-C4-alkenyl, C2-C4-alkynyl, C1-C4-acyloxy, benzoyloxy, C1-C4-alkoxy, oxo, thioxo, carboxyl, carbamoyl or phenyl, and X is oxygen, sulfur or selenium.

2~6~85 In a yet more preferred group of compounds of the formula I or la, 3) n is zero, one or two, the individual substituents R' independently of one another are fluorine, chlorine, bromine, trifluoromethyl, hydroxyl, C1-C4-alkyl, C,-C4-alkoxy, (C1-C4-alkoxy)-(C1-C4-alkoxy), C1-C4-alkylthio, nitro, amino, C1-C4-alkylamino, di(C,-C4-alkyl)amino, piperidino, morpholino, 1-pyrrolidinyl, 4-methylpiperazinyl, Cl-C4-acyl, C1-C4-acyloxy, Cl-C4-acylamino, cyano, carbamoyl, carboxyl, (C1-C4-alkyl)oxycarbonyl, hydroxysulfonyl or sulfamoyl, or a phenyl, phenoxy, phenylthio, phenylsulfonyl, phenoxysulfonyl, benzoyl, 2-pyridyl, 3-pyridyl or 4-pyridyl radical which is substituted by up to two radicals R6 which are independent of one another, where R6 can be fluorine, chlorine, bromine, cyano, trifluoromethyl, nitro, amino, C1-C4-alkyl, C1-C4-alkoxy, (C1-C4-alkyl)oxycarbonyl, phenyl or phenoxy, R2 is hydrogen and R5 is C1-C6-alkyl, optionally substituted by fluorine, chlorlne, hydroxyl, C1-C4-acyloxy, benzoyloxy, benzylo~y, phenoxy, :

2 ~

C1-C4-alkoxy, C1-C4-alkylamino, di(C,-C4-alkyl)amino, Cl-C4-alkylthio, oxo, thioxo, carboxyl or carbamoyl;

C2-C6-alkenyl, optionally substituted by fluorine, chlorine, hydroxyl, Cl-C4-acyloxy, benzoyloxy, benzyloxy, phenoxy, C,-C4-alkoxy, C1-C4-alkylamino, di(C1-C4-alkyl)amino, C,-C4-aikylthio, oxo, thioxo, carboxyl or carbamoyl;

C3-t:~B-allenyl, C3-C8-alkynyl, optionally substituted by fluorine, chlorine, hydroxyl, C,-C4-acyloxy, benzoyloxy, benzyloxy, phenoxy, C,-C4-alkoxy, C,-C4-alkylamino, di(C,-C4-alkyl)amino, C,-C4-alkylthio, oxo, thioxo, carboxyl or carbamoyl;

C3-Ca-cycloalkyl, optionally substituted by fluorine, chlorine, hydroxyl, C,-C4-alkyl, C,-C4-acyloxy, benzoyloxy, benzyloxy,phenoxy, C,-C4-alkoxy, C,-C4-alkylamino, di(C,-C4-alkyl)amino, C,-C4-alkylthio, oxo, thioxo, carboxyl or carbamoyl;

C3-C8-cycloalkenyl, optionally substituted by fluorine, chlorine, hydroxyl, C,-C4-alkyl, C;,-C4-acyloxy, ben7oyloxy, benzyloxy, phenoxy, C,-C4-alkoxy, C,-C4-alkylamino, di(C,-C4-alkyl)amino, C,-C4-alkylthio, oxo, thioxo, carboxyl or carbamoyl;

2~98~

(C3-Cs-cycloalkyl)-(C1-C2-alkyl~, optionally substituted by fluorine, chlorine, hydroxyl, C1-C4-alkyl, C1-C4-acyloxy, benzoyloxy, benzyloxy,phenoxy, C1-C4-alkoxy, C1-C"-alkylamino, di~C1-C4-alkyl)amino, C1-C4-alkylthio, oxo, thioxo, carboxyl or carbamoyl;

(C3-C6-cycloalkenyl)-(C,-C2-alkyl), optionally substituted by fluorine, chlorine, hydroxyl, C1-C4-alkyl, C1-C4-acyloxy, benzoyloxy, benzyloxy,phenoxy, C1-C4-alkoxy, C1-C~-alkylamino, di(C1-C4-alkyl)amino, C1-C4-alkyithio, oxo, thioxo, carboxyl or carbamoyl;

C1 -C6-alkylcarbonyl, optionally substituted by fluorine, chlorine, hydroxyl, C1-C4-alkyl, C1-C4-acyloxy, benzoyloxy, benzyloxy,pheroxy, C1-C4-alkoxy, C1-C4-alkylamino, C,-C4-alkenylamino, di(C1-C4-alkyl)amino, 1-pyrrolidinyl, piperidino, morpholino, 4-methylpiperazin-1-yl, Cl-C4-alkylthio, oxo, thioxo, carboxyl or carbamoyl;

C2-C6-alkenylcarbonyl, optionally substituted by fluorine, chlorine or hydroxyl;
(C3-C6-cycloalkyl)carbonyl, (C5-C6-cycloalkenyl)carbonyl, (C3-C6-cycloalkyl)-(C1-C2-alkyl)carbonyl, (Cs-C6-cycloalkenyl)-(C,-C2-alkyl)carbonyl, C1-C6-alkyloxycarbonyl, optionally substituted by flvorine, ehiorine, bromine, hydroxyl, C1-C4-alkoxy, C1-C4-alkylamino, di(C1-C4-alkyl~amino or C1-C4-alkylthio;

2~6~9~

C2-C6-alkenyloxycarbonyl, optionally substituted by flusrine, chlorine, hydroxyl, C,-C4-alkoxy;

C2-C6-alkynyloxycarbonyl, optionally substituted by fluorine, chlorine, hydroxyl, Cl-C4-alkoxy;

Cl-C6-alkylthiocarbonyl, optionally substituted by fluorine, chlorine, hydroxyl, Cl-C4-alkoxy;

C2-C6-alkenylthiocarbnnyl, optionally substituted by fluorine, chlorine, hydroxyl, C1-C4-alkoxy;

C1-C6-alkylamino- and di(C1-C6-alkyl)aminocarbonyl, in each case optionally substituted by fluorine, chlorine, hydroxyl, Cl-G4-alkoxy;
pyrrolidin-1-yl, morpholino-, piperidino-, piperazinyl-, or 4-methylpiperazin-1 -ylcarbonyl;

C2-C6-alkenylamino- and di(C1-C~-alkenyl)aminocarbonyl, in each case optionally substituted by fluorine, chlorine, hydroxyl, Cl-C4-alkoxy;

Cl-C4-alkylsulfonyl, optionally substituted by fluorine, chlorine, hydroxyl, C1-C4-alkoxy;

C1-C4-alkenylsulfonyl;

or aryl, arylcarbonyl, (arSlthio)carbonyl, aryloxycarbonyl, arylaminocarbonyl, (arylamino~thiocarbonyl, arylsulfonyl, arylalkylaminocarbonyl, arylalkyl, arylalkenyl, arylalkylcarbonyl, arylalkoxycarbonyl or aryl(alkylthio)carbonyl, each of which is substituted by up to two radicals R6 which are independent of one 2 ~

another, it being possible for the alkyl radical to contain in each oase 1 to 3 carbon atoms, and R6 being as defined above, or 1- or 2-naphthylmethyl, 2-, 3- or 4-picolyl, 2- or 3-furylmethyl, 2- or 3-thienylmethyl, 2- or 3-pyrrolylmethyl, 2-, 3- or 4-pyridylcarbonyl, 2- or 3-furylcarbonyl, 2- or 3-thienylcarbonyl, 2- or 3-thienylacetyl, 2-, 3- or 4-picolyloxycarbonyl, 2- or 3-furylmethyloxycarbonyl or 2- or 3-thienylmethyloxycarbonyl, sach of which is substituted by up to two radicals R6 which are independent of one another, and R3 and R4 are identical or different and independently of one another are hydrogen, C1-C4-alkyl, optionally substitu~ed by fluorine, chlorine, hydroxyl, amino, mercapto, C1-C4-acyloxy, benzoyloxy, phenoxy, Cl-C4-alkoxy, Cl-C4-alkylamino, di(Cl-C4-alkyl)amino, Cl-C4-alkylthio, Cl-C4-alkylsulfonyl, C1-C4-alkylsulfinyl, carboxyl or carbamoyl;

C2-C6-alkenyl, optionally substituted by fluorine or chlorine;
C3-C6-cycloalkyl, optionally substituted by fluorine, chlorine, hydroxyi, amino,mercapto, Cl-C4-acyloxy, benzoylo~y, benzyloxy, phenoxy, C1-C4-alkoxy, Cl-C4-alkylamino, di~C,-C4-alkyl)amino, C1-C4-alkylthio, C1-C4-alkylsulfonyl, C~-C4-alkylsulfinyl, carboxyl or carbamoyl;
~5 C3-Ca-cycloalkenyl, optionally substituted by fluorine or chlorine;

- aryl, benzyl, heteroaryl or heteroarylmethyl, each of which is su~stituted by up to two radicals R~ which are independent of one another, 2 ~ 5 2û
R3 and R4 can furthermore also be part of a saturated or unsaturated carbo- or heterocyclic ring which has 3 to 6 carbon atoms and which can optionally be substituted by fluorine, chlorine, hydroxyl, amino, C1-C4-acytoxy, benzoyloxy, C,-C"-alkoxy, oxo, thioxo, carboxyl or carbamoyl, and X is oxygen or sulfur.

In a yet again preferred group of compounds of the formula I or la, 4) n is zero, one or two, the individual substituents R' independently of one another are fluorine, chlorine, bromine, trifluoromethyl, hydroxyl, C1-C4-alkyt, C1-C4-alkoxy, (C1-C4-alkoxy)-(C1-C2-alkoxy), C1-C4-alkylthio, nitro, amino, C1-C4-alkylamino, di(C,-C4-alkyl)amino, piperidino, morpholino, 1-pyrrolidinyl, 4-methylpiperazinyl, C1-C4-acyl, C1-C4-acyloxy, C,-C4-acylamino, cyano, carbamoyl, carboxyl, (C1-C4-alkyl)oxycarbonyl, hydroxysulfonyl or sulfamoyl or a phenyl, phenoxy, phenylthio, phenylsulfonyl, phenoxysulfonyl, benzoyl, 2-pyridyl, 3-pyridyl or 4-pyridyl radical, each of whk:h is substituted by up to two radicals R6 which are independent of one anoth0r, where R6 can be ~ ~ .

2 ~

fluorine, chlorine, bromine, cyano, trifluoromethyl, nitro, amino, C1-C"-alkyl, C1-C4-alkoxy, (C1-C4-alkyl)o~carbonyl, pheny~ or phenoxy, R2 is hydrogen and R5 is C1-C6-alkyl, optionally substituted by C1-C"-alkoxy or C1-C"-alkylthio;

C2-C6-alkenyl, optionally substituted by oxo;

C3-C6-allenyl;

C3-CB-alkynyl, in particular 2-butynyl;

C3-C6-cycloalkyl;

Cs-C6-cycloalkenyl;

(C3-C6-cycloalkyl)-(C1-C2-alkyl), in particular cyclopropyimethyl, optionally substituted by C1-C4-alkyl;

(C3-C6-cycloalkenyl)-(C,-C2-alkyl), in particular cyclohexenylmethyl;

C1-C6-alkylcarbonyl, optionally substituted by fluorine, chlorine, hydroxyl, benzyloxy, phenoxy, C,-C4-alkoxy, C1-e;4-alkylamino, C1-C4-alkenylamino, di(C1-C4-alkyl)amino, 1-pyrrolidinyl, piperidino, morpholino, 4-methylpiperazin-1-yl or C1-C4-alkylthio;

22 2 ~ 8 C2-C6-alkenylcarbonyl;

Cl-C6-alkyloxycarbonyl, optionally substituted by fluorine, chlorine, bromine, hydroxyl, C1-C4-alkoxy, Ct-C4-alkylamino, di(C1-C4-alkyl)amino or C1-C4-alkylthio;
C2-C6-aikenyloxycarbonyl, in particular vinyloxycarbonyl, allyloxycarbonyl, isoprnpenyloxycarbonyl, butenyloxycarbonyl or pentenyloxycarbonyl;

C2-C6-alkynyloxycarbonyl, in particular propynyloxycarbonyl or butynyloxycarbonyl;

C1 -C6-alkylthiocarbonyl;

C2-C6-alkenylthiocarbonyl, in particular allylthiocarbonyl;
C,-C6-alkylamino- and di(C1-C6-alkyl)aminocarbonyl;

pyrrolidin-1-yl, morpholino-, piperidino-, piperazinyl-, or 4-methylpiperazin-1-ylcarbonyl;
C2-C6-alkenylamino- and di(C,-C6-alkenyl)aminocarbonyl;

C1 -C4-alkylsulfonyl;

~5 C,-C4-alkenylsulfonyl;

or aryl which is substituted by up to two radicals R6 which are inciependent of one another, in particular phenyl, aryicarbonyl, in parSicular benzoyl, (arylthio)carbonyl, aryloxycarbonyl, arylaminocarbonyl, (arylamino~thiocarbonyl,arylalkylaminocarbonyl, arylsulfonyl, arylalkyi, in particular benzyl, phenylethyl, ~$~

arylalkenyl, arylalkylcarbonyl, arylalkoxycarbonyl or aryl(alkylthio)carbonyl, it being possible for the alkyl radical to contain in each case 1 to 3 carbon atomsand R6 being as defined above, or 1- or 2-naphthylmethyl, 2-, 3- or 4-picolyl, ~- or 3-furylmethyl, 2- or 3-thienylmethyl, 2- or 3-pyrrolylmethyl, 2-, 3- or 4-pyridylcarbonyl, 2- or 3-furylcarbonyl, 2- or 3-thienylcarbonyl, 2- or 3-thienylacetyl, 2-, 3- or 4-picolyloxycarbonyl, 2- or 3-furylmethyloxycarbonyl, or 2- or 3-thienyl-methyloxycarbonyl, each of which is substituted by up to two radicals R6 which are independent of one another, and R3 and R4 are identical or different and independently of one another are hydrogen, Cl-C4-alkyl, optionally substituted by hydroxyl, mercapto, C1-C4-alkoxy, C1-C4-alkylthio, C,-C4-alkylsulfonyl, C,-C4-alkylsulfinyl, carboxyl or carbarnoyl;

C2-C6-alkenyl, aryl, benzyl, thienyl or thienylmethyl, each of which is substituted by up to two radicals R6 which are independent of one another, R6 beinç3 as defined above, R3 and R4 can also be part o~ a saturated or unsaturated carbo- or heterocyclic ring which has 3 to 6 carbon atoms and can optionally be substituted by oxo or thioxo, an~

2 ~ 8 ~

X is oxygen or suifur.

Compounds of the formula I or la as defined above wherein the substituents mentioned have the following meanings are very particularly important:

n is zero or one, the individual substituents R' independently of one another are fluorine, chlorine, bromine, C1-C2-alkyl, C,-C2-alkoxy, C2-C4-acyl or cyano, R2 is hydrogen and Rs is 1 5 C2-C6-alkenyl, C3-C8-alkynyl, in particular 2-butynyl;

(C3-C6-cycloalkyl)-(C1-C2-alkyl), in particular cyclopropylmethyl, optionally substituted by C1-C4-alkyl;

(C3-C6-cycloalkenyl)-(C1-C2-alkyl), in particular cyclohexenylmethyl;

C2-C6-alkylcarbonyl, C2-C6-alkenylcarbonyi;

C1 -C6-alkyloxycarbonyl;

2 ~ 5 C2-C6-alkenyloxycarbonyl, in particular vinyloxycarbonyl, allyloxycarbonyl, isopropenyloxycarbonyl, butenyloxycarbonyl or pentenyloxycarbonyl;

C~-C6-alkynyloxycarbonyl, in particular propynyloxycarbonyl or butynyloxycarbonyl;

C2-C6-alkenylthiocarbonyl, in particular allylthiocarbonyl;

Cl-C4-alkylsulfonyl;
C1 -C4-alkenylsuHonyl;

or arylalkyl, in particu!ar benzyl or arylalkenyl, which is substituted by up to two radicals R6 which are independent of one another, it being possible for the alkyl radical to contain in each case 1 to 3 carbon atoms and for the alkenyl radical to contain 2-3 carbon atoms, or 1-naphthylmethyl, 2- or 3-picolyl, 2-furylme~hyl or 2- or 3-thienylmethyl, each of which is substituted by up to two radicals R6 which are independent of one another, where R6 is fluorine, chlorine, bromine, cyano, C1-C2-alkyl or C1-C2-alkoxy, ~5 and R3 and R4 are identical or different and independently of one another are 2 ~

hydrogen, C1-C4-alkyl, optionally substituted by hydroxyl, mercapto, C,-C4-alkoxy. C1-C2-aikylthio, and 5 X is oxygen or sulfur.

The alkyl groups in the above definitions can be straight-chain or branched. Unless otherwise defined, they preferably contain 1-8, particularly preferably 1-6, in particular 1-4, carbon atoms. Examples are the methyl, ethyl, propyl, 1-methylethyl, butyl,10 1-methylpropyl, 2-methylpropyl and 1,1-dimethylethyl ~roup, and similar groups.

The alkenyl groups mentioned in the above definitions can be strai~ht-chain or branched and contain 1 to 3 double bonds. Unless otherwise defined, these groupspreferably contain 2-8, in particular 2-6, carbon atoms. Examples are the 2-propenyl, 1-methylethenyl, 2-butenyl, 3-butenyl, 2-methyl-2-propenyl, 3-methyl-2-butenyl, 2,3-dimethyl-2-butenyl, 3,3-dichloro-2-propenyl and pentadienyl groups and similar groups.

The alkynyl groups mentioned in the above definitions can be straight-chain or 20 branched and contain 1 to 3 triple bonds. Unless otherwise defined, they contain preferably 2-8, particularly preferably 3-6, carbon atoms. Examples are the 2-propynyl and 3-butynyl group and similar groups.

Unless otherwise defined, the cycloalkyl and cycloalkenyl groups mentioned in the 25 above definitions contain ,orefsrably 3-8, particularly preferably 4-6, carbon atoms.
Examples are the cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl or cyclohexenyl group.

The acyl groups mentioned in the above definitions can be aliphatic, cycloaliphatic or 30 aromatic. Unless otherwise defined, they preferably contain 1-8, particularly preferably 2 ~ 5 2-7, carbon atoms. Examples of acyl ~roups are the formyl, acetyl, chloroacetyl,trifiuoroacetyl, hydroxyacetyl, propisnyl, butyryl, isobutyryl, pivaloyl, cyclohexanoyl or benzoyl group.

5 The aryl groups mentioned in the above definitions are preferably aromatic groups having 6-14 carbon atoms, in particular 6-10 carbon atoms, for example phenyl ornaphthyl.

Suitable hetero atoms in the abovementioned heterocyclic rings Dr heteroaryi groups 10 are, in particular, oxygen, sulfur and nitrogen, where, in the case of a nitrogen-containing ring which is saturated in this position, a structure N-Z is present in which Z
is H or R5 w1th the individual above-described definitions.

Unless otherwise defined, the heterocyclic rings preferably have 1-13 carbon atoms and 1-6 hetero atoms, in particular 3-9 carbon atoms and 1-4 hetero atoms.

Suitable radicals for the heteroaryl groups mentioned in the above definitions are, for example, heteroaromatic radicals such as 2- or 3-thienyl, 2- or 3-furyl, 2-, 3- or 4-pyridyl, pyrimidyl, indolyl, quinolyl or isoquinolyl.
Examples of the aralkyl groups mentioned in the above definitions are benzyl, phenylethyl, naphthylmethyl or styryl.

The abovementioned substituents R1 to Rs are preferably trisubstituted, particularly 25 preferably disubstituted, in particular monosubstituted, by the particular substituents mentioned.

In the case of the particular definitions of composite substituents (such as, for example, arylalkoxycarbonyl~, the ranges which have been described above as being 30 preferred for the individual substituents are also preferred.

2 ~ 6 ~ 9 8 ~

Depending on the various substituents, compounds of the formulae I and la can have several asymmetric carbon atoms. The invention therefore relates both to the pure stereoisomers and to mixtures thereof such as, for example, the corresponding racemate.
The pure stereoisomers of the compounds of the formulae I and la can be prepareddirectly by known methods or analogously to known methods, or they can be resolved later.

The compounds of the formulae I and la can be prepared by known methods or 10 modifications thereof (seel for example, Rodd's Chemistry of Carbon Compounds, S.
Coffey, M. F. Anse!l (Editor); Elsevier, Amsterdam, 1989; Vol. IV Part IJ, p. 301-311.
Heterocyclic Compounds. R. C. Elderfield (Editor); Wiley, New York, 1957; Vol. 6, p.
491-495)-The present invention furthermore includes a process for the preparation of 15 compounds of the formulae I and la as explained in 1) - 4) above, which comprises A) for preparing compounds of the formula I where X is oxy~en and the radicals R1, R2, R3, R4 and R5 are as defined under 1) - 4), reacting a compound of the formula ll H
I

R n~N~R 3 ( I I ) with the definitions mentioned under 1) - 4) applying to R1, R3 and R4, with a compound of the ~ormula lll R-Z

;

2 ~

where R has the meanings for R5 and R2 which have been mentioned above under 1) -4) with the exception of hydrogen, hydroxyl, Cl-C6-alkoxy, aryloxy, C1-C8-acyloxy, amino, C,-C6-alkylamino, di(C1-C;6-alkyl)amino, arylamino and C,-C6-acylamino, and Z is a leaving group, 5 or B) preparing compounds of ~he formula I where X is sulfur and R1, R2, R3, R4 and R5 are as defined under 1) - ~) by reacting a compound of the formula I where X is oxygen and the definitions mentioned under 1) - 4) apply ~o R1, R2, R3, R4 and Rs, with a sulfurizing reagent, 10 or C) preparing compounds of the formula la where X and the radicals R1 to Rs are as defined under 1) - 4), by reacting a compound of the formula IV
H
I

R ~ ~N~R 3 ( I V

20 or R 1 n~N~ ( I V ~ ) where the definitions mentioned under 1) - 4) apply to R1, R3, R4 and R5, with acompound of the tormula lll 2~3 R2 z (111) where the definitions described under 1) - 4) for formula I and la apply to R2, with the exception of hydrogen, hydroxyl, C1-C8-alkoxy, aryloxy, C1-C6-acyloxy, amino, 5 C,-C6-alkylamino, di(C1-C6-alkyl)amino, arylamino or C1-C6-acylamino, and Z is a leaving group, or D) preparing compounds of the formula I where X is oxygsn and the radicals R' to Rs are as defined under 1) - 4) by cyclizing a compound of the formula V

I

R n ~ J~R 3 V

R

where R' to Rs are as defined under 1) - 4) and Y is hydroxyl, C1-C4-alkoxy, optionally halogenated C,-C4-acyloxy, chlorine, bromine or iodine, or 20 E) preparing compounds of the formula i where X is oxygen, R4 and R5 are hydrogen and the definitions mentioned under 1) - 4) apply to R1 to R3, from the quinoxalinones of the formula Xl 25 R ~N~R 3 X I

where R1 to R3 are as defined under 1) - 4), by addition of hydrogen on the C=N
30 bond, 2 ~

or F) preparing compounds of the formuia I where X is oxygen and Rl to R5 are as defined under 1) - 4), from compounds of the formula Vl R 1 ~N H V I

N H

where R1, R2 and R5 are as defined under 1) - 4), by reacting them with chloroform or bromoform and a carbonyl cornpound of the formula Xlll R3-Co-R4 Q(lll) where R3 and R4 are as defined under 1) - 4), or with a-(trihalomethyl)alkanols of the formula XIV

Hal3C-C(OH)-R3R4 (XIV) where Hal is Cl, Br or 1, in which R3 and R4 are as defined under 1) - 4), 25 or G) praparing compounds of the formula I where X is oxygen and R', R2, R3, R4 and R5 are as defined under 1) - 4), by reacting a compound of the formula I where X isoxygen and the definitions mentioned und0r 1) - 4) apply to Rl, R2, ~5 and to R3 and R4, with the exception that at least one of the radicals R3 or R4 is hydrogen; ~ith an 30 alkylating reagent of the formula XV

2 ~

R'-Z (XV) where R' has the meanings mentioned above for R3 and R4 with the exception of hydrogen and Z is a leaving group, or H) preparing compounds of the formula I where X is oxygen, Rl, R2, R3 and R4 are as defined under 1) - ~) and R5 is C1-C8-alkyl, optionally substituted by fluorine, chlorine, bromine, iodine, hydroxyl, C1-C6-acyloxy, benzoyloxy, pheno)~y, C1-C6-alkoxy, C1-C6-alkylamino, di(C1-C6-alkyl)amino, C1-C6-alkylthio, cyano, carboxyl, carbamoyl, C3-C8-alkenyl, optionally substitut~d by fluorine, chlorine, bromine, iodine, hydroxyl, Cl-C6-acyloxy, benzoyloxy, phenoxy, C:l-C6-alkoxy, C,-C6-alkylamino, di(C1-C6-alkyl)amino, Cl-C6-alkylthio, cyano, carboxyl or carbamoyl, C3-C8-alkynyl, optionally substituted by fluorine, chlorine, bromine, iodine, hydroxyl, C1-C6-acyloxy, benzoyloxy, phenoxy, C1-C6-alkoxy, C1-C6-alkylarrlino, di(Cl-C6-alkyl)amino, C1-C6-alkyi-1~ thio, cyano, carboxyl or carbamoyl, C4-Ca-cycloalkyl, optionally substituted by fluorine, chlorine, bromine, iodine, hydroxyl, C1-C6-acyloxy, benzoyloxy, phenoxy, Cl-C6-alkoxy, C1-C6-alkylamino, di(Cl-C6-alkyl)amino, C,-C6-alkylthio, cyano, carboxyl or carbamoyl, Cs-C6-cycloalkenyl, optionally substituted by fluorine, chlorine, bromine, iodine, hydroxyl, C1-C6-acyloxy, benzoyloxy, phenoxy, Cl-C6-alkoxy, C,-C;6-alkylamino, C1-C6-dialkylamino, Cl-C6-alkylthio, cyano, carboxyl or carbamoyl, (C1-C6-alkoxy)-(C1-C6-alkyl), di(C1-C6-alkylamino)-(C1-C6-alkyl) or (C3-C6-cycloalkyl)alkyl, (C6-C8-cyclo-alkenyl)alkyl, or arylalkyl, naphthylalkyl or heteroarylalkyl, each of which is substituted by up to five radicals R6 which are independent of one another, it being possible for the alkyl radical to contain in each case 1 to 3 oarbon atoms, by reductive alkylation of a compound of the formula I where R5 is hydrogen and X is oxygen and the definitions mentioned under 1) - 4) ~pply to R1, F~2, R3 and R4, with a carbonyl compound of the formula XVI, 2~5~5 R''-C(=O)-R''' (XVI) whsre R" and R~" are identical or different and independently of one another arehydrogen, C,-C7-alkyl, optionally substituted by fluorine, chlnrine, bromine, iodine, hydroxyl, C,-C6-acyloxy, benzoyloxy, phenoxy, C1-C6-alkoxy, Cl-C6-alkylamino, ditC.-C6-alkyl)amino, C1-C6-alkylthio, cyano, carboxyl or carbamoyl, C3-C7-alkenyl, optionally substituted by fluorine, chlorin~, bromine, iodine, hydroxyl, C,-C6-acyloxy, benzoyloxy, phenoxy, C,-C6-alkoxy, Cl-C5-alkylamino, di(C,-C6-alkyl)amino, C1-C6-alkylthio, cyano, carboxyl or carbarnoyl, C3-C7-alkynyl, optionally substituted by fluorine, chlorine, bromine, iodine, hydroxyl, C,-C;6-acyloxy, benzoyloxy, phenoxy, C,-C6-alkoxy, C,-C6-alkylamino, di(C,-C6-alkyl)amino, C,-C6-alkylthio, cyano, carboxyl or carbamoyl, C4-C8-cycloalkyl, optionally substituted by fluorine, chlorine, brornine, iodine, hydroxyl, C1-C6-acyloxy, benzoyioxy, phenoxy, C,-C6-alkoxy, C1-C6-alkylamino, di(C1-C6-alkyl)arnino, C,-C6-alkylthio, cyano, carboxyl or carbamoyl, C6-cycloalkenyl, optionally substituted by fluorine, chlorine, bromine, iodine, hydroxyl, C,-C6-acyloxy, benzoyloxy, phenoxy, C1-C6-alkoxy, Cl-C6-alkylamino, di(C,-C5-alkyl)amino, Cl-C6-alkylthio, cyano, carboxyl or carbamoyl, (C,-C6-alkoxy)-(C,-C5-alkyl), [di(C1-C6-alkyl)aminol-(C1-Cs-alkyl) or (C4-C6-cycloalkyl)alkyl, (C6-cyeloalkenyl)alkyl, or arylalkyl, naphthylalkyl or heteroarylalkyl, each of which is substituted by up to five radicals R5 which are independent of one another, it being possible for the alkyl radical to contain in each case 0 to 2 carbon atoms, and where R" and R"' can be linked to each other to form a 4- to 8-membered ring, or 1) preparing compounds of the formula I where X is oxygen and R1, R2, R3 and R4 are as defined under 1) - 4) and R5 is Cl-C8-alkyloxycarbonyl, C1-C8-alkylthiocarbonyl, C2-C~-alkenyloxycarbonyl, C2-C8-alkenylthiocarbonyl, C2-C8-alkynyloxycarbonyl, Cl-C6-alkylaminocarbonyl, C3-C6-alkenylaminocarbonyl, di(C,-C6-alkyl)aminocarbonyi, pyrrolidin-1-yl, morpholino-, piperidino-, piperazinyl-, 4-methylpiperæin-1-ylcarbonyl, optionally substituted by fluorine, chlorine, bromine3 iodine, cyano, amino, mercapto, 30 hydroxyl, C1-C6-acyloxy, ben~oyloxy, benzyloxy, phenoxy, C1-G6-alkoxy, .

2 ~

C1-C6-alkylamino, di(Cl-C6-alkyl)amino, C1-C6-alkylthio, C1-C6-alkylsulfonyl, phenylsul-fonyl, oxo, thioxo, carboxyl or carbamoyl;
or aryloxycarbonyl, arylthio(carbonyl), arylaminocarbonyl, heteroaryloxycarbonyl, heteroary!thiocarbonyl, hateroarylaminocarbonyl, arylalkyloxycarbonyl, (aryl-5 alkylthio)carbonyl, arylalkylaminocarbonyl, heteroalkyloxycarbonyl, (heteroalkylthio)carbonyl or heteroalkylaminocarbonyl, each of which is substituted by up to five radicals R6 which are independent of one another, it being possible for the alkyl radical to contain in each case 1 to 3 carbon atoms, by reacting a compound of the formula X\/ll n ~ ~R 3 )( V I I
to ( C H 2 ) n where the definitions mentioned under 1~ - 4) apply to R1, p~2, R3 and R4, n is 0, 1, 2 or 2a 3, X is oxygen and U is a leaving group, with a compound of the formula XVIII

Nu-H ~NIII) where Nu is Cl-C8-alkoxy, C2-Ca-alkenyloxy, C2-C~-alkynyloxy, C,-CB-alkylthio, C2-C8-alkenylthio, Cl-C8-alkylamino- and di(C,-Ca-alkyl)amino, C2-C8-alkenylamino- and di(C1-C6-alkyl)amino, optionally substituted by fluorine, chlorine, bromine, hydroxyl, C,-C4-alkoxy, C1-C4-alkylamino, di(C1-C4-alkyl)amino, C,-C4-alkylthio, pyrrolidin-1-yl, morpholino-, piperidino-, piperazinyl- or 4-methylpipera~in-1-ylcarbonyl, optionally substituted by C,-C4-alkyl, C2-C~-alkenyl, C,-C4-acyl, oxo, thioxo, carboxyl or phenyl, or aryloxy, arylthio, arylamino, arylalkyloxy, arylalkylthio, arylalkylamino, 2 ~

heteroaryloxy, heteroarylthio, heteroarylamino, heteroarylalkyloxy, heteroarylalkylthio or heteroarylalkylamino, each of which is ~ubstituted by up to five radicals R6 (R6 is as defined at the outset) which are independent of one another, it being possible for the alkyl radical to contain in aach oase 1 to 3 carbon atoms.

The abovementioned method A preferably proceeds under the following conditions:

The substituent Z in formula lll is a suitable leaving group such as, for example, chlorine, bromine or iodine, a suitable radical of sulfuric acid, an aliphatic or aromatic 10 sulfonate, or optionally halogenated acyloxy.

The reaction is expediently carried out in an inert sol\lent. Suitable solvents are, for example, aromatic hydrocarbons such as toluene or xylene, lower alcohols such asmethanol, ethanol or 1-butanol, ethers such as tetrahydrofuran or glycol dimethyl 15 ether, dipolar aprotic solvents such as N,N-dimethylforrnamide, N-methyl-2-pyrro-lidone, acetonitrile, nitrobenzene, dimethyl sulfoxide, or mixtures of these solvents.
Two-phase systems with aqueous solutions of bases in the presence of a phase transfer catalyst such as, for example, benzyltriethylammonium chlorid~, are also possible.
The presence of a suitable base, for example of an alkali metal carbonate, alkali metal hydrogen carbonate, alkaline earth mstal carbonate or alkaline earth rnetal hydrogen carbonate such as sodium carbonate, calcium carbonate or sodium bicarbonate, of an alkali metal nydroxide or alkaline earth metal hydroxide such as potassium hydroxide 25 or barium hydroxide, an alcoholate such as sodium ethanolate or potassium tert.-butylate, an organolithium compound such as butyllithiurn or lithiumdiisopropylamine, an alkali metal hydride or alkaline earth rnetal hydride such as sodium hydride or calcium hydride, an alkali metal fluoride such as potassium fluoride, or an organic base such as triethylamine or pyridine for scavenging the acid which is liberated 30 during tne reaction, may be expedient.

2 ~

In some cases, the addition of an iodide, for example potassium iodide, is expedicnt.
The reaction is generally carried out at temperaturss between -10 and 160C, preferably at room ternperature.

5 To carry out this reaction, any nucleophilic substihJents such as, ~or example, hydroxyl, mercapto or amino groups, with the exGeption o~ the 1- and/or 4-position in compounds of the formula ll or lll, must, before the reaction is carried out, bederivatized in a suitable manner or provided with conventional protective groups such as, for example, acetyl or benzyl, which can then be eliminated.
The sulfurizing reagent which is preferably used for the reaction as described above under B) is 2,4-bis(4-methoxyphenyl)-1,3-dithia-2,4-diphosphetane 2,4-disulfide (Lawesson's reagent), bis(tricyclohexyltin) sulfide, bis(tri-n-butyltin) sulfide, bis(triphenyltin) sulfide, bis(trimethylsilyl) sulfide or phosphorus pentasulfide. The 15 reaction is carried out expediently in an organic solvent or in a solvent mixture, at room temperature or above, preferably at the boiling point of the reaction mixture, and, if possible, under anhydrous conditions. Suitable substances are, for example, carbon disulfide, toluene, xylene, pyridine and 1,2-dichloroethane. If the tin sulfides or silyl sulfides which have been mentioned are used, it is advisable to carry out the 20 sulfurization reaction in the presence of a Lewis acid, such as boron trichloride.

In the presence of other carbonyl groups in a compound of the formula 1, for example in a compound where X is oxygen and one or more radicals p~1 to R6 are acyl, thecarbonyl is to be protected by known methods prior to the sulfurization reaction by a 25 suitable protective group, for example by acetalization; subsequent elimination of the protective groups results in the desired compound.

For the reaction described above under C, the substituent Z is a suitable leaving group, preferably chlorine, bromine or iodine, a suitable radical o~ sulfuric acid, an 30 aliphatic or aromatic sulfonate, or optionally halogenated acyloxy.

2~$~

The reaction conditions for this reaction correspond to those of method A.

The cyclization described under D) is effec~ed in a suitabie solvent such as rnethanol, ethanol, N,N-dimethylformamide or N-methylpyrrolidone, in the pres~nce of a base;
S suitable bases are alkali metal carbonates, alkali nnetal hydrogen carbonates, alkaline earth metal carbonates or alkaline earth metal hydrogen carbonates such as sodium carbonate, calcium carbonate or sodium bicarbonate, alkali metal hydroxides or alkaline earth metal hydroxides such as potassium hydroxide or bariu~ hydroxide,alcoholates such as sodium ethanolate or potassium tert.-butylate, organolithium10 compounds such as butyllithiurn or lithium diisopropyiamine, aikali metal hydrides or alkaline earth metal hydrides such as sodium hydride or calcium hydride, or an organic base such as triethylamine or pyridine - the latter substances can also be used as solvents, or organic or mineral acids such as glacial acetic acid, trifluoroacetic acid, hydrochloric acid or phosphoric acid. The reaction is preferably earried out at temperatures between 20 and 120C, particularly preferably at room temperature.

The compounds of the formula V, where R1 to R5 and Y are as defined under 1) - 5), can be obtained from compounds of the formula Vl R n~N H V I

where R', R2 and R5 are as defined under 1) - 4), by alkylation with a compound of the formula Vll ~.

.

2~$~

C O - Y
kR3 V I I

5 where R3, R4 and Y are as defined under 1) - 5) and Z is as defined undar A). The reaction conditions for this alkylation correspond to those given in method A.
Simultaneous cyclization to give the dihydroquinoxaline of the formula I takes place under suitable conditions.

10 Compounds of the formula V in which R', R3 to R5 and Y are as defined under 1) - 5) and R2 is hydrogen can also be prepared from compounds of the formula Vlll R 1 ~XN/~ ( V I I I ) where R', R3 to Rs and Y are as defined under 1) - 5) by reducing ~he nitro group by known processes to the amino group.
Simultaneous cyclization to give the dihydroquinoxaline of the formula I takes place under suitable conditions, for example by carrying out the reduction in the presence of an acid.
The reduction is carried out by standard methods (see, for example, Methoden derOrganischen Chemie [Methods in Organic Chemistry3 (Houben-Weyi), E. Muller (Editor); G. Thieme Verlag, Stuttgart, 1957; Vol. Xl/1, p. 360-490), for example using tin(ll) chloride in glacial acetic acid, TIC13 in hydrochloric acid, or by catalytic hydrogenation, the choice of reagent being determined by the chemical stability of the various substituents R1 and R3 to R5; if, for example, one of the radicals is alkenyl, the first method will be selected to obtain the double bond.

;

The phenylenediamines of the formula Vl which are required as startin0 materials for the syntheses described are known from the literature or commercially available or can be synthesized by methods known from the literature.

5 N-ortho-nitrophenylamino acid derivatives of the formula Vlll, where Rln and R3 to Rs are as defined under 1) - 4) and Y is oR7, where R7 is hydrogen, C,-C6-alkyl, optionally in each case for example halo~en-substituted phenyl, benzyl or 9-fiuorenylmethyl, can be obtained for example by amination of ortho-halonitro aromatic substances of the formula IX
,~N 2 R n~ t ll I x ~w where R' is as defined under 1) - 4) and W is fluorine, chlorine, bromine or iodine, with 15 amino acids or their esters of the formula X

~R~ X

R S

where R3, R4, Rs and R7 are as defined under 1) - 5). The reaction can be carried out in the presence of an inorganic or organic auxiliary base such as, for exampie, sodium carbonate, potassium carbonate, sodium hydroxide or triethylamine. It is advantageous to use an inert solvent at temperatures between 0 and 150C, preferably at reflux temperature. Suitable solvents are open-chain or cyclic ethers, for example tetrahydrofuran or glycol dimethyl ether, aromatic hydrocarbons, for example toluene or chlorobenzene, alcohols, for example ethanol, isopropanol or glycol monomethyl ether, dipolar aprotic solvents, for ~xample N,N-dimethylformamide, N-methyl-2-pyrrolidone or 1,3-dimethyl-tetrahydro-2~1H)-pyrimidinone.

2 ~

The N-ortho-nitrophenylamino acids of the formula Vlll where Y is hydroxyl can, if desired or necessary, be converted by well-known standard methods into the acid derivatives of the formula Vlll where Y is hydroxyl, C:1-C4-alkoxy, optionally halogenated C,-C4-acylo)ty, chlorine, bromine or iodine.

Ortho-halonitroaromatic compounds of the formula IX and amino acids of the formula X are known from the literature and comrnercially available or can be prepared by methods known from the literature.

The reaction described above under E) is preferably effected by means of catalytic hydrogenation (using hydrogen) or hydrosilylation (using alkylsilanes, for example diphenylsilane) in the presence of a hydrogenation ca~alyst, for example Raney nickel or palladium-on-charcoal, at a hydrogen pressure of 1 to 5 bar, or by means of areducing agent from the class of the complex metal hydrides such as sodium borohydride or sodium cyanoborohydride, or using metals, or metal salts, and acid such as, for example, zinc/glacial acetic acid or SnCI2/HCI. It is advantageous to carry out the reaction in an inert solvent such as lower aicohols, for example methanol or isopropanol, ethers such as tetrahydrofuran or glycol dimethyl ether, dipolar aprotic solvents such as N,N-dimethylformamide, aromatic hydrocarbons such as toluene orxylene, or mixtures of these solvents, at temperatures between -20 and 100C, preferably at room temperature.

If a chiral hydrogenation catalyst, for example di-/u-chloro-bis[(cycloocta-1c,5c-diene~-rhodium(l)]/(~) or (-)-4,5-bis-(diphenylphosphinomethyl)-2,2-dimethyl-1,3-dioxolane, or a chiral complex metal hydride, for example sodium tris-lN-benzyloxycarbonyl-L-prolinoyloxy)-borohydride, are used in the above-described reaction, the individual enantiomers can be prepared selectively.

If, in compounds of the formula Xl, substituents are present which can be hydrogenated or reduced under the above-described conditions, for example oxo, it is 2 ~

necessary to use an intermediate of the formula Xl with substituents which are not attacked, but which can be derivatized to give the ~roup raquired, for example hydroxyl. The substituents can also be provided with a customary protective group, for example an acetal protective group, which can then be removed after th~ above-des-5 cribed reaction.

Quinoxalinones of the formula Xl where R1 to R3 are as defined uncler 1) - 4) can be obtained by known processes by condensing a phenylenediamine of the formula Vl, where R' and R2 are as defined under 1) - 43 and Rs is hydrogen, with an alpha-10 ketocarboxylic acid of the formula Xll R3-Co-CooH (Xll) where R3 is as defined under 1) - 4).
15 The reaction is expediently carried out in an inert solvent in a temperature range of between 0 and 150C; examples of suitable solvents are alcohols, for exampls ethanol or isopropanol, open-chain or cyclic ethers, for example glycol dimethyl ether or tetrahydrofuran, or dipolar aprotic solvents, for example N,N-dimethylformamide or acetonitrile.
2~
The reaction described above under F) is expediently carried out in a two-phase system cornposed of an organic solvent or solvent mixture which is not miscible with water, composed of, for example, halogenated hydrocarbons, for example dichlorornethane or 1,2-dichloroethane, or aromatic hydrocarbons, for example toluene 25 or xylene, and a concentrated aqueous solution of an alkali metal hydroxide or alkaline earth metal hydroxide, for example sodium hydroxide or barium hydroxide. The presence of a phase transfer catalyst such as, for example, benzyltriethylammonium chloride or tetrabutylammonium ~romide, is advantageous.
The reaction is usuaily carried out at temperatures be~ween 0 and ~0C, preferably at 30 room temperatur~.

2 ~

Substituents in compounds of th~ ~ormulae Vl and Xlll, or XIV, which arc not stable under the reaction conditions must be replaced by those which can be derivatized to the required group. The substituents can also be provided with a customary protective group which can then ~e removed a~ter the above-described reaction.

In the reaction described above under G), Z in formula XV is a suitabl~ leaving group such as, for example, chlorine, bromine or iodine, a suitable sulfuric acid radical, an aliphatic or aromatic sulfonate, or optionally halogenated acyioxy.

10 The reaction conditions for this reaction correspond to those in method A.

The reaction described under H) is preferably effected by catalytic hydrog0nation (using hydrogen) in the presence o~ a hydrogena~ion catalyst, for example palladium-on-charcoal, at a hydrogen pressure of 1 to 5 bar, or by means of a reducing agent 15 from the class of the complex metal hydrides, such as sodium borohydride, sodium triacetoxyb¢rohydride or sodium cyanoborohydride.

The reaction is expediently carried out in an inert solvent, sur,h as lower alcohols, for example methanol or isopropanol, ethers, for example tetrahydrofuran or glycol 20 dimethyl ether, halogenated hydrocarbons, ~or example dichloromethane or dichloroethane, at temperatures between -20 and 100C, preferably at room tempera-ture. The presence of an acid such as, for example, acetic acid or trifluoroacetic acid, or of a Lewis acid such as, for example, titanium tetrachloride, is advantageous. If, in compounds of the formulae I and XVIJ substituents are pres~nt which can be 25 hydrogenated or reduced under the above-described conditions, for example oxo, the use of an intermediate of the formulae I and XVI with substituents which are notattacked but which can be derivatized to the required group, for example hydroxyl, is necessary. Acid-labile groups such as, for example, acetals, or groups which react under the reaction conditions, such as, ~or exarnple, primary amines, are also ~o be 30 avoided or to be provided with a customary protective group.

2 ~

The reaction described under 1) is expediently carried ou~ in an inert solvent. Examples of suitable solvents are aromatic hydrocarbons such as toluene or xylene, lower alcohols such as methanol, sthanol or 1-butanol, ethers such as tetrahydrofuran or glycol dirnethyl ether, dipolar aprotic solvents such as N,N-dimethylformamide, N-methyl-2-pyrrolidone, acetonitrile, nitrobenzene, dimethyl suHoxid~, or mixtures of these solvents. Two-phase systems wlth aqueous solutions of bases in the presence of a phase transfer catalyst such as, for example, benzyltriethylamrnonium chloride, are also possible.
The presence of a suitable base, for example an alkali metal hydroxide or alkaline earth metal hydroxide such as potassium hydroxide or barium hydroxide, of an alcoholate such as sodium ethanolate or potassium tert~-butylate, an or~anolithium compound such as butyllithium or lithium diisopropylamide, an alkali metal hydride or alkaline earth metal hydride such as sodium hydride or calciurn hydride, an alkali metal fluoride such as potassium fluoride, or an organic base such as triethylamine orpyridine, may be useful. The reaction is usually carried out at temperatures between -10 and 160C, preferably at room temperature.

To carry out this reaction, any nucleophilic ~ubstituents in compounds XVII and XVIII
which do not participate in the reaction, such as, for example, hydroxyl, mercapto or arnino groups, are to be derivatized in a suitable manner or to be provided withcustomary protective groups such as, for example, acetyl or benzyl, which can then be eliminated.

The compounds XVII which are required for the abovementioned reaction and in which the definitions described under 1) - 4) apply to R', p~2, R3 and R4, n is 0, 1, 2 or 3, X is oxygen and U is a suitable leaving group, halogen ~uch as, for example, chlorine, bromine, iodine, a halogenated aliphatic or aromatic alcoholate such as, for example, 2,2,2-trichloroethoxy, chlorophenoxy, or ~ heterocycle which is linked via nitro~en such as, for example, imidazolyl, tria~olyl or benzotri~olyl, are prepared by reac~ing a compound of the formula I where Rs is hydrogen and X is oxygen, and the definitions 2 ~ 8 ~
~4 described under 1) - 4) apply to R', R2, R3 and R4, with a suitable carbonic acid derivative, for exarnple phosgene, diphosgene, triphosgene, trichloroethyl chloroformate or carbonyldiimidazole, or with a suitable halo carbonyl halide, for example bromoacetyl chloride.

The reaction is expediently carried out in an inert solvent. Examples of suitable solvents are aromatic hydrocarbons such as toluene or xylene, ethers such as tetrahydrofuran or glycol dimethyl ether, or halogenated hydrocarbons such as dichloromethane or dichloroethane.
The presence of a suitable base, for exarnple of an alkali metal hydroxide or alkaline earth metal hydroxide, such as potassium hydroxide or bariurn hydroxide, or an organic base such as triethylamine or pyridine, may be useful.

15 The reaction is usually carried out at temperatures be~veen -30 and 16ûC, preferably at room temperature.

The present invention furthermore relates to the compounds as described under 1) to 4) as pharmaceuticals, preferably for treating viral diseases, in particular diseases 20 caused by HIV.

The invention furthermore relates to pharrnaceuticals comprising at least one compound according to the invention, and to the use of the abovementioned compounds for the preparation of pharmaceuticals, preferably for the treatment of viral 25 diseases, in particular for the treatment of diseases caused by HIV.

The present invention furthermore relates to the use of compounds of the abovementioned formula I or IA in which 2 ~ 8 ~
~5 n is zero, one, two, three or four, the individual substituents R1 independentiy of one another are fluorine, chlorine, bromine, iodine, ~rifluoromethyl, trifluoromethoxy, hydroxyl, C,-C8-alkyl, Cs-C8-cycloalkyl, C1-C6-alkoxy, (C,-C6-alkoxy)-(Cl-C;4-alkXY3, C1-C6-alkylthio, C1-C6-alkylsulfinyl, C1-C6-alkylsulfonyl, nitro, amino, æido, C1-C6-alkylamino, di(C,-C6-alkyl)amino, piperidino, morpholino, 1-pyrrolidinyl, 4-methylpiperazinyl, thiomorpholino, imidazolyl, triazolyl, tetrazolyl, C1-C6-acyl, C1-C6-acyloxy, C1-C6-acylamino, cyano, carbamoyl, carboxyl, (C,-C6-alkyl)oxycarbonyl, hydroxysulfonyl, sulfamoyl 1~
or a phenyl, phenoxy, phenoxycarbonyl, phenylthio, phenylsulfinyl, phenylsulfonyl phenoxysulfonyl, phenylsulfonyloxy, anilinosulfonyl, phenylsulfonylamino, benzoyl, 2-pyridyl, 3-pyridyl or 4-pyridyl radical which is substituted by up to five radicals R6 which are independent of one another, where R6 can be fluorine, chlorine, bromine, iodine, cyano, trifluoromethyl, trifluoromethoxy, nitro, amino, azido, C,-C6-alkyl, C3-C8-cycloalkyl, C1-C:6-alkoxy, C1-C6-alkylthio, C1-Cs-alkylsulfinyl, C;l-C6-alkylsulfonyl, C,-/:~6-alkylamino, di(C,-C6-alkyl)amino, (Cl-C6-alkyl)oxycarbonyl, phenyl, phenoxy, 2-, 3- or 4-pyridyl, 2~6~5 R2 and R5 are identical or different and independently of one another are hydrogen, hydroxyl, C,-C6-alkoxy, aryloxy, Cl-C6-acyloxy, cyano, amino, C,-C6-alkylamino, di(C1-C6-alkyl)amino, arylamino, C,-C~-acylamino, Cl-C8-alkyl,optionally substituted by fluorine, chlorine, bromine, iodine, cyano, amino, mercapto, hydroxyi, C1-C6-acyloxy, benzoyloxy, benzyloxy, phenoxy, Cl-C~-alkoxy, C,-C6-alkylamino, di(C1-C6-alkyl)amino, C,-C6-alkylthio, C,-C6-alkylsulfonyl, phenylsulfonyl, oxo,thioxo, carboxyl or carbamoyl;

C2-Ca-alkenyl, optionally substituted by fluorine, chlorine, bromine, iodine, cyano, amino, mercapto, hydroxyl, C1-C6-acyloxy, benzoyloxy, benzyloxy, phenoxy, C1-C6-alkoxy, C1-C6-alkylamino, di(C,-C6-alkyl)amino, C,-C6-alkylthio, C1-C6-alkylsulfonyl, phenylsulfonyl, oxo,thioxo, carboxyl and carbamoyl;

C3-C~,-allenyl, optionally substituted by fluorine, chlorine or hydroxyl, C1-C4-alkoxy, oxo, phenyl;
C3-CB-alkynyl, optionally substituted by fluorine, chlorine, bromine, iodine, cyano, amino, m0rcapto, hydroxyl, C,-Cs-acyloxy, benzoyloxy, ben7yloxy, ph~noxy, Cl-C6-alkoxy, Cl-C6-alkylamino, di(C1-C6-alkyl)amino, C,-C6-alkylthio, C1-C6-alkylsulfonyl, phenylsulfonyl, oxo,thioxo, carboxyl or carbamoyl;

C3-CB-cyClOalkyl~
optionally substituted by fluorine, chlorine, bromine, iodine, cyano, amino, mercapto, hydroxyl, 2~3~
~7 Cl-C6-acyloxy, benzoyloxy, benzyloxy, phenoxy, C1-C6-alkoxy, C,-C~-alkylamino, di(C,-C6-alkyl)amino, C1-C6-alkylthio, Cl-C6-alkylsulfonyl, phenylsuKonyl, oxo, thioxo, carboxyl or carbamoyl;

C3-C8-cycloalkenyl, optionally substituted by fluorine, chiorine, bromine, iodine, cyano, amino, mercapto, hydroxyl, C1-C6-acyloxy, benzoyloxy, benzyloxy, phenoxy, C1-C;6-alkoxy, Cl-C6-alkylamino, di(C1-C6-alkyl)amino, C1-C6-alkylthio, C1-C6-alkylsulfonyl, phenylsul~onyl, oxo,thioxo, carboxyl or carbamoyl;

(C3-C8-cycloalkyl)-(C1-C4-alkyl), optionally substituted by fluorine, chlorine, bromine, iodine, cyano, amino, mercapto, hydroxyl, C1-C6-acyloxy, benzoyloxy, benzyloxy, phenoxy, C1-C6-alkoxy, C1-C6-alkylamino, di(C1-C6-alkyl)amino, C1 C6-alkylthio, Cl-C6-alkylsulfonyl, phenylsulfonyl, oxo,thioxo, carboxyl or carbamoyl;

(C3-C8-cycloalkenyl)-(C1-C4-alkyl), optionally substituted by fluorine, chlorine, bromine, iodine, cyano, amino, mercapto, hydroxyl, C1-C6-acyloxy, benzoyloxy, benzyloxy, phenoxy, C:1-C6-alkoxy, C,-C6-alkylamino, di(C1-C6-alkyl)amino, C1-C6-alkylthio, C1-C6-alkylsuHonyl, phenylsulfonyl, oxo, thioxo, carboxyl or carbamoyl;
~5 C1 -C6-alkylcarbonyl, optionally substituted by fluorine, chlorine, bromine, iodine, cyano, amino, mercapto, hydroxyl, C1-C;6-acyloxy, benzoyloxy, benzyloxy, phenoxy, C1-C6-alkoxy, C1-C6-alkyiamino, 2 ~

di(C1-C6-alkyl)amino, C1~C6-alkylthio, C1-C6-alkylsulfonyl, phenylsulfonyl, oxo,thioxo, carboxyl or carbamoyl;

C2-C8-alkenylcarbonyl, optionally substituted by fluorine, chlorine or hydroxyl,C,-C4-alkoxy, oxo, phenyl;

(C3-C8-cycloatkyl)carbonyl, op~ionally substituted by fluorine, chlorin~ or hydroxyl, C1-C4-alkoxy, oxo, phenyl;

(C5-C8-cycloalkenyl)carbonyl, optionally substituted by fluorine~ chlorine or hydroxyl, C1-C4-alkoxy, oxo, pnenyl;

(C3-Ca-cycloalkyl)-(C1-C3-alkyl)carbonyl, optionally substituted by fluorine, chlorine or hydroxyl, C1-C4-alkoxy, oxo, phenyl;
(C5-C6-cycloalkenyl)-(Cl-C3-alkyl)carbonyl, optionally substituted by fluorine, chlorine or hydroxyl, C1-C4-alkoxy, oxo, phenyl;

C1-C8-alkyloxycarbonyl, optionally substituted by fluorine, chlorine, bromine, hydroxyl, C1-C4-alkoxy, C1-C4-alkylamino, di(Cl-C4-alkyl)amino, C1-C4-alkylthio;
C2-Ca-alkenyloxycarbonyl, optionally substituted by fluorine, chlorine, hydroxyl, C,-C4-alkoxy, oxo, phenyl;

C2-Ca-alkynyloxycarbonyl, op~ionally substituted by fluorine, chlorine, hydroxyl, C1-C4-alkoxy, oxo, phenyl;

C1-C8-alkylthiocarbonyl, optionally substituted by ~luorine, chlorine, hydroxyl,C1-C4-alkoxy, oxo, phenyl;

2 ~

C2-C0-alkenylthiocarbonyl, optionally substituted by fluorine, chlorine, hydroxyl, Cl-C4-alkoxy, oxo, phenyl;

C1-C~-alkylarnino- and di(C1-Ca-alkyl)aminocarbonyl, in each cas~ optionally substituted by fluorine, chlorine, hydroxyl, Cl-Cs-alkoxy, oxo, phenyl;

pyrrolidin-1-yl, morpholino-, piperidino-, piperazinyl-, or 4-methylpiperazin-1-ylcarbonyl, in each case optionally substituted by C1-C4-alkyl, C2-~6-alkenyl,C,-C4-acyl, oxo, thioxo, carboxyl, or phenyl;
C2-C8-alkenylamino- and di(C1-C6-alkenyl)aminocarbonyl, in each case optionally substituted by fluorine, chlorine, hydroxyl, C1-C,,-alkoxy, oxo, phcnyl;

C1-C6-alkylsulfonyl, optionally substituted by fluorine, chlorine, hydroxyl, C~-C4-alkoxy, oxo, phenyl;

C1-C6-alkenylslilfonyl, optionally substituted by fluorine, chlorine, hydroxyl, Cl-C4-alkoxy, oxo, phenyl;

or aryl, arylcarbonyl, aryl(thiocarbonyl), (arylthio)carbonyl, (arylthio)thiocarbonyl, aryloxycarbonyl, arylaminocarbonyl, (arylamino)thiocarbonyl, arylalkylaminocarbonyl, arylsulfonyl, arylalkyl, arylalkenyl, arylalkynyl, arylalkyl-carbonyl, arylalkenylcarbonyl, ary1alkoxycarbonyl or aryl~alkylthio)carbonyl, each of which is substituted by up to five radioals R6 which are independent ~f one another, it being possible for the alkyl radical to contain in each case 1 to 5 carbon atoms, and R6 being as defined above, or heteroaryl, heteroarylalkyl, heteroarylalkenyl, heteroarylalkylcarbonyi or heteroarylalkenylcarbonyl, heteroaryloxycarbonyl, (het~roarylthio)carbonyl, heteroarylaminocarbonyl, heteroarylalkyloxycarbonyl, 2 ~

heteroaryl(alkylthio)carbonyl or heteroarylalkylaminocarbonyl, each of which is substituted by up to three radicals R6 which are independent of one another, it being possible for the alkyl radical to contain in each case 1 to 3 carbon atoms, R3 and R4 are identical or different and, independently of one another~ are hydrogen, C,-C8-alkyl which is optionally substituted by fluorine, chlorine, hydroxyl, amino, mercapto, C,-C~-acyloxy. benzoyloxy, benzyloxy, phenoxy, C,-C4-alkoxy, C1-C4-alkylamino, di~C1-C4-alkyl)amino, Cl-C"-alkylthio, Cl-C4-alkylsulfonyl, Cl-C4-alkylsulfinyl, carboxyl or carbarnoyl;
C2-C8-alkenyl, optionaliy substituted by fluorine or chlorine, hydroxyl, amino, mercapto, C1-C4-acyloxy, benzoyloxy, ben~yloxy, phenoxy, Cl-C4-alkoxy, Cl-C4-alkylamino, di(Cl-C4-alkyl)amino, C1-C4-alkylthio, C,-C4-alkylsulfonyl, Cl-C4-alkylsulfinyl, carboxyl or carbamoyl;
C3-Ca-cycloalkyl, optionally substituted by fluorine, chlorine, hydroxyl, amino,mercapto, C,-C4-acyloxy, benzoyloxy, benzyloxy, phenoxy, C,-C4-alkoxy, C,-C4^
alkylamino, di(C,-C4-alkyl)amino, Cl-C4-alkylthio, C,-C4-alkylsulfonyl, C,-C4-alkylsulfinyl, carboxyl or carbamoyl C3-CB-cycloalkenyl, optionally substituted by fluorine or chlorine, hydroxyl, amino, mercapto, C,-C~,-acyloxy, benzoyloxy, bsnzyloxy, phenoxy, C,-C4-alkoxy, C,-C,,-alkylamino, di(Cl-C4-alkyl)amino, S:~l-C4-alkylthio, Cl-C4-alkylsulfonyl, Cl-C4-alkylsulfinyl, carboxyl or carbamoyl;
aryl, arylalkyl, heteroaryl or heteroarylalkyl, each of which is substituted by u,p to five radicals R6 which are independent of one another, it being possibi~ for thealkyl radical to contain 1 to 3 carbon atoms in eaeh case, and R6 bein0 as defined above, 2 ~

R3 and R4 or R3 and R5 can furthermore aiso be part of a saturated or unsaturated carbo- or heterocyclic ring which has 3 to 8 carbon atoms and which can optionally be substituted by fluorine, chlorine, hydroxyl, amino, C1-C6-alkyl, C2-CB-alkenyl, C2-C6-alkynyl, C,-C6-acyloxy, benzoyloxy, C1-C6-alkoxy, oxo, thioxo, carboxyl, carbamoyl or phenyl, X is oxy~en, sulfur, selenium or substituted nitrogen N-P~2, it being possible for R2 to have the abovementioned meanings, for the preparation of pharmaceuticals ~or the treatment of viral diseases.

The compounds mentioned and elucidated above under 1)-4) are preferred for this use.
The pharmaceuticals according to the invention can be aclministered enterally (orally), parenterally (intravenously), rectally, subcutaneously, intramuscularly or locally (topically).
They can be administered in the form of solutions, powders, (tablets, capsules including microcapsules), ointments (creams or gels) or suppositories. Suitable ad~uvants for such formulations are the liquid or solid fillers and extenders, solvents, emulsifiers, glidants, flavorings, colorings and/or buffer substances which are customary in pharmacology.

0.1 - 10, pr~erably 0.2 - 8 mg/kg of body weight are administered on~e or several times daily as an expedient dosage. The dosage units used depend expediently on the specific pharmacokinetics of the substanc~ usecl, or on the pharmaceutical formulation used.

2 ~

For example, the dosage unit of the compounds according to the invantion is 1 - 1500 mg, preferably 50 - ~00 mg.

The compounds according ~o th0 invention can also be administered as a combination with other antiviral agents such as, for example, nucleoside analogs, protease inhibitors or adsorption inhibitors, immunostimulants, interferons, interleukins and colony-stimulating factors ffor example (àM-CSF, G-CSF, M-CSF).

Activity tests Test of preparations against HIV in cell culture Description of method Medium:
RMPI pH 6.8 Complete medium additionally contains 20% fetal calf serum and 40 IU/ml recombinant interleukin 2.

Cells:
Lymphocytes which have been isolated frorn fresh donor blood by means of Ficoll~gradient centrifugation are cultured for 36 hours in complete medium with an addition of 2 ,L~g/ml phytohemagglutinin ~IVellcome) at 37C under 5% of CO2. A~ter 10% of DMSO has been added, the cells are frozen at a density of 5 106 and stored in liquid nitrogen. For the test, the cells are defrosted, washed in RPMI medium and cul~ured for 3 - 4 days in the complete medium.

Mixture:
The test preparations were dissolved in DMSO at a concentration of 16.7 mg/ml and diluted in complete medium to 1 mg/ml.
0.4 ml of medium was introduced into 24-multiwell dishes. 0.1 ml of ~he dissolvsd 2~6~9~

preparation was ad~ed to the upper row of the dish, and, by transferring 0.1 ml portions, a geometric dilution series was established. Controls without preparation always contained 0.4 ml of complete medium containing 0.5% of DMSO. Lymphocyte cultures with a cell density of 5 ~ 105 cells/ml were infected by adding 1/50 volume 5 supernatant from HlV-infected Iymphocyte cultures. The titer of these culture supernatants was determined by end-point titration as 1 5 106 infectious units/ml.
After 30 minutes' incubation at 37C, the infected Iymphocytes were removed by centrifugation and taken up in an equal volume of medium. From this cell suspension, 0.6 ml aliquots were transferred into all wells of the test plate. The mixtures were 10 incubated for 3 days at 37C.

Evaluation:
The infected cell cultures were examined under the microscope for the presence of giant cells, which indicate active virus multiplication in the culture. The lowest 15 concentration of preparation where no giant cells were observed was de~ermined as inhibitory concentration against HIV. As a control, the supernatants from the culture plates were tested for the presence of HIV antigen with the aid of an HIV antigen test following the manufacturer's instructions (Organon).

20 Results:

The results from this test are shown in Table 1.

Compound ofT-cell oulture assay Examp e No. MIC (ug/ml) ~ .
IV >0,8 _ _ Vl-A 0,16 2~$~85 _ _ Compound of T-cell culture assay Example No. MIC ~ug/ml) Vl-B 20 ¦
Vl-C < 0,8 Vll < 0,16 X 0,8 Xll < 0,8 Xlll < 0,16 . . _ ^11 XIV <0,16 3-7 0,08 ~1 3-21 0,16 . 11 3-23 0,08 3-24 0,08 3-25 0,4 3-26 0,4 ._ 3-29 < 9,4 3-30 . _ 3-32 < 0,4 3-33 -- 0,4 3-36 < 2,0 3-44 ' __ 2 ~ 5 _ ~ I
Compound of T-cell culture assay ¦ Example No. MIC Cug/ml) 3-48 <0,8 3-49 0,8 3-52 >0,8 __ 1 3-53 > 0,8 3-57 < 0,8_ 3-62 ~4,0 3-64 > 0,8 3-66 > 0,08 3-67 < 0,8 3-73 > 0,4 3-75 <0,8 3-76 ~ 0,08 3-80 ~,4 ¦ 3-81 0,08 3-87 > D B
3-88 - 0,8 XX <4,0 6-1 0,4 6-16 0,3 Compound of T-cell cul~ure assay Example No. ~ MIC ~g/ml) 6-17 < 0,8 6-19 < 0,8 6-20 <0,8 6-22 > 0,8 _ 6-27 < 0,4 6-32 c 0,08 6-33 > 0,8 6-34 ` - < 0,4 ¦ 6-35 < D,08 6 33 0,8 L 6-39 0,4 6-50 < 0,01 I
XXIII 0,01 l 7-1 < 0,16 7-2 < 0,01 _ I
7-3 ~ 0,01 I
1 7-7 0,04 ¦ 7-1 D ~ 0,04 ~7 2~p~
_._ . .
Compourld of T-cell culture assay Example No. MIC ~ug/ml) 7-11 < 0,01 7-12 < 0,8 ¦
7-13 < 0,08 7-14 < 0,08 7-16 0,4 7-21 < 0,01 ... . .. . _ ~
7-22 < 0,01 ¦ 7-23 < 0,01 10-4 0,4 10^5 < 0,8 10-9 < 0,8 . .
_ . .. _ .. . . . _ 10-10 0,08 10-13 0,08 10-14 < 0,8 10-17 0,~
10-18 ~ 0,8 10-20 _ ~_0,8 ~0-2~ < 0,~ _ 10-27 0,8 2~9~

. .__ Compound of T-cell culture assay Example No. MIC Gug/ml) 10-28 < 0,8 11-1 < 0,8 11-2 > 0,8 11 4 < 0,8 ._ 11 -11 0,01 Assay of the substances for HIV reverse transcriptase inhibition The activity of reverse transcriptase (RT) was determined with the aid of a scintillation proximity assay (SPA).
The reagent kit for the RT-SPA was obtained from Amersham/Buchler (Braunschweig).
The enzyme RT (from HIV cloned in E. coli) originated from HT-Biotechnology Ltd,15 Cambridge, UK.

Mixture The assay was carried out using the manufacturer's (Amersham) protocol manual, 20 with the following modifications:

- bovine serum albumin was added to the assay buffer to give an end concentration of 0.5 mg/ml 2 9 ~

- the assay was carried out in Eppendorf reaction vessels, using 100 ~JI volume per batch - the manufacturer's RT concentrate (5000 U/ml) was diluted in Tris-HCI buffer 20 mM; pH 7.2; 30% of glycerol, to an activity of 15 U per ml - the incubation time for ~he mixtures was 60 minutes (37C) - after stopping ~he reaction and ~developing~ with the bead suspension, 130 ,ul of mixture were transferred to 4.5 ml of Tris-HCI buffer, 10 mM; pH 7.4; 0.15 M
NaCI, and the tritium activity was measured by means of a -counter.

Assay For a pre-assay for inhibitory activity, the substances were dissolved in DMSO (stock solution c = 1 mg/ml), and tested as a 101, 102, 103, etc., dilution in DMSO.

To determine IC50 values, the inhibitor stock solutions were diluted further in Tris-HCI
buffer, 50 mM, pH 8, and tested in suitable concentrations.
The concentration corresponding to a 50% enzyme inhibition was determined from aplot of RT activity versus log Cjnh.

The test results are shown in Table 1a.

.
:

2 ~

Table 1a Compound of Reverse Transcriptase Assay Example No. ICso ~u9/ml) V - ~ 7,5~
Vl-A 0,08 Vl-C 0,8 Vll 0,1 Xlll 0,04 I
XIV 0,16 3-23 0,1 -1 I _ _ _ I
3-24 0,1 - 1 3-25 0, 1 -1 I
1 3-29 0,1-1 3-30 0,025 3-32 approx. 0,1 _ _ 3-36 0,1 -1 _ _ 3-49 approx. 1 . _ _ _ _ 3-57 approx. 1 3-75 ~ -I _ 1 3-76 0,~18 ¦ 3-~1 approx. 1 . ~

2~98~

Compound ofReverse Transeriptase Assay ¦Example No.IG50 ~ug/ml) 6-1 approx. 1 I . . . .. I
6-8 0l1 -1 6-9 approx. 1 ~_ 6-16 approx. 1 6-1 7 0,1 -1 .. . .... . . ___ 6-27 approx. 1 6-35 0,1 - 1 6-50 0,01-0,1 XXIII 0,025 7-1 0,08 7-2- --~-~ 0,07 ~
7-3 0,07 _ . _ 7-7 0,1 7-10 0,1 1 7-11 0,01 . .. _ .
7-12 approx. 1 _ . e _ r 7-13 0,1 -1 _ .
7-16 appro)t. 1 10-9 _pprox.

2 ~ 5 _ ..... _ _ _ Compound of Reverse Transcriptase Assay Example No. ICso ~ug/ml) . .
10-10 approx. 1 . ............. _ 10-13 approx. 1 10-17 approx. 1 .. _ I
10-18 0,1 -1 1 0-20 0, 1 -1 . .
1 0-21 0, 1 -1 10-27 0,1 -1 10-28 0,1 - 1 11-11 0,1 - 1 10-34 0,1 -1 11-6 0,1 - 1 0,1 - 1 11-7 approx. 1 11-13 approx. 1 1 5 7-20 0, 1 -1 7-14 0,01 - 0,1 . ...
7-15 0,01 - 0,1 7-17 0,01 - 0,1 7-18 0,01 - V,1 2 ~ 8 ~ .

¦ Compound of Reverse Transcriptase Assay lExample No ICso ~ug/ml) ¦ 7-19 0,01 - 0,1 I
¦ 7-21 0,01 - 0, l I
¦ 7-22 0,01 - 0,1 I _ ¦ 7-23 0,01 - 0,1 ¦ 3-34 0, 1 -1 I
¦ 3-35 0, 1 -1 ¦ 3-37 0, 1 -1 3-7 0,08 I _ ¦ 3-127 0,01 - 0,1 3-128 0,01 - o,1 3-129 0,01 - 0,1 7-24 < 0,01 7-25 < 0,01 7-26 0,01 0,1 1 5 7-27 0, 1 -1 7-28 < 0,01 _ _ 7-29 0,01 - 0,1 7-30 < 0,01 . _ _ 7-31 ~ ~,Ot 20 ICsO = 0.08 ~ug/ml . , ~

2 ~

The examples which follow and the content of the patent claims illustrate the present invention in greater detail.

5 Example I
(3S)-6-Chloro-3-methyl-3,4-dihydroquinoxalin-2(1 H)-one A) (S)-N-(3-Chloro-6-nitrophenyl)alanine 2,4-Dichloronitrobenzene ~21.0 y, 0.109 mol) and 23.0 g (0.258 mol) of L-alanine were refluxed for 48 hours in 400 ml of 2-methoxyethanol with an addition o~ 120 rnl of 2N
sodium hydroxide solution. The mixture was subsequently concentrated in vacuo, and the residue was taken up in aqueous sodium hydrogen carbonate solution. the mixture was extracted three times using ethyl acetate, the extract was then acidified wlth 6N
15 hydrochloric acid, and the yellow product was extracted using ethyl acetate. The organic phase was washed once with saturated aqueous sodium chloride solution and dried (magnesium sulfate), and the solvent was removed under reduced pressure.
14.7 g (55%) of a yellow solid of melting point 167-169C remained (after crystallization from ethyl acetate).
1H NMR (270 MHz, d6-DMSO): ~ = 1.47 (d, J = 7 Hz, 3 tl), 4.57 (quintet, J = 7 Hz, 1 H), 6.77 (dd, J = 9, 2 Hz, 1 H), 7.11 (d, J = 2 Hz, 1 H), 8.12 (d, J = 9 Hz, 2 H), 8.41 (br. d, J = 7 Hz, 1 H), 13.2 pprn ~br., 1 H).
MS: (M + H)~ - 245 B) (3S)-6-Chloro-3-methyl-3,4-dihydroquinoxalin-~1H)-one The product of Example IA (14.0 g, 0.057 mol) was dissolved in 400 ml of methanot and hydrogenated with Raney nickel catalysis at room temperature, using 1 atm hydrogen. After the calculated amount of hydrogen had been taken up, the catalyst 30 was removed by filtration with suction, and the reaction solution was concentra~ed in 2 ~

vacuo. The residue was puri~ied by silica gel chromatography using ethyl acetate/heptane = 1:2 and 1:1 as the eluent. The yield was 6.0 g (53%) of a brownish solid of melting point 122-123C ~after reerystallization from isopropanol/heptane).
'H NMR (60 MHz, d6-DMSO): ~ = 1.23 (d, J = 11 H~, 3 H), 3.~1 (dq, J = 11, 4 Hz 1 H), 6.27 (br., 1 H), 6.3 - ~.9 (m, 3 H), 10.3 ppm (br., 1 H).
MS: (M + H)~ = 197 [~]D23 = +77.3 (c = 1, MeOH) C) ~3R)-6-Chloro-3-methyl-3,4-dihydroquinoxalin 2(1H)-on~
The compound was prepared from D-alanine by the methods described under Example IA and IB. Melting point 123-124C (after recrystallization frorn isopropanol/heptane) The NMR data agree with those of the compound described in Example IB.
[a]D23 = -81.0 (c = 1, MeOH) D) (3RS)-6-Chloro-3-methyl-3,4-dihydroquinoxalin-2(1H)-one The compound was prepared starting from D,L-alanine by the methods described in 20 Examples IA and IB. Melting point 110C (after recrystallizati~n from isopropanol/heptane) The NMR data agree with those of the compound described in Example IB.

The fsllowing compounds of the formula i were synthesized analogously using the 25 corresponding haloaromatic compounds and ~rnino acid derivatives:

2~$~

Example ll (3S)-3-Benzyl-7-chloro-3l4-dihydroquinoxalin-2(1 H)-one A) (S)-N-(4-chloro-2-nitrophenyl)-phenylalanine L-Phenylalanine (8.3 9, 0.05 mol) and 4.8 g (0.025 mol) of 2,5-dichioronitrobenzene were dissolved in 40 ml o~ anhydrous dimethyl sulfoxide (DMSO), and the stirred solution was heated to 80C under an argon atmospher Potassium tert.-butylate (4.2 9, 0.025 mol), dissolved in 30 ml of DMSO, was added dropwise in the course of 40 minutes. Stirrina was continued for 3 hours at 8û to 90C, the mixture was allowed to cool, and unreacted phenylalanine was removed by filtration with suction and washed with water. The collected alkaline filtrates were extracted twice using diethyl ether to remove unreacted dichloronitrobenzene. The mixture was then acidified using glacial acetic acid and extracted several times using cthyl acetate, and the extracts were dried over magnesium sulfate and evaporated.

The product was obtained in the form of a red oil (6.7 9, ~4%), which was further reacted without purification.

B) (3S)-3-Benzyl-7-chloro-3,4-dihydroquinoxalin-2(1H)-one The product of Example IIA (12 g) was dissolved in 300 ml of anhydrous methanol and hydrogenated at room temperature with palladium/charcoal catalysis, using 1 atm hydrogen. When the reaction had ended, solids were filtered off with su~tion, the liquid 25 was concentrated, and the concentrate was ehromatographed on silica gel usingdiisopropyl ether as the eluent. This gave 1.32 ~ of the desired product which crystallized from isopropanol, melting point 185~.

2 ~ 8 ~

1H NMR (270 Mtlz, d6-DMSO): ~ = 2.9 (m, 2 H), 4.08 (m, 1 H), 6.09 (d, 1 H), 6.7 (m, 2 H), 6.78 (m, 1 H), 7.2 (m, 5 H), 10.34 pprn (br. s, 1 H).
MS: (M + H)~ = 273, (M - 92)' = 181.

5 The compounds in Table 2 were prepared as described in the ~bove examples.

Table 2 H
I

R l n~ ~ H

. ~ ~
Nr. R~n R3 Rs M.P. C
1 ~-CI CH3 H Wax 6-CI C2Hs 120 . _ _ 6-CI -CH2cH2~O-6-CI (CH3)2CH H
_ .
6-CI ~CH3)2CH( ~H2 H Oil 6-Ci C2Hs(CH3)CH Oil 6-C;1 C6HsCH2 _ _ _156-157 2~6~9~3 - -Nr. Rln R3 Rs M.P. C
_ .__ ..

.. __ . ...... _ 11 6-CI CH2(OH) H _ .
13 7-Ci CH3 il 142 14 7-CI (CH312CH H
.. . ._ ~_ ~

_ 17 6,7-CI2 CH3 H
1E~ 7-F CH3 H 230 ~ ___ .
19 6-F CH3 H Wax 6-F CH3 C3Hs 182 21 6-F C6HsCH2 ~3Hs 23 6-CH3Oc2H4O C2Hs H 107 _ . . .

. ~, . . .
6-CI CH2-S-Bn __ 170 26 6-CI CH2-S-i.-Pr H 190 _ 27 6-CI CH2O-t.-Bu H 12E~
_ ._ 28 6-CI C,~tl9 ==-. 115 2 ~

Bn = benzyl i-Pr = isopropyl t-Bu = tert.-butyl Example lll (3S)-4-N-(Benzyloxycarbonyl)-6-chlors -3-methyl-3,~-di-hydroquinoxalin-2(1 H)-one The compound of Example IB (1.0 9, 5.1 mmol) was dissolved in 2D ml ~
dichloromethane. 10 ml of 2N aqueous sodium hydrogen carbona~e solution were added, and 0.9 ml (90%; 5.7 mmol) of benzyl chloroformate was added with ice-cooling and vigorous stirring. The two-phase system was subsequently stirred for60 hours at room temperature. After 30 hours, another 0.2 ml (1.3 mmol) of benzyl 15 chloroformate was added. When the reaction was complete, the phases wsre separated, the organic phase was washed once with water and dried (magnesium sulfate), and the solvent was rernoved in vacuo. The product was purified by silica gel chromatography with methyl tert.-butyl ether/h~ptane = 1:1 as the eluent This gave 1.65 g (98%) of a white, foam-like product.
'H NMR (270 MHz, d6-DMSO): ~ = 1.15 (d, J = 7 Hz, 3 H), 4.85 (q, J = 7 Hz, 1 H), 5.20 (d, J = 12 Hz, 1 H), 5.27 (d, J = 12 Hz, 1 H), 6.97 (d, J = 7 Hz, 1 H), 7.19 (dd, J = 8.2 Hz, 1 H), 7.3 - 7.45 (m, ~ H), 7.67 (d, J = 2 Hz, 1 H), 10.81 ppm (br- s, 1 H).
MS: (M + H)~ = 381 2~
Example IV

(3S)-4-N-(Benzyloxycarbonyl)-6-Chloro-3-methyl-8-nitro-3,4-dihydroquinoxalin-2(1 H)-one The compound of Example lll (1.5 9, 4.5 mmol) was nitrat~d in glacial ac~tic acid (15 ml). A to~al of 5 rnl (124.3 mmol) of fuming nitric acid were added dropwise in 2 ~ 8 ~

the course of 4 hours at O~C to room temperature. The mixture was subsequently poured into 100 ml of ice-water, and the product, whioh was obtained in the form of a yellow solid, was filtered off, washed thoroughly wlth water, and dried. Melting point 85C (subl.).

'H NMR (270 MHz, d6-DMSO): ~ - 1.22 (d, J = 8 Hz, 3 H3, 4.89 (q, J = 8 Hz, 1 H), 5.24 (d, J = 12 Hz, 1 H), 5.31 (d, J = 12 Hz, 1 H), 7.35 - 7.~ (m, 5 H), 7.69 (s, 1 H), 8.Q0 (s, 1 H), 11.11 ppm (br. s, 1 H).
MS: (M + H)' = 376 Example V

(3S)-8-Amino-4-N- (benzyloxycarbonyl)-6-chloro-3-methyl-3,4-dihydroquinoxalin-2(1 H)-one The compound of Example IV (1.5 g, 4.0 mmol) was dissolved in 150 ml ofmethanol and hydrogenated at room temperature with Raney nickel catalysis, using1 atm hydrogen. When the calculated amount of hydrogen had been taken up, the catalyst was r emoved by filtration with suction, and the filtrate was concentrated in 20 vacuo. The product was purified by silica gel chromatography using ethyl acetate/heptane = 2:1 as eluent. The yield was 0.68 g (49%) of brownish solid ofmelting point 152-154C.
H NMR (270 MHz, d6-DMSO): ~ = 1.11 (d, J = 8 Hz, 3 H), 4.79 (q, J - 8 Hz, 1 H), 5.15 (d, J = 12 Hz, 1 H), ~.24 (d, J = 12 Hz, 1 H), ~.38 ~br. s, 2 H), 6.42 (s, 1 H), 7.3-7.4 (m, 6 H), 19.59 ppm ~br. s, 1 H).
MS: (M + H)~ = 346 2 ~

Example Vl A) (3S)-6-Chloro-3-methyl-4-N-(3-methyl.2-buten-1-yl)-3,4-dihydroquinoxalin-2(1 H)-one The compound of Example IB (1.0 y, 5.0 mrnol) was dissolved in 20 n~l of acetonitrile and alkylated with 3-methyl-2-buten-1-yl bromide (90%; 0.92 ml, 7.0 mmol) at room temperature in the presence of ~.0 9 (7.0 mrnol) of pulverulent potassium carbonate. After 7 hours, the reaction had ended. The mixture was filtered off with suction, the filtrate was concentrated in vacus, and the product was purified by silica gel chromatography usin~ ethyi acetate/heptane = 1:2 as eluent.
The yield was 0.97 g (72%) of brownish solid of melting point 117-118C (after crystallization from methyl tert.-butyl ether/heptane).
lH NMR ~270 MHz, d6-DMSO): ~ = 1.02 ~d, J = 8 Hz, 3 I l), 1.74 (s, 6 tl), 3.69 (dd, J = 14, 8 Hz, 1 H), 3.85 - 3.9 (m, ~ H), 5.19 (m, 1 H), 6.65 - 6.8 (m, 3 H), 10.47 ppm (br. s, 1 H).
MS: (M + H)' = 265 [a]D23 = +168.0~ ~c = 1, MeOH) B~ (3R)-6-Chloro-3-methyl-4-N-(3-methyl-2-buten-1-yl)-3,4-dihydroquinoxalin-2(1 H)-one The compound was prepared by the method described in Example VIA, starting from the compound of Example IC. Melting point 115-117C (af~er reerystalli7ation from isopropanol/diethyl ether) The NMR data agreed with those of the compound deseribed in Exarnple VIA.
[a]D23 = -172 (c = 1, MeC~H) 2 ~

C) t3RS)-6-Chloro-3-methyl-4-N-(3-methyl-2-buten-1-yl)-3,4-dihydroquinoxalin-2(1 H)-one The compound was prepared by the method described in Example VIA starting with the compound of Example ID. Melting point 148-14gG (after recrystallization from isopropanol/diethyl ether) The NMR data agreed with those of the compound described in Example VIA.

Example Vll (3S)-6-Chloro-3-methyl-4-N-(2-buten-1 -yl)-3,4-dihydroquinoxalin-2(1 H~-one The substance was prepared analogously to the compound described in Example VIA, but with 2-buten-1-yl bromide as the alkylating agent. Melting point 87-88C
(after crystallization from diethyl ether/heptane) 'H NMR (270 MHz, d6-DMSO): ~ = 1.01 (d, J = 8 Hz, 3 H), 1.70 (dd, J = 8, 1 Hz, 3 H), 3.63 (dd, J = 16, 6 llz, 1 H), 3.85 -4.0 (m, 2 H), 5.47 (m, 1 H), 5.75 (m, 1 H), 6.65 - 6.8 (m, 3 H), 10.48 ppm (br. s, 1 H).
MS: (M + H)~ = 251 Example Vlll 4-N- (Isopropenyloxycarbonyl)-3,3,7-trimethyl-3,4-di-hydroquinoxalin-2(1 H)-one 3,3,7-Trimethyl-3,4-dihydroquinoxalin-2(1H)-one (0.4 g, 2.1 mmol~ were dissolved in 10 ml of anhydrous pyridine, and the stirred solution was tre~ted at ro~m temperature with 0.24 ml (2.2 mmol) of isopropenyl chloroformate. The mixture was stirred for 6 hours at room temperature and treated with water, thc precipi~ate which formed was filtered off with suction, washed with water and dried. This gave 0.4 9 (6~%) of eolorless crystals of melting point 185~G.
'H NMR (270 MHz, d,;-DMSO~: d = 1.~ (s, 6 H~1 1.9 (s, 3 H~, 2.25 ~s, 3 I l), 4.7 (m, 2 H), 6.7 - 6.9 (m, 2 H), 7.15 (d, J = 8 Hz, 1 H), 10.6 ppm (br. s, 1 H).
MS: t = 274 2 ~

Example IX
(3S)-6-Chloro-4-N- ~4-methoxyphenoxycarbonyl)-3-methyl-3,4-dihydroquinoxalin-~(1 H)-one The compound of Example IB (0.5 9, 2.5~ mmol) was dissolved in 10 ml of anhydrous N,N-dimethylformamide, and 0.41 ml (2.8 mmol) of triethylamine were added. To the stirred mixtur~ there was first added dropwise 0.4~ ml (2.8 mmol) of 4-methoxyphenyl ohloroformate and, after ~ hours, another 0.21 ml (1.9 mmol).
When ~he reaction was complete (18 hours), the solvent was stripp~d off under reduced pressure, ~he residue was taken up in ethyl acetate, and the mixture waswashed with water and dried (sodium sulfate). 0.4~ g (54%) of a whit~ solid remained after concentration. Melting point 187-19ûC (after recrystallization from isopropanol) 1H NMR (270 MHz, d6-DMSO): ~ = 1.24 (d, J = 8 Hz, 3 H), 3.77 (s, 3 H), 4.94 (q, J = 8Hz, 1 H),6.97 (dd,J = 8,2Hz, 1 H),7.03 ~d,~l = 8Hz, 1 H),7.2-7.3(m, 3 H), 7.78 (s, 1 H), 10.89 ppm (br. s, 1 H).
MS: (M + H)~ = 347 Example X
(3S)-6-Chloro-4-N-(4-fluorophenoxycarbonyl)-3-methyl-3,4-dihydroquinoxalin-2(1 H)-one The compound was prepared analogously to the compound described in Example VIA, but 4-fluorophenyl chloroformate was used as ar~lating a~ent. Melting point168-170C (after crystallization from isopropanol) 'H NMR ~270 MH~, d6-DMSO): ~ - 1.24 (d, J = 8 Hz, 3 H), 4.94 (q, J = 8 H~, 1H),7.03(d,8Hz,lH),7.2-7.5(m,5H~,7.83(d,J=2Hz,1H),10,90ppm (br. s, 1 H).
MS: (M + H)~ = 335 2 ~
Example Xl (3S)-6-Chloro~-N-(4-chlorophenoxycarbonyl)-3-methyl-3,4-dihydroquinoxaiin-2(1 H)-one The compound was prepared analogously to ~he compound described in Example VIA, but 4-chlorophenyl chloroformate was used as acylating agent. Melting point185-188C (af+er crystallization from isopropanol/diethyl ether) 'H NMR (270 MHz, d6-DMSO): ~ = 1.2~ (d, J = 8 Hz, 3 H), 4.94 (q, J ~ 8 Hz, 1 H), 7.04 (d, 8 Hz, 1 H), 7.25 (dd, J = 8, 2 Hz, 1 H), 735 - 7.6 (m, 4 11), 7.80 (s, 1 H), 10.91 ppm (br. s, 1 H).
MS: (M + H)+ = 351 Example Xll (3S)-4-N - (2-Bromoethyloxycarbonyl)-6-chloro-3-rnethyl-3,4-dihydroquinoxalin-2~1 H)-one The compound was prepared analogously to the compound described in Example VIA, but 2-bromoethyl chloroformate was used for the acylation. Melting point 133-136~C (after crystallization from isopropanol) 2û lH NMR (270 MHz, d6-DMSO): ~ = 1.16 (d, J = 8 Hz, 3 H), 3.7 - 3.8 (m, 2 H), 4.4 -4.6 (m, 2 H), 4.86 (q, J = 8 Hz), 6.99 (d, 8 Hz, 1 H), 7.21 (dd, 8, 2 Hz, 1 H), 7.74 (d, J = 2 Hz, 1 H), 10.84 ppm (br. s, 1 H).
MS: (M + H)+ = 348 Example Xlll (3S)-6-Chloro-N-~isopropenyloxycarbonyl)-3-methyl-3,4-dihydroqllinoxalin-2~1 H)-one The substance was prepared analogously to the compound described in i-~ample VIA, but isopropenyl chloroformate was used for the acylati~n. Meiting paint 2 ~

'H NMR (270 MHz, CDC13): ~ - 1.33 (d, J = 8 Hzl 3 H), 2.02 (s, 3 H), 4.79 (s, 1 H),4.83~s,1 H),5.17~q,J=8Hz,1 H),6.86(d,J=8Hz,1 H),7.12(dd, J=8,2Hz,1H),7.74(br.s,1H),9.28ppm(br.s,1H).
MS: (M + H)~ = 281 Exarnple XIV
~3S)-6-Chloro-3-methyl-4-N-(vinyloxyearbonyl)~3~4-di- hydroquinoxalin-~(1H)-one The substance was prepared analogously to the compound described in Example VIA, but vinyl chloroformate was used ~or the acylation. Melting point 177-179C'H NMR (270 MHz, CDC13): ~ = 1.33 (d, J - 8 Hz, 3 H), 4.96 (dd, J = 14, 2 Hz, 1 H), 5.20 (q, J = 8 Hz, 1 H), 6.83 (d, J = 8 Hz, 1 H), 7.12 (dd, J = 8, 2 Hz, 1 H), 7.2 - 7.3 (m, 2 H), 7.71 (br. s, 1 H), 9.42 ppm (br. s, 1 H).
MS: (M + H)~ = 267 Example X\/ and Example XVI

6-Chloro-3,4-dihydroquinoxalin-2(1H)-one was reacted with 3-methyl-2-buten-1-yl bromide analogously to the process described in Example VIA. It was possible to 20 isolate two products by silica gel chromatosraphy.
6-Chloro-4-N-(3-methyl-2-buten-1-yl)-3,4-dihydro- quinoxalin-2(1H)-one Melting point 150-151 C ~after recrystallization frorn ethyl aeetate) 'H NMR (270 MHz, d6-DMSO): ~ = 1.72 (s, 6 H), 3.ô7 (s, 2 H), 3.89 ~d, .1 = 7 Hz,2 H), 5.20 (m, 1 H), 6.7 - 6.8 (m, 3 H), 10.49 ppm (br. s, 1 H).
MS: (M ~ H)~ = 251 6-Chloro-4-N-(3-methyl-2-buten-1-yl)-3-(1 ,1 -dimethyl-2-propen-l-yl) 3,4-dihydroquinoxalin-2(1 H)-one Melting point 110-112C (after crystalli~ation from heptane) 2 ~ 5 'H NMR (270 MHz, d6-DMSO): ~ = 0.94 (s, 3 H), 0.97 (s, 3 H), 1.65 (s, 3 H), 1.66(s, 3 H), 3.77 (dd, J = ~6, 7 H7, 1 H), 4.23 (dd, J = ~6, 7 Hz, 1 H), 4.8 - 4.9 (m, 2 H), 5.02 (m, 1 H), 5.75 (dd, J = 17, 11 Hz, 1 H), 6.6 - 6.7 (m, 3 H), 10.49 ppm (br s, 1 H).
5 MS: ~M + H)~ = 319 The following compounds of the formula I were synthesize~ from the correspondingunsubstituted quinoxalinones in analogous manner and, K appropriate, derivatizedfurther:
Table 3 R n~ N

2~6~5 _ . _ __ _ _ _=

O 11~) O N 00 N N N N ~-I T ~.) O C.) ~: T ~ ~ _ ~ e oN T T
_ _ ~: I I I I I I I I I I I :C
_ _ _ _ . _ _ U~ ~ ~ ~ -~, O ~,~ ~ ~ ~.~

Z ~ N C~ ~ L~ ) ~ r- aD a) ~_ ~ r ~_ _--_ _ = _ _ _ _ :

2 ~

r _-5 U C~l t) ~ o E cl) u~ o ~ ,_ N
. N tD O 0 0 t~5 . ~) ~) cr) C~ O T-¦~ N N LL O ~ LL I~ u~ O ~ ~ ~ ~_ ~ (.) ( ) ~.) O t ) (.) O t~ N t ) t~ ~ t~) I .

tr I I I I I I I I I I I I I

_' O C) ~ O (.) O ~ O S~) O ~ (~ V
~ CD (D ~) t~ U) ~ ~J (~ ~D CD CD ~D

Z d In tD ~ ~ O) ; N N C~l N C~l ;~ N

2 ~ 5 _ _ _ _ . _ cc I u~ O t ) ~ O O 6 u~ O O ( ) o) ~ t~l N C~l O

cr: I ~ ~ ~ N t~l r~ ~q t l I
_ _ _ . _ _ CC I I I I I I I I I I I I I
tr~ T
G: CD ~D C~ ~D ~ ~ ~D CD ~D ~D ~D ~D tD

. ~ 0~ O> ~ . Cl c7) ~ U ~D ~ 00 ~
Z N C~l N cr) ~ S~ C~ C~ t~) ~ ~ ~) C') ___ _ =_ _. __ _ __ _ s ~ ~ T rl~
~ D ,_ ~ O O o co o .

tru~u~ ~u~ O O u~u~ O O , o co r~ ~ I I I N

~7 I II I I (~')NI I I

G ~ ~.) O O (..) (~) t ) O O O O t.) t.) ~: :C ~ ~ I~ L
.

~ o o ~ o ~ ~ v o ~ ~ ~) ~ ~

~ CD CD ~D tD tD tD tD tD tD ~ U~- ~0 U~

~ 1~ ~ N~ d- U ) lD I~ t~ ~) O ~ N
Z ~t ~ ~~ ~ ~ ~ ~ ~ ~ ~) Ir) Lr _ _ __ __ = _ ~ `.

2 ~

- - - ~ : ~

~ O N . N ~ N O ~ a) ~ ~ I` I~`) _ _ _ _ U7 O 1 LU~ O O ~n OU~ O 6 O

~: I I IN N t~) _ _ _ _ a: I I I I I I I I I I :C :1:
_ _ _ _ _ __ __ c O O ~ ~ ~ O O ~ ~ O ~ ~ ~
CC ~ I` ~` r- t- ~ ~ I~ r- ~ ~ I`_ ~ _ _ _ . _ _ _ Z ~ d Ll~ tD 1~ 00 cn O ~ N ~r~ ) I _ _ _ _ _--2~9~

o _ = _ ___ E ~ E 3 n CD ~ N ~ ~ ., O ~ O ~ N N N
_ _ a: ~ u~ ~ O ,0 O u~ O O ~n O O O
. _ _ ~ N
~ _ _ _ c LL IL LL IL ll~ 1~ O," T ~ O ~ t.) V
a: ~ ~D ~C) ~O t- r- ~ I~ ~D (5) Cl:~ ~1 ~

Z ~ ~D t~ ~D 1~ r` N ~ 1` 1`~ 1~ ~ 0 2~6~8~

_ _ _ ~ 1~ 1~ N tD CO ~ O ~ _ tC~ ~ ~ 1 J) B I I ¦ O

! I I I I,~, L~ I I 1: I I I I I I I I: T
I

I _ C O O O LL C~ ~ V ~ ~ ~~ ~ ~ ~
~ tD ~D tD ~ (D ~D tD ~D t.D CD ~D tD ~D

Z 1~ O 0 N 00 co 0~ 0 CO --0 O a~

~ .

2 ~ 8 ~

In__ N _ _ _ _ =_ __ _ ~_ CU N O O ~ OD 'u~ O _ O O ';t I I I I q II u~ I q I
~ __ _ __ l ~

L ~ . D ~ ~ L~ o D L o ~ _L~

2 ~

- - - = -~ N O tDa)a:~~Dtt:~ 't N 1~ O O
_ ~N _ _ ~ I ~ C .n Z L;N~ ~
~ 8 8 8 8 88 Q 8 o 8 ~ ~
_ _ _ _ ~qt"r~~rJ",I:'J ", r) N I`J
~ I II II I I I I II
~: ~ O ~ O V ~ ~ O ~ O

u I I I I I ~ I I I
~ r _c ~ ~ ~ ~ ~ ~ V ~ t~ ~ ~ ~
G U:) C~:) tD CD CD ~S) ~D CD ~ ~:1 ~D ~
_ _ . _ _ _ . In t~:) I~ :~ o) o ~ N ~) ~ Ir) C~:) ~ O O O O ~ ~ ~_ ~ ~ _- ,_ . __ _ _ --~ _ _ I ~ ~ l a '~

_ _ _ _ _ _ a: O ~ O u~ O u~ O O O O O O

a: I I I I ~ T I

~ ~ o~

Z ~ OD ~ N C~l N N N N t~J N N N

2 ~

Key: C5Hg - 3-methyl-2-buten-1-yl C4H7 = 2-butenyl CsHl1 = 3-methyl-1-butyl C6H,1 = 2,2-dimethylcyclopropyl-1-methyl sC6H11 = 4-methyl-3-penten-2-yl C3H3 = 2-propen-1-yl (CH3)2CCHCO = 3,3-dimethylacryl IPOC = isopropenyloxycarbonyl ALAC = allylaminocarbonyl ALOC = allyloxycarbonyl C4H30 = furanyl C4H3S = thienyl CsH4N = pyridyl Ph = phenyl , 2 ~

Example XVII
6,7-Dimethoxy-3-methyl-3,4-dihydroquinoxalin-2(1 H)-one 4,5-l~imethoxy-1,2-dinitrabenzene (34.2 g, Q.15 mol) was hydrogenated in 500 ml of 5 methanol with Raney nickel catalysis using 1 atm hydrogen. After the calculated amount of hydrogen had been taken up, the process was stopped, the catalyst was removed by filtration with suction, and the solvent was stripped off in vacuo.
To remove the water completely, the mixture was taken up hNice in methanol and reconcentrated. 4,5-Dimethoxy-1,2-phenylenediamine (24.0 g), which remained as abrown oil, was refluxed for 48 hours in 200 ml of ethanol (96%) together with 17.1 ml (0.15 mol) of methyl 2-chloropropionate, with an addition of 21.0 ml (0.15 mol) of triethylamine. The solution, which was very dark, was concentrated, the concentrate was taken up in ethyl acetate, the mixture was washed twice withwater and dried (sodium sulfate), and the solvent was stripped off in vacuo.
15 The crude product was crystallized by stirring with diethyl ether (6.2 g, 19%). A
analytically pure sample of melting point 151 C was obtained by silica gel chromatography using ethyl acetate as the eluent.
H NMR (60 MHz, d6-DMSO): ~ = 1.22 (d, J = 7 Hz, 3 H), 3.63 (s, 3 H), 3.67 (s, 1 H), 3.6 - 3.7 (m, 1 H), 5.62 (br. s, 1 H), 6.40 (s, 1 H), 6.45 (s, 1H), 9.90 ppm 20 (br s, 1 H).
MS: Mt = 222 The following compounds of the formula I were synthesized in analogous manner and, if appropriate, derivatized further:

.

2 ~ 6 Table 4 H

g~
N~H
R

Nr. R1n R3 Rs X M.P. C
. _ _ 16,7-(CH30)2 CH3 IPOC O '133 26,7-(CH30)2 CH3 IPOC S
36-C6HsS CH3 C5H9 O 115 .
47-C6HsS CH3 C5Hg O 107 I _ 56-C6HsS CH3 H O
I
67-C6HsS CH3 H O
76,7(CH30)2 CH3 H O 151 Key: CsHg = 3-methyl-2-buten-1-yl IPOC = isopropenyloxycarbonyl Example XVIII
(3RS)-6-Chloro-4-N-(cyclopropyl)-3-methyl-3,4-dihydroquinoxalin-2(1 H)-one A) (2RS)-N-(4~Chloro-2-cyclopropylaminophenyl)-(2-brornopropionamide) 4-Chloro-2-cyclopropylaminonitrobenzene (2.10 9, 0.01 mol) was hydrogenated in 100 ml of methanol with Raney nickel catalysis, using 1 atm hydrogen. After the calculated amount of hydrogen had been taken up, the process was stopped, the catalyst was removed by filtration with suction, and the solvent was stripped off i 2~6~

acuo. To remove water completely, the mixture was taken up ~vice in methanol and reconcentrated 4-Chloro-2-cyclopropylaminoaniline (1.80 g), which r~mained in the form of a brown oil, was dissolved in 50 ml of anhydrous 1,2-dimethoxyethaneand cooled to -60C, with stirring. A solution of 1.1 ml (0.01 mol) of 2-bromopropionyl chloride in 5 ml of anhydrous 1,2-dime~hoxyethane was slowly added dropwise, and stirring of the reaction mixture was continued ~or 2 hours at -60 - -70C. The mixture was then allowed to warm ~o approx. -20C and poured into 150 ml of ice-cold, saturated aqueous sodium hydrogen carbonate soiution.
The mixture was extracted twice usir~g ethyl acetate, and the organic phase was washed once with water, dried (sodium sul~ale) and concentrated in vacuo. After crystallization with diethyl ether/pentane, 2.51 9 (79%) of the desired product of melting point 130C remained.
'H NMR (270 MHz, d6-DMSO): ~ = 0.4 - 0.5 (m, 2 H), 0.7 - 0.8 tm, 2 H), 1.75 (d, J = 7Hz,3H),2.39(m,1 H),4.72(q,J =7Hz,1 H),5.6(br.s,1 H),6.66(dd, J = 8, 2 Hz, 1 H), 6.96 ~d, J = 2 Hz, 1 H), 7,21 (d, J = 8 Hz, 1 H), 9.36 ppm (br.
s, 1 H).
MS: (M + H)+ = 319, 317 B) (3RS~-6-Chloro-4-N- (cyclopropyl)-3-methyl-3,4-dihydroquinoxalin-2 ~1 H)-one The compound of Example XVIIIA (318 mg, 1.0 mmol) was dissolved in 20 rnl of ethanol (96/o), 0.28 ml (2.0 mmol) of triethylamine were added, and the mixturewas reflux~d for 18 hours. The solvent was removed under reduced pressure, and the reaction product was purified by silica gei chromatography using ethyl acetate/heptane = 1 :2 as eluent. The yield was 200 mg ~85%~ of white crystals of melting point 167C (after crystallization from pentane).
1H NMR (270 MHz, d6-DMSO): ~ = 0.40 (m, 1 H~, 0.63 (m, 1 H), 0.76 (m, 1 tl), 0.98 ~m, 1 H), 1.12 (d, J = 7 Hz, 3 H), 2.47 (m, 1 H~, 3.87 ~q, J = 7 ~z, 1 H), 6.78 (s, 2 H), 7.0 (sl 1 H), 10.46 ppm (br. s, 1 H~.
MS: (M ~ H)~ = 237 2 ~

The following compounds of the formula I were synthesized analogously to the procedure described in Example XVIII using the correspondingly substituted ortho-nitroanilines and 2-halo carboxylic acid derivatives and, if appropriate, derivatized further:

Table 5 H

R 1 n~ N\I(~ R 3 R

Nr. Rln R3 R4- - R5 XM.P.C
~ I
1 6-CI CH3 H C6Hs O 191 2 6-CI CH3 CH3 ~3Hs O
_ 3 6-CI CH3 CH3 C3Hs S
. _ 4 6-CI CH3 CH3 C3Hs __ 6-CI CH3 CH3 C3Hs S

Key: C3Hs = cyclopropyl C6Hs = phenyl 92 2 ~ 5 Example XIX
7-Chloro-1-N-(cyclopropyl)-3,3-dimethyl-3,4-dihydroquinoxalin-2(1 H)-one 4-Chloro-2-cyclopropylaminonjtrobenzene (2.0 g, 9.4 mmol) was hydrogenated as described in Example XVIIIA. The resulting 4-chloro-2-cyclopropylaminoaniline (1.70 g) was taken up in 20 ml of dichloromethane. 1.~ ml (2.01 mmol) of chloroform, 1.8 ml (2.45 mmol) of acetone and 0.10 g (0.4 mmol) of benzyltriethylammoniurn chloride were added, and the reaction solution was cooled to 10C. 4 ml of 50% strength sodium hydroxide solution were slowly added dropwise with vigorous stirring, during which process the reaction temperature should not exceed ~0C. After stirring for 5 hours at 10DC, the phases were diluted and separated. The organic phase was washed once with water, dried (magnesium sulfate) and evaporated in vacuo. The crude product was purified by silica gel chromatography using ethyl acetate/heptane = 1:2 as the eluent. the yield was 1.0 g (42%) of white crystals of melting point 132-133C (after recrystallization from toluene/heptane) .
'H NMR (270 MHz, d6-DMSO): ~ = 0.45 - 0.55 (m, 2 H), 1.05 -1.1 (m, 2 H), 1.19 (s,6H),2.71(m,1H),6.09(br.s,1H),6.71(d,J=8Hz,lH),6.88(dd,J=8, 2 Hz, 1 H), 7.19 ppm (d, J = 2 Hz, 1 H).
MS: (M ~ H)~ = 251 The following compounds of the formula I were synthesized in analogous manner and, if appropriate, derivatized further:

2 ~

Table 6:

R 1 --t~ ~

1~1 R5 _ _ _ Nr. R'n R3 R4 R5 M.P.C
I _ _ 1 6-CI CH3 CH3 CsHs 179 I
L~ 7-CI CH3 CH3 CsHs 171 3 6,7-(CH30)2 CH3 CH3 H
4 6,7-(CH3O)2 CH3 CH3 CsHs _ CH3 CH3 SC6H1l 113 __ ~ C6Hs CH3 H .
7 C~Hs CH3 C5H9 _ 9 7-CI C:;H3 CH3 IPOC 169 _ _ , _ 7-~H3 CH3 CH3 CsH~ 168 . , _ . _ _ 2~ 12 6-CH3C) CH, CH~, _ 138 13 6/7-COOH CH3 CH3 H > 240 2 ~

- ._ Nr. R' R3 R4 Rs M.P. ~C
14 6/7-COOH CH3 CH3 CsH9 180 . .

16 ~-CH3 CH3 CH3 CsHs 160 18 6/7-CH3 C2Hs C2Hs H 160 _ 19 6-CH3 C2Hs C2Hs CsHs 100 ~ _ _ ._ 7-CH3 C2Hs C2Hs CsHs 110 _ 22 7-F CH3 CH3 CsHg 155 23 7-C2tlsO CH3 CH3 H i55 _ 24 7-C2HsO CH3 CH3 CsHs 123 6-COOH CH3 CH3 GsHs 245 _ 26 7,8-(CH3)2 CH3 CH3 H 196 I _ _ _ 27 7,8-(CH3)2 CH3 CH3 CsHs 155 I
28 6,7-(CH3)2 CH3 CH3 H 248 I
29 6,7-(CH3)2 CH3 ~ 3 G5Hg 200 _ _ _ _ 6-CI,7- CH3 C:H3 H 211 (2,3-CI2C6H30) _ .
31 6-CI,7- C:H3 CH3 C5Hg 205 (2~3-cl2c6H3o) _ , .

I _ . _ 33 7-C2H,O CH CH3 IPOC 150 2 ~
~5 Nr.Rln R3 R4 Rs M.P. C

357,8-(CH3)2 CH3 CH3 IPOC 147 _ 366,7-(CH3)2 CH3 CH3 IPOC 161 377-C6H5 CH~ CH~ ~ H 167 ¦ 387-C6H50 CH3 CH3 C5Hg 138 I
¦ 416-CH30, CH3 CH3 H > 240 7-(4-Pyridyl) 426-CI, CH3 CH3 219 7-Piperidino .
l 436/7-CI,7/6- CH3 CH3 H 236 Morpholino (mixture) 446/7-(N-Methyl- CH3 CH3 H > 240 l piperazin-1 -yl) I
456/7-CI,7/6- CH3 CH3 H 147 (N-Methyl-piperazin- 1 -yl) _ L~ 7-CI CH3 CH3 _ ¦ 48 6-CICH3 CH3 ALOC 128-129 I _ Nr. R' R3 - R4 Rs M.P. C
sO 6-CI CHD CH3 COOCH(CH3)2 118 51 7-CI CH3 CH3 COOCH(CH3)2 171 52 7-(4-F-Ph-SO20) CH3 ~H3 H
._ _ 537-(4-F-Ph-S02C)) CH3 CH3 IPOC 204 _ 546-CI,7-Piperidino CH3 CH3 IPOC 152 6-CI,7- CH3 CH3 IPOC 11 3 Morpholino _ 56 6-CI,7-(N- CH3 CH3 IPOC 168 Methyl-piperazin-1 -yl) ~
~57 6-CI,7-NEt2 CH3 CH3 141 58 6-CI,7-NEt2 CH3 CH, IPOC C)il 10 59 6,7-CI2 CH3 CH3 H 232 6,7-CI2 CH3 CH3 IPOC 171 :
61 7-(N-Methyl- CH3 CH3 H 198 piperazinyl-1 -yl) 62 7-(N-Methyl- CH3 CH3 IPOC 123 piperazinyl-1 -yl) _ _ 63 6-C;H30 CH3Ctl3 IPOC 128 ~ __ - ___ . .. - --. _ ., _ 15 1~ 7-CI -(CH2)3- IPOC 172 7-CI -(CH2)~,- iPOC 181 66 6-CI -(CH2~3- IPOC 157-158 I
67 6-CI - (CH2)4- I POC 179- 180 2 ~ 3 5 _ __ Nr. R' R3 R4 Rs M.P. CC ¦
_ _ I
68 6-Clq CH3 CH3 cOOC2H5 137 I _ ~ _ Key: c5~3 = 3-methyl-2-buten-1-yl sC6H'1 = 4-methyl-3-penten-2-yl IPOC = isopropenyioxycarbonyl Example XX
3,3-Dimethyl-4-N-(3-methyl-2-buten-1-yl)-3,4-dihydroquinoxalin-2(1 H)-one The compound was prepared analogously to the compound described in Example VIA, starting from 3,3-dimethyl-3,4-dihydroquinoxalin-2(1H~-one (J. T. Lai, Synthesis 1982, 71). Melting point 146-147C (after crystallization ~rom methyl tert.-butyl 1 5 ether/heptane) 'H NMR (270 MHz, d6-DMSO): ~ = 1.27 (s, 3 H), 1.68 (s, 3 H), 1.72 (s, 3 I l), 3.88 (d, J = 7 Hz, 1 H), 5.15 (m, 1 H), 6.60 td, J = 7 Hz, 1 H), 6.67 (t, J = 7 H2l 1 H), 6.78 (d, J = 7 Hz, 1 H), 6.87 (t, J = 7 Hz, 1 tl), 1û.33 ppm (br. s, 1 H).
MS: (M + H)' = 245 Example XXI
4-N-(3-Methyl-2-buten-1 -yl)-3,4-dihydroquinoxalin-2(1 H)-one-3-spiro-1 '-cyclohexane The compouncl was prepared analogously to the compound described in Example VIA, starting from spiroEcyclohexane-1,3'-(3',4'-dihydroquinoxalin-(1'H)-one)] (J. T.
Lai, Synthesis 1982, 71). Melting point 82-83C ~a~ter crystallization from h~ptane) H NMR (270 MHz, d6-DMSO): ~ = 1.25~1.75 (rn, 1D H~, 3.75 (d, J = 6 tlz, 2 H), 5.07 (m, 1 H), 6.7 - 7.U (m, 4 H), 10.15 pprn (br. s, 1 H).
MS: (M + H)t = 285 2 ~ 5 Example X)(ll 4-N-(3-Methyl-2-buten-1-yl)-3,4-dihydroquinoxaline-2(1 H)-thione-3-spiro-1 '-cyclohexane 5 The compound of Example XXI (50~ mg, 1.~ mmol) was refluxed for 1.5 hours under argon together with 370 mg (0.9 mmol3 of ~,4-bis-(4-methoxyphenyl)-1~3-dithia-2~4-diphosphetane 2,~-disulfide (Lawesson~s reagent) in 10 ml of anhydrous toluene. The mixture was subsequently ~oncentrated in vacuo, and the products were isolated by silica gel chrornatography using methyl tert.-butyl ether/heptane = 10:1 as eluent. The yield was 50 mg (9%) of yellow crystals of melting point 125C.
'H NMR (270 MHz, d6-DMSO): ~ = 1.1 1.9 ~m, 16 H), 3.64 (d, J = 7 Hz, 2 H), 4.99 (m, 1 H), 6.95 - 7.1 (m, 3 H), 7.18 (d, J = 7 H~, 1 H), 12.2 ppm (br. s, 1 H).
MS: (M + H)+ = 301 3,4-Dihydroquinoxaline-2(1H)-thione-3-spiro-1'-cyclohexane was isolated as a further product in a yield of 110 mg (26%); yellow crystals of melting point 178C.
~H NMR (270 MHz, cDC13 ~ = 1.25 - 2.2 (m, 10 H), 4.18 (br. s, 1 H), 6.7 - 6.8 (m, 3 H), 6.97 (m, 1 H~, 9.42 ppm (br. s, 1 H).
MS: (M + H)~ = 233.

Example XXIII
(3S)-6-Chloro-4-N- (isopropenyloxycarbonyl)-3-methyl-3,4-dihydroquinoxaline-2(1 H)-thione The cornpound of Example Xlll (0.5 ~, 1.78 mmol), dissolved in îO ml of anhydrous pyridine, was refluxed for 4 hours together with 0.47 g ~2.12 mmol) of phosphorus pentasulfide. The mixture was concentrated in vacuo, and lhe residue was chromatographed on silica gel using ethyl acetate/heptane = 1:1 2S eluent. This gave 0.25 g (47%) of a yellow crystalline solid of rnelting point 148-150C (after recrystallization from ethyl acetate/heptane).

2 ~

H NMR (270 MHz, d6-DMSO): ~ = 1.24 (d, J = 7 Hz, 3 H), 1.96 (s, 3 H), 4.8 - 4.9 (m,2H),5.28(q,J=7Hz,1H),7.22(d,J=8Hz,1H),7.30(dd,J=8,2Hz, 1 H), 7.72 (br. s, 1 H), 12.84 ppm (br. s, 1 H).
MS: (M + H)~ = 297.

The following compounds of the formula I were ~ynthesized in analogous rnanner ~rom the corresponding 3,4-dihydroquinoxalin-2(1H)-ones:

Table 7 H
I

R ~ ~ -- R 3 .
Nr. R'n R3 R4 Rs M.P.C
1 CH3 H C5Hg 119 2 6-CI CH3 H CsHg 109- 110 _ .

. _ .. . , . _ _ 6 C6Hs CH3C5H~
_ _ 7 6-CI CH3 CH3CsH5 157 _ 8 7-CI CH3 CH3C5Hg 160 _ .

2~6~9~

~oo _ _ I
12 7-CI CH3 CH3 IPOC 174 l _ I
l 14 6-CI C2Hs H IPOC 176-1.77 6-CI C2Hs H ALOC 159-161 l I
166,7-(CH3)2 CH3 CH3 CsH9 173 17 6-CI C3H7 H IPOC 154-1~5 l _ ~ I

_ l 19 6-CI CH3 (2-csH4N)-cH2 175-178 6-CI CH3 H (3-C5H4N)-CH2 77 I _ 22 6-CI CH3 CH3 COOCH(CH3)2 151 l 23 6-CI CH2SCH3 H IPOC 128 l 24 6-CI H3 CH3 COOC2Hs 163 l 25 6-CI CH3 CH3 COOC3H7 164 l _ .
26 6-CI C2Hs H (2-csH4N)-cH2 162-164 27 6-CI C4Hg H IPOC 132 I _ ~ _ l 28 6-CI CH2SCH3 HCOOCH(Ctl3)2 124 l 29 6-CI CH2SCH3 J (2-csH4N)-cH2 1~9 I .
¦ 30 6-CH30 CH2S~H3 H IPOC _ 31 6-CH30 CH2SCH3 HCOC)CH(CH3)2 163 2 ~

, r-32 6-CI ¦ CH2SCH3 H ¦ C~H2C6H4-2-CI __=

Key; CsHg = 3-methyl-2-buten-1-yl IPOC = isopropenyloxycarbsnyl 5ALOC = allyloxycarbonyl CsH4N = pyridyl Example X)(IV
(3RS)-3-Methyl-4-N-(3-methyl-2-buten-1-yl)-2-methylthio-3,4-dihydroquinoxaline (3RS)-3-Methyl-4-N-(3-methyl-2-buten-1-yl)-3,4-dihydroquinoxaline-2(1 H)-thione (Table 7, No. 1) (0.49 g, 2.0 mmol) was dissolved in 20 ml of ethanol (96%), andthe solution was treated with 5.1 ml (2.2 rnmol) of a 1% strength sodium ethanolate 1~ solution. After the mixture had been stirred for 15 minutes at room temperature, û.14 ml (2.2 mmol) of methyl iodide was added dropwise, and the mixture was stirred for a further 2 hours at room temperature. The reaction solution was concentrated, and the residue was chromatographed on silica gel. 500 mg (96%) ofa yellow oil were isolated using ethyl acetate/heptane ~ 1:6.
1H NMR d6-DMSO): ~ = 0.96 (d, J = 7 Hz, 3 H), 1.72 (s, 6 H), 2.44 (s, 3 H), 3.71(dd, J = 15, 6 Hz, 1 H), 3.89 (dd, J = 15, 6 Hz, 1 H), 4.00 (q, J = 7 llz, 1 H), 5.20 (m, 1 H), 6.65 - 6.75 (m, 2 H), 7.02 (t, J = B Hz, 1 H), 7.11 ppm (d, J = 8 Hz, 1 H).
MS: (M ~ H)~ - 261 The following compound of the formula i was synthesized in the same manner:

4-lsopropenyloxycarbonyl-2-(isopropenylOXyCarbOnyl)-thiO-3,~,7,8-tetramethyl-3,4-dihydroquinoxaline.
Melting point: 11~C

2~6~

Example XXV
~3Rs)-3-Methyl-4-N-(3-methyl-2-buten-l-yl)-3l4-dihydroquinoxalirl-2(1 H)-one (3RS)-3-Methyl-3,4-dihydroquinoxalin-2(1~)-on0 (4.86 g, 0.03 mol) dissolved in 50 ml of N,N-dimethylformamide was alkylated with 4.2 ml ~0.033 mol) of 3-methyl2-buten-1-yl bromide (90%) in the presence of 4.60 9 (0.033 mol) of pulverulent potassium carbonate. The reaction mixture was stirred at room temperature until reaction of the educt was complete. The solvent was th~n stripped off in vacuo, the residue was taken up in ethyl acetate and water, the phases were separated, the aqueous phase was extracted twioe with ethyl acetate, and the combined organic extracts were washed twice with water. Dryin~ over sodium sulfa~e, concentration in vacuo and crystatlization from pentane gave 5.80 9 (84%) of white crystalline product of melting point 92-93C.
lH NMR (270 MHz, d6-DMSO): ~ = 0.99 (d, J = 7 Hz, 3 H), 1.72 (s, 6 H), 3.67 (dd,J = 15, 7 Hz, 1 H), 3.86 (q, J = 7 Hz, 1 H), 3.88 (dd, J = t5, 7 Hz, 1 H), 5.21 (m, 1 H), 6.65 - 6.9 (m, 4 H), 10.31 ppm (br. s, 1 H).
MS: (M + H)+ = 231 Example XXVI
3,3a-Dihydropyrrolo[1,2-a]quinoxaline-1,4(2H,5H)-dione 2-Fluoronitrobenzene (14.1 9, 0.1 mol) and L-glutamic acid (45.0 9, 0.3 mol) were heated in 100 ml of 2-rnethoxyethanol at 95C, with stirring, and 300 ml of 2N
sodium hydroxide solution were added dropwise. Stirring was then continued for 25 another 3 hours at this temperature. After cooling, the solution was treated with 400 ml of methanol and hydrogenated under atmospheric pressure with Raney nickel as catalyst.
When the uptake of hydrogen had ended, the catalyst was removed by filtration with suction, and the solution was concentrated under reduced pressure.
30 The residue was acidified with 250 ml of 2N hydrochloric acid and heatecl in a steam bath for approx. 30 minutes. The precipitate which resulted in this process 2~6~8~

was filtered off with suction, washed with water and alcohol and subsequently dried, melting point 255C, decomposition.
'H NMR (60 MHz, d6-DMSO): ~ = 1.9 - 2.7 ~m, 4 H), 4.5 (t, J = 8 Hz, 1 H~, 6.8 - 7.3 (m, 3 H), 7.8 - 8.2 (m, 1 H), 10.7 ppm (br. s, 1 H).
MS: (M + H)+ = 202 Example XXVII
7-Phenoxysulfonyl-3,3a-dihydropyrrolo[1 ,2-a~iquinoxaline-1 ,4~2H,5H~-dione The compound was obtained in analo~ous manner by r0acting phenyl 4-chloro 3-nitrobenzenesulfonate with L-glutamic acid, melting point 140C: (decomp.).
1H NMR (60 MHz, d6-DMSO): ~ = 1.6 - 2.5 (m, 4 H), 4.07 (t, J = 6 Hz, 1 H), 6.7 - 7.6 (m, 8 H), 10.57 ppm (br. s, 1 H).
MS: (M + H)~ = 358 Example XXVIII
3-Carboxymethyl-3,4-dihydroquinoxalin-2(1 H)-one 2-Fluoronitrobenzene (14.1 g, 0.1 mol) and L-aspartic acid (40.0 g, 0.3 mol) were heated to 95C in 100 ml of 2-rnethoxyethanol, with stirring, and 300 rnl of 2N
sodium hydroxide solution were added dropwise. Stirring was then continued for 1hour at this temperature. After the solution had cooled, it was treated with 500 ml of methanol and hydrogenated under atmospheric pressure with Raney nickel as catalyst.
When the uptake of hydrogen had ended, the catalyst was removed by filtration with suction, and the solution was concentrated under reduced pressure.
The residue was acidified with 500 ml of 2N hydrochloric acid, the mixture was subsequently concentrated, neutralized with sodium acetate anci extracted with ethyl acetate. The mixture was dried with sodium suifate, the solvent was stripped off, and the residue was then obtained which was first oily and crystailized upon stirring with water, melting point 152-154t::.

2~6~

'H NMR (60 MHz, d6-DMSO): ~ = 2.5 - 2.7 (dd partly concealed, 2 H), 4.1 (td, J = 6, 2 Hz, 1 H), 5.98 (br. s, 1 H), 6.5 - 6.9 (m, 4 H), 10.30 (br. s, 1 H), 12.37 ppm (br. s, 1 H).
MS: M+ = 206 CHN analysis: calculated C 58.2; H 4.8; N 13.6%
found C 58.4; H 4.7; N 13.7%

Example X)(IX
7-Phenoxysulfonyl-3,4-dihydroquinoxalin-2(1H) one A) Methyl N- [ (2-nitro-4-phenoxysulfonyl)phenyl] glycinate Phenyl 4-chloro-3-nitrobenzenesulfonate (62.7 g, 0.2 mol) and methyl glyeinate hydrochloride (100.4 g, 0.8 mol), dissolved in 250 ml of methanol, were treated with 200 ml of triethylamine, and the mixture was refluxed for 15 minutes. After cooling, the mixture was treated with 1 1 of 2N acetic acid, subjected to filtration with suction and washed with water. The residue was recrystallized from ethyl acetate and washed with methanol and diisopropyl ether, melting point 120-123C.

B) 7-Phenoxysulfonyl-3,4-dihydroquinoxalin-2(1 H)-one Methyl N-[(2-nitro-4-phenoxysulfonyl)phenyl]glycinate (36.6 9, 0.1 mol) was hydrogenated under atmospheric pressure in a mixture of 250 ml of N,N-dimethylformamide and 250 ml of methanol, with Raney nickel as catalyst.
When the uptake of hydrogen had ended, the catalyst was removed by filtration with suction, and the solution was freed from solvent in vacuo. The residue was dissolved in 40 rnl of 2-methoxyethanol, and the mixture was hea~ed ior one hour in a steam bath. The resulting precipitate was filtered off with s~ction and washeel with methanol, melting point 253-254C.
'H NMR (60 MHz, d6-DMSO): g = 4.0 (d, J = 4 Hz, 2 H), 6.6 - 7.6 (m, 9 H), 10.43 ppm (br. s, 1 H).
MS: (M ~ H)+ = 305 2 ~

Example XXX
4-(3-Methyl-2-buten-1-yl)-7-phenoxysul~onyl-3,Wihydroquinoxalin-2(1 H)-one 7-Phenoxysulfonyl-3,4-dihydroquinoxalin-2(1H)-one (1.52 g, 5.0 mmol) in 20 ml ofN,N-dimethylacetamjde was stirred for 8 hours at 100~C with 2 ml of 3-methyl-2-buten-1-yl bromide. After cooling, the mixture was treated with water and extracted with ethyl acetate. The solution was dried using magnesium sulfate andthen concentrated, and the residue was chromatographed over a silica gel column using ethyl acetate/heptane = 1:~. The fractions which contained th~ substance were evaporated on a rotary evaporator, and the product was subsequently stirredwith pentane and filtered off with suction, melting point 132~
H NMR (270 MHz, d6-DMSO): ~ = 1.73 (s, 6 H), 3.90 (s, 2 H), 3.93 (partly concealed d, J = 6 Hz, 2 H), 5.20 (br. t, J = 6 Hz, 1 H), 6.75 - 7.45 (m, 8 H), 10.66 ppm (s, 1 H).
MS: (M + H)~ = 373 The following compounds of the formula I were synthesized in analogous rnanner using the corresponding haloaromatic substances and amino acid derivatives and, if appropriate, derivatized further on nitrogen atom 4:

2~$~

Table 8 H
I

R n~ ~R 3 . . I
Nr. R1n R3 R4 Rs M.P.C l _ . I
1 7-C6H5-O-SO2 H CH2OH H 199 ¦
_ I
7-C6H5-O-SO2 H CH2OH CsHs 120 decomp. l . _ I
4 7-C6Hs-o-so2 H CH2COOH CsHs _ _ _ _ 7-C6H5-O-sO2 H CH2CONH2 H 272 decomp.
_ 7-C6Hs-O-sO2 H CH2CONH2 C5Hg 7 7-C6H5-O-sO2 H CH2-4-lmi H 216 decomp.
_ _ . , .
8 7-C6H5-O-sO2 H Ctl2-4-lmi C5H,~
_ ._ decomp.
_ ..

decomp _ _ I
11 7-C6H5-C)-sO2 H CH3 _ 148 .. - : .

2 ~

_ Nr.R1n R' R4 Rs M.P. C
127-C6H5-O-sO2 H CH3 CsHg Oil _ _ I
137-C6Hs~S02 H CH3 H 1 9E~
_ _ 147-C6Hs~SO2 H CH3 CsHs Oil 157-C6Hs-sO2 H ~H3 IPOC 108 _ _ 167-C6Hso-so2 H H H
I _ _ .
177-C~HsSO2 H H COCH3 270 ~ _ 187-C6H5-OSO2 H CH3 IPOC Resin Key: CsHg = 3-methyl-2-buten-1-yl 4-lmi = 4-imidazolyl IPC)C = isopropenyloxycarbonyl Example XXXI
6-Chloro-7-phenoxysulfonyl-1,2,3,3a-tetrahydropyrrolo[2,1-c]-quinoxalin-4(5H)-one A) Phenyl 2,4-dichloro-3-nitrobenzenesulfonate 2,6-Dichloronitrobenzene was stirred for 7 hours at 130C with an excess of 20 chlorosulfonic acid. After cooling, the mixture was poured onto ice, the sulfochloride was filtered off with suction, washeci to neutrality and dried over sodium hydroxide, melting point 91 C. The resulting sulfochlsride ~29.05 g, 0.1 mol) and phenol (11.5 g, 0.12 mol) were dissol~ed in 150 ml of acetone and treated with 14 ml of triethylamine at 10C. The mixture was stirred for 1 hour with 25 cooling, stirring was then continued for a further 4 hours at room temperature, the mixture was then treated with 200 mi of water, the resultin~ precipitate was filtered off with suction at 10C, washed with water and dried in vacuo at 80 :;, melting point 102C.

:

:

2 ~

B) N-[(3-Chloro-2-nitro-4-phenoxysulfonyl)phenyl]proline Phenyl 2,4-dichloro-3-nitrobenzenesulfonate (34.8 g, 0.1 mol), 69.0 g (0.6 mol) of L-proline, 200 ml of 2N sodium hydroxide solution and 200 ml of 2-methoxyethanolwere stirred for 10 minutes at 80C. The clear solution was acidified at 50C using concentrated hydrochloric acid and poured onto ice. The precipitate was filtered off with suction, washed with water to neutrality and ~ried at 80C. Melting point 148C (after recrystallization from methanol) C) 6-Chloro-7-phenoxysulfonyl-1 ,2,3,3a-tetrahydropyrrolo[2, 1 -c]-quinoxalin-4 (5H)-one N-[(3-Chloro-2-nitro-4-phenoxysulfonyl)phenyl]proline (38.0 9, 0.075 mol) in 500 ml of methanol and 25 ml of concentrated ammonia solution was hydrogenated under atmospheric pressure with Raney nickel as catalyst.
When the uptake of hydrogen had ended, the catalyst was removed by filtration with suction, the solution was concentrated, the residue together with 2N
hydrochloric acid was heated for approximately 30 minutes in a steam bath, cooled, subjected to filtration with suction and washed with water to neutrality. Melting point 197C (after recrystallization from glacial acetic acid) Example X~O(II
8-(4-Methyl-1 -piperazinyl)-3-(2-methylpropyl)-5-phenoxysulfonyl-3,4-dihydroquinoxalin-2(1 tl)-one A) Phenyl 2-chloro-4-(4-methyl-1-piperazinyl)-3-nitrobenzenesulfonate Phenyl 2,4~dichloro-3-nitrobenzenesulfonate (17.4 9, 0.05 mol) and 25 ml of rnethylpiperazine in 100 ml of isopropanol were refluxed for 10 minutes and subsequently concentrated. The residue was stirred with 50 mi of 50% methanol, filtered off with suction, and washed with 50% methanol and finally with water.
Melting point 94-95C (after recrystallization from cyclohexane) 2~3~5~

B) N-[(3-(4-Methyl-1-piperazinyl)-2-nitro-~-phenoxysuifonyl)-phenyl]leucine hydrochloride Phenyl 2-chloro-4-(4-methyl-1-piperazinyl)-3-nitrobenzenesulfonate t41.1 g, û.1 mol) and L-leucine (39.3 g, 0.3 mol) were stirred for 8 hours at 95C in a mixture of100 ml of N,N-dimethylformamide, 50 ml of 2-methoxyethanol and 100 ml of 2N
sodium hydroxide sslution. When cold, the reaction mixture was acidified with concentrated hydrochloric acid. The precipitate was taken up in ethyl acetate, and the mixture was dried using sodium sulfate and freed from solvent in vacuo. Thisgave an orange oil.

C) 8-(4-Methyl-1-piperæinyl)-3-(2-methylpropyl)-~-phenoxysulfonyl-3,4-dihydroquinoxalin-2(1H)-one hydrochloride N-[(3-(4-Methyl-1-piperazinyl)-2-nitro-6-phenoxysulfonyl)-phenyl]leucine hydrochloride (25.3 g, 0.05 mol) in 250 ml of methanol and 25 ml of glacial acetic acid was hydrogenated under atmospheric pressure using Raney nickel as catalyst.When the uptake of hydrogen had ended, the ca~alyst was removed by filtration with suction, the solution was concentrated, and the residue together with 2N ofhydrochloric acid was heated for approximately 10 minutes in a steam bath and then concentrated in vacuo. The residue was dissolved in water, the mixture was rendered alkaline using ammonia, and this was taken up in ethyl acetate. The oilwhich remained after concentration was dissolved in 400 ml ~f diisopropyl ether,and the mixture was rendered neutral using ethanolic hydrochloric acid. The ~5 precipitate was filtered off with suction, washed with diisopropyl ether and dried, melting point 90~C and above (decomp.).
MS: M+ = ~58 The following compounds of the forrnula I were synthesized in analogous manner using the corresponding haloaromatic substances and amino acid derivatives and, if appropriate, derivatized ~urther on nitrogen atorn 4:

2 ~ g ~

Table 9 l H3 ~N H

~0~
¦ Nr. R3 R4 Rs M.P. C
¦ 1 H (CH3)2CHCH2CsHs l _ , ~ H GH3 H (HCI) ¦ 3 tl CH3 C5Hg I _ ¦ 4 H H H 126- 127 (base) I _ H H C5Hg Key: C5Hg = 3-methyl-2-buten-1-yl Example XXXlil (3RS)-4-N-Cyclohexyl-3-rnethyl-3,4-dihydroquinoxalin-2(H)-one (3RS)-3-Methyl-3,4-dihydroquinox31in-2(1H)-one (0.81 9, 0.005 mol) and 1 ml (0.1 mol) of cyclohexanone were introduced into 20 ml vf 1,2-dichioroethans.
Trifluoroacetic acid (1.9 ml, 0.025 mol) was addsd dropwise, during which process a clear solution formed with gentle heating. 2.1 g (0.01 mol) of sodium triacetoxyborohydride were added, the exothermic reaction was then allowed to -:

2~65~5 proceed for 30 minutes with stirring, and quenching was then effected by adding saturated aqueous sodium hydrogen carbonate solution. The phases were separated, the organic phase was washed with saturated aqueous sodium chloride solution, dried (magnesium sulfate) and concentrated. The crude product was chromatographed on silica gel using ethyl acetate/heptane = 1:1. 1.15 g (94%) ofthe d~sired product were obtained, melting point 131-132~C (toluene/heptane).
'H NMR (270 MHz, d6-DMSO): ~ = 0~97 (d, J = 7 Hz, 3 H), 1.0 - 2.0 (m, 10 H), 3 39 (m, 1 H), 3.91 (q, J = 7 Hz, 1 H), 6.68 - 6.94 (rn, 4 H), 10.27 ppm (br. s, 1 H).
MS: (M + H)t = 245.
The following compounds of the formula I were synthesized in analogous manner.

Table lQ
H

R n~

_ _ I
Nr. Rln R3 R4 R5 M.P. C
I _ _ 1 CH3 H C2Hs 106 -1 07 I _ _ 2 CH3 H CH2C(CH3)3 162 . .
3 CH3 H c-C5~19 120 . _ 4 6-CI CH3 H c-~4H7 100 _ 6-CI CH3 H CsH,1 94 - 95 ~, .

112 2~59 _ Nr. R'n R3 R4 M.P.C
6 6-CI CH3 H CH2C(CH3)3 158- 160 _ 7 6-CI C2Hs H CH2C(CH3)3 158 -1 59 8 6-CI CH3 H CH =CH(:~HO 140 -146 L~ 6-CI CH3 H CH2C--CH3 166-168 6-CI CH3 H 2-Picolyl 198 -199 I _ 11 6-CI CH3 H 3-Picolyl 136 I
12 6-CI CH3 H 4-Picolyl 19t - 193 _ 13 6-CI CH3 H Furanyl-2-methyl 116- 118 14 6-CI CH3 H CH2C6H4 4-Rr 149 - 150 I
¦ 17 6-CI CH3 H CH2C6H4-3-NO2 125 I
¦ 18 6-CI CH3 H CH2C6Hq-2-NO2 153- 154 I
¦ 19 6-CI CH3 H CH2C6H4-4-CI 122 - 1~3 I . _ L~ 6-CI CH3 H CH2C6H4-3-CI 156 - 157 L~ 6-CI CH3 H CH2C6H4-2-CI 138 ¦ 22 6-CI CH3 ll CH2C6H4~-F 147 I _ ¦ 23 6-CI CH3 H CH2C6H4-4-C6H5 164-165 I _ ~ 6-CI CH3 H C;H2C6H4-4-OC6Hs il _ _ _ 26 6-CI CH3 11 CH2C6H4-4-COC)CH3 139 _ _ 27 6-CI CH3 H CH2C6H3-2,~-Cl2 190-191 2 ~ a _ _ _ ¦~ ~ R1n R3 R4 Rs M.P. C .
l _ . I
28 6-CI CH3 H CH2C6H3-3,5-Cl2 139-140 I
29 6-CI CH3 H Naphthyl-1 -methyi 164-166 I _ 6-CI CH3 H Naphthyl-2-methyl 161-164 _ 32 6-CI CH3 H Cyclohex-2-enyl Oil _ _ .
34 6-CI CH3 H Thienyl-3-rnethyl 141-142 6-CI CH3 H (5-Methyl~hienyl)- 58-60 2-methyl 36 6-CI CH3 H (3-Methylthienyl)-2- 124 methyl l _ 37 6-CI CH3 H Thienyl-2-methyl 121-123 I
~8 6-CI CH3 H CH2CH = CH-~6H5 _ I _ 6-CI CH2SCH3 H CH2C6tl4-2-NO2 134 _ 41 6-CI CH2SCH3 H 2-Picolyl Oil 42 6-CI CH2SCH3 H CH2C6H3-2,4-cL2 t43 _ _ _ 43 6-CI CH2S-i. Pr H CH2C6H3-2,4-Cl2 Oil _ 44 6-CI CH2S-Bn H Cff2C6H3-2,4-Cl2 Oil _ 6-CI CH2-S-H H CH2C6H3-2,4-Cl2 ¦__~ _~ . T-- . .. ...
46 6-CI C2H5 H 2-PiCQiyl 160-162 I _ .
1~_ 6-CI CH3 H (6-CH3)2-Picolyl 158 2 ~ 8 ~

Key: CsH11 = 3-methyl-1-butyl c-C4H7 = cyclobutyl c-CsH9 = cyclopentyl Example X)O~IV

(3RS~-3-Methyl-4-N-(3-oxo-1-butyl)-3,4-~ihydroquinoxalin-2(1 H)-one 3-Methyl-3,4-dihydroquinoxalin-2(1H)-one (0.5 y, 3.1 mmol) together with 0.35 ml(4.3 mmol) of methyl vinyl ketone and a catalytic amount of triethylamine were stirred for 20 hours at room temperature in 20 ml of anhydrous ethanol. Silica gel chromatography with methyl tert.-butyl ether/heptane = 2:1 gave 620 mg (87%) of the desired product, melting point 108-109~C (rnethyl tert.-butyl ether/heptane).
t5 1H NMR ~270 MHz, d6-DMSO): ~ = 1.03 (d, J = 7 Hz, 3 H), 2.11 (s, 3H), 2.77 (t, J=6Hz,2H),3.30(m,1H),3.50(m,1H),3.88(q,J=7Hz,1H),6.68(m, 1 H), 6.78 (m, 1 H), 6.88 (m, 1 H), 10.31 ppm (br. s, 1 H).
MS: (M + H)~ = 233, M~ = 232 Example XXXV
(3S)-6-Chloro-4-N-chlorocarbonyl-3-methyl-3,4-dihydroquinoxalin-2(1 H)-one The compound of Example IB (2.0 g, 0.01 mol~ in 100 ml of anhydrous toluene was heated with bis-(trichloromethyl) carbonate (triphosgene) (1.5 g, 0.005 mol) for 1 hour at 80C in the presence of 2 ml (0.û14 mol) of triethylamine. After cooling, the mixture was washed with water and saturated aqueous sodium chloride solu~ion and dried (magnesium sulfate), and the solvent was removed under reduced pressure. The residue (2.5 g) crystalli~ed after stirring with heptane, its purity being sufficient for preparative purposes. A sample of analytical purity was obtained by silica gel chromatography using ethyl acetate/heptane = 1:1 as eluent. Melting point 142-144C.

2 ~

'H NMR (270 MHz, d5-DMSO): ~ = 1.25 (d, J = 7 Hz, 3 H), 3.83 (q, J = 7 Hz, 1 H), 6.61 (dd, J = 6, 2 Hz, 1 H~, 6.70 (s, 2H), 10.3 ppm (br. s, 1 H).
MS: (M + H)+ = ~59 5 Example X)O~VI

(3S)-6-Chloro4-N-(2-methoxyethoxycarbonyl)-3-methyl-3,4-dihydroquinoxalin-2(1 H)-one 1Q To a solution of 0.24 ml (3.0 mmol) of 2-methoxyethanol in 10 ml of anhydrous 1,2-dimethoxyethane there was added 0.16 ~ of a 55% suspension of sodium hydride in mineral oil, and the reaction mixture was stirred for 30 minutes at room temperature. 0.50 g (1.9 mmol) of the compound of Example XXXV was subsequently added, with ice-cooling, and the mixture was allowed to warm to 15 room temperature and stirred for a further 30 rninutes. The mixture was treated with saturated aqueous sodium chloride solution, extracted several times wi~h ethyl acetate, the organic phase was washed once with saturated aqueous sodium chloride solution and dried (magnesium sulfate), and the solvent was removed in vacuo. After silica gel chromatography (ethyl acetate/heptane = 1:1) and crystallization from ether/heptane, 0.29 9 (51%) of the desired product was obtained, melting point 93-94C.
'H NMR (200 MHz, d6-DMSO): ~ = 1.13 (d, J = 7.5 Hz, 3 H), 3.32 (s, 3 H), 3.6 (m,2H), 4.24 (m, 1 H), 4.35 (m, 1 H), 4.81 (q, J = 7.5 Hz, 1 H), 6.98 (d, J = 9 Hz,1 H), 7.2 (dd, J = 9, 3 Hz, 1 H), 7.66 (d, J = 3 Hz, 1 H, 10.81 ppm (br. 2, 1 H).
MS: (M + H)+ = 299 Example XXXVII

(3S)-6-Chloro-3-methyl-4-N-[(phenylthio)carbonyl)l-3,4-dihydroquinoxalin-2(1 H)-one To a solution of 0.31 ml (3.0 mmol) of thiophenol in 10 ml of 1,2-dimethoxyethane there was added û.17 g of a 55% suspension of sodium hydride in mineral oil, with 116 20~985 ice-cooling, and the mixture was stirred for 1 hour at room temperature. 0.5 g (1.9 mmol) of the compound of Example XXXV were introduced, again with ice-cooling, and stirring was then continued for 2 hours at room temperature. For working-up, the mixture was treated with saturated aqu~ous sodium chloride 5 solution, extracted twice with ethyl acetate and dried (sodium sulfate), and the solvent was stripped off. The solid residue was recrystallized frorn heptane/isopropanol, 0.35 g (35%), melting point 194-195C.
H NMR (200 MHz, d6-DMSO): ~ = 1.10 (d, J = 7 Hz, 3 H), 4.93 (q, J = 7 Wz, 1H),7.08(d,J=9Hz,1H),7.33(dd,J=9,3Hz,1H),7.4-78.6(m,5H),7.78 (d, J = 3 Hz, 1 H), 10.16 ppm (br. s, 1 H).
MS: (M + H)' = 333, (M - C~H5SH + H)' 223 The following compounds of the formula I were synthesized in analogous manner.

15 Table 11 H
I

R n~ J~R 3 . _ Nr. R1n R3 ~4 Rs M.P. C
. _ 1 6-CI CH3 H COOCH2CH = CHCH3 1 16-1 17 2 6-CI ~H3 H COOCH2= C(CH3)2 87-89 _ . . _ I _ _ L~ 6-CI CH3 H COOCH2G ~ CCH3 135 2 ~

_. .
R~ n _ R4 Rs M . P. C
S 6-CI CH3 H COSCH2C6Hs 158 6 6-CI CH3 H COSCH2CH = CH2 Oil _ .
7 6-CI CH3 H COOCH2C(CH3) = CH2 125-127 _ 8 6-CI CH3 H COOC(CH3)3 _ 9 6-CI CH3 H COO-Cyclohex-2-en-1 -yl _ .
10 6-CI CH3 H COOCH (CH2OCH (CH3)2)2 Oil I _ 11 6-CI CH3 H COOCH (CH3)2 1 41 -1 42 I
12 6-CI CH3 H COOC2H4N ~CH3)2 Oil I _. _ _ .

I
14 6-CI CH3 H cOSC6H5 194-195 6-CI CH3 H CoocH2c6H4-3-No2 183-185 17 6-CI CH3 H COO~H2C6H4-4-CI 177-180 I .

19 6-CI CH3 H COOCH2CH = CHCH2CH3 Oil _ _ _ 20 6-CI CH3 H CO0(3-Picolyl) 160-161 _ 21 6-CI CH3 H COO(2-Picolyl) 114-116 22 6-CI CH3 H CoocH2c6H4-4-No2 230-233 _ _ ._ _ _ 23 6-GI GH3 H COOCH2CH2C(CH3) = CH2 (:)il . _ _ _ I
¦ 24 6-CI ~H3 H CO-(4-Nlethylpiperazin-1-yl) _ _ 25 6-CI CH3 H CO-N (CH2)~ 218-220 __ I
26 6-CI CH3 H CO-N (CH2)4 ~00-203 I _ _ 2~6~9~

~ R~n R3 R4 Rs ~ M.P. ~ C
I ...
27 6-CI CH3 H CO-Morpholin-1~yl 193-195 I
28 6-CI CH3 H CO-HNCH2Ph 94-96 I , , , 29 6-CI CH3 H Cyclopropyl-methyloxy- 119-122 carbonyl

Claims (9)

1. A compound of the formula I or Ia, (I) (Ia) and physiologically acceptable salts and prodrugs thereof, where, in formulae I and Ia, n is zero, one, two, three or four, the individual substituents R1 independently of one another are fluorine, chlorine, bromine, iodine, trifluoromethyl, trifluoromethoxy, hydroxyl, C1-C8-alkyl, C5-C8-cycloalkyl, C1-C6-alkoxy, (C1-C6-alkoxy)-(C1-C4-alkoxy), C1-C6-alkylthio, C1-C6-alkylsulfinyl, C1-C6-alkylsulfonyl, nitro, amino, azido, C1-C6-alkylamino, di(C1-C6-alkyl)amino, piperidino, morpholino, 4-pyrrolidinyl, 4-methylpiperazinyl, thiomorpholino, imidazolyl, triazolyi, tetrazolyl, C1-C6-acyl, C1-C6-acyloxy, C1-C6-acylarnino, cyano, carbamoyl, carboxyl, (C1-C6-alkyl)oxycarbonyl, hydroxysulfonyl, sulfamoyl or a phenyl, phenoxy, phenoxycarbonyl, phenylthio, phenylsulfinyl, phenylsulfonyl, phenoxysulfonyl, phenylsulfonyloxy, anilinosulfonyl, phenylsulfonylamino, benzoyl, 2-pyridyl, 3-pyridyl or 4-pyridyl radical which issubstituted by up to five radicals R6 which are independent of one another, where R6 can be fluorine, chlorine, bromine, iodine, cyano, trifluoromethyl, trifluoromethoxy, nitro, amino, azido, C1-C6-alkyl, C3-C8-cycloalkyl, C1-C6-alkoxy, C1-C6-alkylthio, C1-C6-alkylsulfinyl, C1-C6-alkylsulfonyl, C1-C6-alkylamino, di(C1-C6-alkyl)amino, (C1-C6-alkyl)oxycarbonyl, phenyl, phenoxy, 2-, 3- or 4-pyridyl, R2 is hydrogen, C1-C6-alkoxy, hydroxyl, picolyl, cyclo-propyl or isopropenyloxycarbonyl and R5 is hydrogen, hydroxyl, C1-C6-alkoxy, aryloxy, C1-C6-acyloxy, cyano, amino, C1-C6-alkylamino, di(C1-C6-alkyl)amino, arylamino, C1-C6-acylamino, C1-C8-alkyl, optionally substituted by fluorine, chlorine, bromine, iodine, cyano, amino, mercapto, hydroxyl, C1-C6-acyloxy, benzoyloxy, benzyloxy, phenoxy, C1-C6-alkoxy, C1-C6-alkylamino, di(C1-C6-alkyl)amino, C1-C6-alkylthio, C1-C6-alkylsulfonyl, phenylsulfonyl, oxo, thioxo, carboxyl or carbamoyl;

C2-C8-alkenyl, optionally substituted by fluorine, chlorine, bromine, iodine, cyano, amino, mercapto, hydroxyl, C1-C6-acyloxy, benzoyloxy, benzyloxy, phenoxy, C1-C6-alkoxy, C1-C6-alkylamino, di(C1-C6-alkyl)amino, C1-C6-alkylthio, C1-C8-alkylsulfonyl, phenylsulfonyl, oxo, thioxo, carboxyl and carbamoyl;

C3-C8-allenyl, optionally substituted by fluorine, chlorine or hydroxyl, C1-C4-alkoxy, oxo, phenyl;
C3-C8-alkynyl, optionally substituted by fluorine, chlorine, bromine, iodine, cyano, amino, mercapto, hydroxyl, C1-C6-acyloxy, benzoyloxy, benzyloxy, phenoxy, C1-C6-alkoxy, C1-C6-alkylamino, di(C1-C6-alkyl)amino, C1-C6-alkylthio, C1-C6-alkylsulfonyl, phenylsulfonyl, oxo, thioxo, carboxyl or carbamoyl;

C3-C8-cycloalkyl, optionally substituted by fluorine, chlorine, bromine, iodine, cyano, amino, mercapto, hydroxyl, C1-C6-acyloxy, benzoyloxy, benzyloxy, phenoxy, C1-C6-alkoxy, C1-C6-alkylamino, di(C1-C6-alkyl)amino, C1-C6-alkylthio, C,-C6-alkylsulfonyl, phenylsulfonyl, oxo, thioxo, carboxyl or carbamoyl;

C3-C8-cycloalkenyl, optionally substituted by fluorine, chlorine, bromine, iodine, cyano, amino, mercapto, hydroxyl, C1-C6-acyloxy, benzoyloxy, benzyloxy, phenoxy, C1-C6-alkoxy, C1-C6-alkylamino, di(C1-C6-alkyl)amins, C1-C6-alkylthio, C1-C6-alkylsulfonyl, phenylsulfonyl, oxo, thioxo, carboxyl or carbamoyl;

(C3-C8-cycloalkyl)-(C1-C4-alkyl), optionally substituted by fluorine, chlorine, bromine, iodine, cyano, amino, mercapto, hydroxyl, C1-C6-acyloxy, benzoyloxy, benzyloxy, phenoxy, C1-C6-alkoxy, C1-C6-alkylamino, di(C1-C6-alkyl)amino, C1-C6-alkylthio, C1-C6-alkylsulfonyl, phenylsulfonyl, oxo, thioxo, carboxyl or carbamoyl;

(C3-C8-cycloalkenyl)-(C1-C4-alkyl), optionally substituted by fluorine, chlorine, bromine, iodine, cyano, amino, mcrcapto, hyclroxyl, C1-C6-acyloxy, benzoyloxy, benzyloxy, phenoxy, C1-C6-alkoxy, C1-C6-alkylamino, di(C1-C6-alkyl)amino, C1-C6-alkylthio, C1-C6-alkylsulfonyl, phenylsulfonyl, oxo, thioxo, carboxyl or carbamoyl;

C1-C6-alkylcarbonyl, optionally substituted by fluorine, chlorine, bromine, iodine, cyano, amino, mercapto, hydroxyl, C1-C6-acyloxy, benzoyloxy, benzyloxy, phenoxy, C1-C6-alkoxy, C1-C6-alkylamino, di(C1-C6-alkyl)amino, C1-C6-alkylthio, C1-C6-alkylsulfonyl, phenylsulfonyl, oxo, thioxo, carboxyl or carbamoyl;

C2-C8-alkenylcarbonyl, optionally substituted by fluorine, chlorine or hydroxyl,C1-C4-alkoxy, oxo, phenyl (C3-C8-cycloalkyl)carbonyl, optionally substituted by fluorine, chlorine or hydroxyl, C1-C4-alkoxy, oxo, phenyl;

(C5-C8-cycloalkenyl)carbonyl, optionally substituted by fluorine, chlorine or hydroxyl, C1-C4-alkoxy, oxo, phenyl;
(C3-Ca-cycloalkyl)-(C1-C3-alkyl)carbonyl, optionally substituted by fluorine, chlorine or hydroxyl, C1-C4-alkoxy, oxo, phenyl;

(C5-C6-cycloalkenyl)-(C1-C3-alkyl)carbonyl, optionally substituted by fluorine, chlorine or hydroxyl, C1-C4-alkoxy, oxo, phenyl;

C1-C8-alkyloxycarbonyl, optionally substituted by fluorine, chlorine, bromine, hydroxyl, C1-C4-alkoxy, C1-C4-alkylamino, di(C1-C4-alkyl)amino, C1-C4-alkylthio;
C2-C8-alkenyloxycarbonyl, optionally substituted by fluorine, chlorine,hydroxyl, C1-C4-alkoxy, oxo, phenyl;

C2-C8-alkynyloxycarbonyl, optionally substituted by fluorine, chlorine,hydroxyl, C1-C4-alkoxy, oxo, phenyl;

C1-C8-alkylthiocarbonyl, optionally substituted by fluorine, chlorine, hydroxyl,C1-C4-alkoxy, oxo, phenyl;

C2-C8-alkenylthiocarbonyl, optionally substituted by fluorine, chlorine, hydroxyl, C1-C4-alkoxy, oxo, phenyl;

C1-C8-alkylamino- and di(C1-C8-alkyl)aminocarbonyl, in each case optionally substituted by fluorine, chlorine, hydroxyl, C1-C4-alkoxy, oxo, phenyl;

pyrrolidin-1-yl, morpholino-, piperidino-, piperazinyl-, or 4-methylpiperazin-1-ylcarbonyl, in each case optionally substituted by C1-C4-alkyl, C2-C6-alkenyl,C1-C4-acyl, oxo, thioxo, carboxyl, or phenyl;

C2-C8-alkenylamino- and di(C1-C6-alkenyl)aminocarbonyl, in each case optionally substituted by fluorine, chlorine, hydroxyl, C1-C4-alkoxy, oxo, phenyl;

C1-C6-alkylsulfonyl, optionally substituted by fluorine, chlorine, hydroxyl, C1-C4-alkoxy, oxo, phenyl;

C1-C6-alkenylsulfonyl, optionally substituted by fluorine, chlorine, hydroxyl, C1-C4-alkoxy, oxo, phenyl;

or aryl, arylcarbonyl, aryl(thiocarbonyl), (arylthio)carbonyl, (arylthio)thiocarbonyl, aryloxycarbonyl, arylaminocarbonyl, (arylamino)thio-carbonyl, arylalkylaminocarbonyl, arylsulfonyl, arylalkyl, arylalkenyl, arylalkynyl, arylalkylcarbonyl, arylalkenylcarbonyl, arylalkoxycarbonyl or arylalkylthiocarbonyl, each of which is substituted by up to 5 radicals R6 which are independent of one another, it being possible for the alkyl radical to contain in each case 1 to 5 carbon atoms, and R6 being as defined above, or heteroaryl, heteroarylalkyl, heteroarylalkenyl, heteroarylalkylcarbonyl or heteroarylalkenylcarbonyl, heteroaryloxycarbonyl, (heteroarylthio)carbonyl, heteroarylaminocarbonyl, heteroarylalkyloxycarbonyl, heteroaryl(alkylthio)carbonyl or heteroarylalkylaminocarbonyl, each of which is substituted by up to three radicals R6 which are independent of one another, it being possible for the alkyl radical to contain in each case 1 to 3 carbon atoms, R3 and R4 are identical or different and, independently of one another, are hydrogen, C1-C8-alkyl which is optionally substituted by fluorine, chlorine, hydroxyl, amino, mercapto, C1-C4-acyloxy, benzoyloxy, benzyloxy, phenoxy, C1-C4-alkoxy, C1-C4-alkylamino, di(C1-C4-alkyl)amino, C1-C4-alkylthio, C1-C4-alkylsulfonyl, C1-C4-alkylsulfinyl, carboxyl or carbamoyl;

C2-C8-alkenyl, optionally substituted by fluorine or chlorine, hydroxyl, amino, mercapto, C1-C4-acyloxy, benzoyloxy, benzyloxy, phenoxy, C1-C4-alkoxy, C1-C4-alkylamino, di(C1-C4-alkyl)amino, C1-C4-alkylthio, C1-C4-alkylsulfonyl, C1-C4-alkylsulfinyl, carboxyl or carbamoyl;

C3-C8-cycloalkyl, optionally substituted by fluorine, chlorine, hydroxyl, amino,mercapto, C1-C4-acyloxy, benzoyloxy, benzyloxy, phenoxy, C1-C4-alkoxy, C1-C4-alkylamino, di(C1-C4-alkyl)amino, C1-C4-alkylthio, C1-C4-alkylsulfonyl, C1-C4-alkylsulfinyl, carboxyl or carbamoyl;

C3-C8-cycloalkenyl, optionally substituted by fluorine or chlorine, hydroxyl, amino, mercapto, C1-C4-acyloxy, benzoyloxy, benzyloxy, phenoxy, C1-C4-alkoxy, C1-C4-alkylamino, di(C1-C4-alkyl)amino, C1-C4-alkylthio, C1-C4-alkylsulfonyl, C1-C4-alkylsulfinyl, carboxyl or carbamoyl;

aryl, arylalkyl, heteroaryl or heteroarylalkyl, each of which is substituted by up to five radicals R6 which are independent of one another, it being possible for the alkyl radical to contain 1 to 3 carbon atoms in each case, and R6 being as defined above, R3 and R4 can furthermore also be part of a saturated or unsaturated carbo- or heterocyclic ring which has 3 to 8 carbon atoms and which can optionally be substituted by fluorine, chlorine, hydroxyl, amino, C1-C6-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, C1-C6-acyloxy, benzoyloxy, C1-C6-alkoxy, oxo, thioxo, carboxyl, carbamoyl or phenyl, X is oxygen, sulfur, selenium or substituted nitrogen N-R2, it being possible for R2 to have the abovementioned meanings, with the exception of those compounds in which R3 and R4 are both hydrogen, and compounds in which R2 and R5 are hydrogen and R3 and/or R4 are/is arylalkyl, andcompounds in which X is oxygen and R2 and R5 are hydrogen.
2. A compound of the formula I or Ia as claimed in claim 1, wherein the substituents in the abovementioned formulae have the following meaning:

n is zero, one, two or three, the individual substituents R1 independently of one another are fluorine, chlorine, bromine, trifluoromethyl, trifluoromethoxy, hydroxyl, C1-C4-alkyl, C5-C6-cycloalkyl, C1-C4-alkoxy, (C1-C4-alkoxy)-(C1-C4-alkoxy), C1-C4-alkylthio, C1-C4-alkylsulfinyl, C1-C4-alkylsulfonyl, nltro, amino, C1-C4-alkylamino, di(C1-C4-alkyl)amino, piperidino, morpholino, 1-pyrrolidinyl, 4-methylpiperazinyl, thiomorpholino, imidazolyl, C1-C4-acyl, C1-C4-acyloxy, C1-C4-acyiamino, cyano, carbamoyl, carboxyl, (C1-C4-alkyl)oxycarbonyl, hydroxysulfonyl or sulfamoyl or a phenyl, phenoxy, phenoxycarbonyl, phenylthio, phenylsulfinyl, phenylsulfonyl, phenoxysulfonyl, phenylsulfonyloxy, anilinosulfonyl, phenylsulfonylamino, benzoyl, 2-pyridyl, 3-pyridyl or 4-pyridyl radical which issubstituted by up to two radicals R6 which are independent of one another, where R6 can be fluorine, chlorine, bromine, cyano, trifluoromethyl, nitro, amino, C1-C4-alkyl, C3-C7-cycloalkyl, C1-C4-alkoxy, C1-C4-alkylthio, C1-C4-alkylsulfinyl, C1-C4-alkylsulfonyl, C1-C4-alkylamino, di(C1-C4-alkyl)amino, (C1-C4-alkyl)oxycarbonyl,phenyl or phenoxy, R2 is hydrogen and R5 is hydrogen, hydroxyl, cyano, amino, C1-C6-alkyl, optionally substituted by fluorine, chlorine, bromine, iodine, cyano, amino, mercapto, hydroxyl, C1-C4-acyloxy, benzoyloxy, benzyloxy, phenoxy, C1-C4-alkoxy, C1-C4-alkylamino, di(C1-C4-alkyl)amino, C1-C4-alkylthio, oxo, thioxo, carboxyl or carbamoyl;

C2-C8-alkenyl, optionally substituted by fluorine, chlorine, bromine, iodine, cyano, amino, mercapto, hydroxyl, C1-C4-acyloxy, benzoyloxy, benzyloxy, phenoxy, C1-C4-alkoxy, C1-C4-alkylamino, di(C1-C4-alkyl)amino, C1-C4-alkylthio, oxo, thioxo, carboxyl or carbamoyl;

C3-C8-allenyl, C3-C8-alkynyl, optionally substituted by fluorine, chlorine, bromine, iodine, cyano, amino, mercapto, hydroxyl, C1-C4-acyloxy, benzoyloxy, benzyloxy, phenoxy, C1-C4-alkoxy, C1-C4-alkylamino, di(C1-C4-alkyl)amino, C1-C4-alkylthio, oxo, thioxo, carboxyl or carbamoyl;

C3-C8-cycloalkyl, optionally substituted by fluorine, chlorine, bromine, iodine, cyano, amino, mercapto, hydroxyl, C1-C4-acyloxy, benzoyloxy, benzyloxy, phenoxy, C1-C4-alkoxy, C1-C4-alkylamino, di(C1-C4-alkyl)amino, C1-C4-alkylthio, oxo, thioxo, carboxyl or carbamoyl;

C3-C8-cycloalkenyl, optionally substituted by fluorine, chlorine, bromine, iodine, cyano, amino, mercapto, hydroxyl, C1-C4-acyloxy, benzoyloxy, benzyloxy, phenoxy, C1-C4-alkoxy, C1-C4-alkylamino, di(C1-C4-alkyl)amino, C1-C4-alkylthio, oxo, thioxo, carboxyl or carbamoyl;

C3-C8-cycloalkyl)-(C1-C2-alkyl) optionally substituted by fluorine, chlorine, bromine, iodine, cyano, amino, mercapto, hydroxyl, C1-C4-acyloxy, benzoyloxy, benzyloxy, phenoxy, C1-C4-alkoxy, C1-C4 alkylamino, di(C1-C4-alkyl)amino, C1-C4-alkylthio, oxo, thioxo, carboxyl or carbamoyl;

(C3-C8-cycloalkenyl)-(C1-C2-alkyl), optionally substituted by fluorine, chlorine, bromine, iodine, cyano, amino, mercapto, hydroxyl, C1-C4-acyloxy, benzoyloxy, benzyloxy, phenoxy, C1-C4-alkoxy, C1-C4-alkylamino, di(C1-C4-alkyl)amino, C1-C4-alkylthio, oxo, thioxo, carboxyl or carbamoyl;

C1-C6-alkylcarbonyl, optionally substituted by fluorine, chlorine, bromine, iodine, cyano, amino, mercapto, hydroxyl, C1-C4-acyloxy, benzoylnxy, benzyloxy, phenoxy, C1-C4-alkoxy, C1-C4-alkylamino, di(C1-C4-alkyl)amino, C1-C4-alkylthio, oxo, thioxo, carboxyl or carbamoyl;

C2-C6-alkenylcarbonyl, optionally substituted by fluorine, chlorine or hydroxyl,C1-C4-alkoxy, oxo, phenyl;

(C3-C6-cycloalkyl)carbonyl, optionally substituted by fluorine, chlorine or hydroxyl, C1-C4-alkoxy, oxo, phenyl;

(C5-C6-cycloalkenyl)carbonyl, optionally substituted by fluorine, chlorinc or hydroxyl, C1-C4-alkoxy, oxo, phenyl;

(C3-C6-cycloalkyl)-(C1-C2-alkyl)carbonyl, optionally substituted by fluorine, chlorine or hydroxyl, C1-C4-alkoxy, oxo, phenyl;

(C5-C6-cycloalkenyl)-(C1-C2-alkyl)carbonyl, optionally substituted by fluorine, chlorine or hydroxyl, C1-C4-alkoxy, oxo, phenyl;

C1-C6-alkyloxycarbonyl, optionally substituted by fluorine, chlorine, bromine, hydroxyl, C1-C4-alkoxy, C1-C4-alkylamino, di(C1-C4-alkyl)amino, C1-C4-alkylthio;
C2-C6-alkenyloxycarbonyl, optionally substituted by fluorine, chlorine,hydroxyl, C1-C4-alkoxy, oxo, phenyl;

C2-C6-alkynyluxycarbonyl, optionally substituted by fluorine, chlorine,hydroxyl, C1-4-alkoxy, oxo, phenyl;
C1-C6-alkylthiocarbonyl, optionally substituted by fluorine, chlorine, hydroxyl,C1-C4-alkoxy, oxo, phenyl;

C2-C6-alkenylthiocarbonyl, optionally substituted by fluorine, chlorine, hydroxyl, C1-C4-alkoxy, oxo, phenyl;
C1-C6-alkylamino- and di(C1-C6-alkyl)aminocarbonyl, in each case optionally substituted by fluorine, chlorine, hydroxyl, C1-C4-alkoxy, oxo, phenyl;

pyrrolidin-1-yl, morpholino-, piperidino-, piperazinyl-, or 4-methylpiperazin-1-ylcarbonyl;

C2-C6-alkenylamino- and di(C1-C6-alkenyl)aminocarbonyl, in each case optionally substituted by fluorine, chlorine, hydroxyl, C1-C4-alkoxy, oxo, phenyl;

C1-C4-alkylsulfonyl, optionally substituted by fluorine, chlorine, hydroxyl, C1-C4-alkoxy, oxo, phenyl;

C1-C4-alkenylsulfonyl, optionally substituted by fluorine, chlorine, hydroxyl, C1-C4-alkoxy, oxo, phenyl;

or aryl, arylcarbonyl, aryl(thiocarbonyl), (arylthio)carbonyl, (arylthio)thiocarbonyl, aryloxycarbonyl, arylaminocarbonyl, (arylamino)thio-carbonyl, arylalkylaminocarbonyl, arylsulfonyl, arylalkyl, arylalkenyl, arylalkynyl, arylalkylcarbonyl, arylalkenylcarbonyl, or arylalkoxycarbonyl, or aryl(alkylthio)carbonyl, each of which is substituted by up to three radicais R6which are independent of one another, it being possible for the alkyl radical to contain in each case 1 to 5 carbon atoms and R6 being as defined above, or 1- or 2-naphthylmethyl, 2-, 3- or 4-picolyl, 2- or 3-furylmethyl, 2- or
3-thienylmethyl, 2- or 3-pyrroiylmethyl, 2-, 3- or 4-pyridylcarbonyl, 2- or 3-furylcarbonyl, 2- or 3-thienylcarbonyl, 2- or 3-thienylacetyl, 2-, 3- or
4-picolyloxycarbonyl, 2- or 3-furylmethyloxycarbonyl, 2- or 3-thienylmethyl-oxycarbonyl, each of which is substituted by up to two radicals R6 which are independent of one another, and R3 and R4 are identical or different and independently of one another are hydrogen, C1-C6-alkyl, optionally substituted by fluorine, chlorine, hydroxyl, amino, mercapto, C1-C4-acyloxy, benzoyloxy, benzyloxy, phenoxy, C1-C4-alkoxy, C1-C4-alkylamino, di(C1-C4-alkyl)amino, C1-C4-alkylthio, C1-C4-alkylsulfonyl, C1-C4-alkylsulfinyl,carboxyl or carbamoyl;

C2-C8-alkenyl, optionally substituted by fluorine or chlorine, hydroxyl, amino, mercapto, C1-C4-acyloxy, benzoyloxy, benzyloxy, phenoxy, C1-4-alkoxy, C1-C4-alkylamino, di(C1-C4-alkyl)amino, C1-C4-alkylthio, C1-C4-alkylsulfonyl, C1-C4-alkylsulfinyl, carboxyl or carbamoyl;

C3-C8-cycloalkyl, optionally substituted by fluorine, chlorine, hydroxyl, amino,mercapto, C1-C4-acyloxy, benzoyloxy, benzyloxy, phenoxy, C1-C4-alkoxy, C1-C4-alkylamino, di(C1-C4-alkyl)amino, C1-C4-alkylthio, C1-C4-alkylsulfonyl, C1-C4-alkylsulfinyl, carboxyl or carbamoyl;

C3-C8-cycloalkenyl, optionally substituted by fluorine or chlorine, hydroxyl, amino, mercapto, C1-C4-acyloxy, benzoyioxy, benzyloxy, phenoxy, C1-C4-alkoxy, C1-C4-alkylamino, di(C1-C4-alkyl)amino, C1-C4-alkylthio, C1 C4-alkylsulfonyl, C1-C4-alkylsulfinyl, carboxyl or carbamoyl;
aryl, arylalkyl, heteroaryl or heteroarylalkyl, each of which is substituted by up to three radicals R6 which are independent of one another, it being possible for the alkyl radical to contain in each case 1 to 3 carbon atoms and R6 being as defined above, R3 and R4 can furthermore also be part of a saturated or unsaturated carbo- or heterocyclic ring which has 3 to 7 carbon atoms and which can optionally be substituted by fluorine, chlorine, hydroxyl, amino, C1-C4-alkyl, C2-C4-alkenyl, C2-C4-alkynyl, C1-C4-acyloxy, benzoyloxy, C1-C4-alkoxy, oxo, thioxo, carboxyt, carbamoyl or phenyl, and X is oxygen, sulfur or selenium.

3. A compound of the formula I or Ia as claimed in claim 1 or 2, wherein the substituents in the abovementioned formulae have the following meanings:
n is zero, one ortwo, the individual substituents R1 independently of one another are fluorine, chlorine, bromine, trifluoromethyl, hydroxyl, C1-C4-alkyl, C1-C4-alkoxy, (C1-C4-alkoxy)-(C1-C4-alkoxy), C1-C4-alkylthio, nitro, amino, C1-C4-alkylamino, di(C1-C4-alkyl)amino, piperidino, morpholino, 1-pyrrolidinyl, 4-methylpiperazinyl, C1-C4-acyl, C1-C4-acyloxy, C1-C4-acylamino, cyano, carbamoyl, carboxyl, (C1-C4-alkyl)oxycarbonyl, hydroxysulfonyl or sulfamoyl, or a phenyl, phenoxy, phenylthio, phenylsulfonyl, phenoxysulfonyl, benzoyl, 2-pyridyl, 3-pyridyl or 4-pyridyl radical which is substituted by up to two radicals R6 which are independent of one another, where R6 can be fluorine, chlorine, bromine, cyano, trifluoromethyl, nitro, amino, C1-C4-alkyl, C1-C4-alkoxy, (C1-C4-alkyl)oxycarbonyl, phenyl or phenoxy, R2 is hydrogen and R5 is C1-C6-alkyl, optionally substituted by fluorine) chlorine, hydroxyl, C1-C4-acyloxy, benzoyloxy, benzyloxy, phenoxy, C1-C4-alkoxy, C1-C4-alkylamino, di(C1-C4-alkyl)amino, C1-C4-alkylthio, oxo, thioxo, carboxyl or carbamoyl;

C2-C6-alkenyl, optionally substituted by fluorine, chlorine, hydroxyl, C1-C4-acyloxy, benzoyloxy, benzyloxy, phenoxy, C1-C4-alkoxy, C1-C4-alkylamino, di(C1-C4-alkyl)amino, C1-C4-alkylthio, oxo, thioxo, carboxyl or carbamoyl;

C3-C8-allenyl, C3-C8-alkynyl, optionally substituted by fluorine, chlorine, hydroxyl, C1-C4-acyloxy, benzoyloxy, benzyloxy, phenoxy, C1-C4-alkoxy, C1-C4-alkylamino, di(C1-C4-alkyl)amino, C1-C4-alkylthio, oxo, thioxo, carboxyl or carbamoyl;

C3-C8-cycloalkyl, optionally substituted by fluorine, chlorine, hydroxyl, C1-C4-alkyl, C1-C4-acyloxy, benzoyloxy, benzyloxy,phenoxy, C1-C4-alkoxy, C1-C4-alkylamino, di(C1-C4-alkyl)amino, C1-C4-alkylthio, oxo, thioxo, carboxyl or carbamoyl;

C3-C8-cycloalkenyl, optionally substituted by fluorine, chlorine, hydroxyl, C1-C4-alkyl, C1-C4-acyloxy, benzoyloxy, benzyloxy,phenoxy, C1-C4-alkoxy, C1-C4-alkylamino, di(C1-C4-alkyl)amino, C4-C4-alkylthio, oxo, thioxo, carboxyl or carbamoyl;

(C3-C6-cycloalkyl)-(C1-C2-alkyl), optionally substituted by fluorine, chlorine, hydroxyl, C1-C4-alkyl, C1-C4-acyloxy, benzoyloxy, benzyloxy,phenoxy, C1-C4-alkoxy, C1-C4-alkylamino, di(C1-C4-alkyl)amino, C1-C4-alkylthio, oxo, thioxo, carboxyl or carbamoyl;

(C3-C6-cycloalkenyl)-(C1-C2-alkyl), optionally substituted by fluorine, chlorine, hydroxyl, C1-C4-alkyl, C1-C4-acyloxy, benzoyloxy, benzyloxy,phenoxy, C1-C4-alkoxy, C1-C4-alkylamino, di(C1-C4-alkyl)amino, C1-C4-alkylthio, oxo, thioxo, carboxyl or carbamoyl;

C4-C6-alkylcarbonyl, optionally substituted by fluorine, chlorine, hydroxyl, C1-C4-alkyl C1-C4-acyloxy, benzoyloxy, benzyloxy, phenoxy, C4-C4-alkoxy, C1-C4-alkylamino, C1-C4-alkenylamino, di(C1-C4-alkyl)amino, 1-pyrrolidinyl, piperidino, morpholino, 4-methylpiperzin-1-yl, C1-C4-alkylthio, oxo, thioxo, carboxyl or carbamoyl;

C2-C6-alkenylcarbonyl, optionally substituted by fluorine, chlorine or hydroxyl;
(C3-C6-cyoloalkyl)carbonyl, (C5-C6-cycloalkenyl)carbonyl, (C3-C6-cycloalkyl)-(C1-C2-alkyl)carbonyl, (C5-C6-cycloalkenyl)-(C1-C2-alkyl)carbonyl, C1-C6-alkyloxycarbonyl, optionally substituted by fluorine, chlorine, bromine, hydroxyl, C1-C4-alkoxy, C1-C4-alkylamino, di(C1-C4-alkyl)amino or C1-C4-alkyl-thio;

C2-C6-alkenyloxycarbonyl, optionally substituted by fluorine, chlorine,hydroxyl, C1-C4-alkoxy;

C2-C6-alkynyloxycarbonyl, optionally substituted by fluorine, chlorine,hydroxyl, C1-C4-alkoxy;

C1-C6-alkylthiocarbonyl, optionally substituted by fluorine, chlorine, hydroxyl, C1-C4-alkoxy;

C2-C6-alkenylthiocarbonyl, optionally substituted by fluorine, chlorine, hydroxyl, C1-C4-alkoxy;

C1-C6-alkylamino- and di(C1-C6-alkyl)aminocarbonyl, in each cass optionally substituted by fluorine, chlorine, hydroxyl, C1-C4-alkoxy;
pyrrolidin-1-yl, morpholino-, piperidino-, piperazinyl-, or 4-methylpiperzin-1-ylcarbonyl;

C2-C6-alkenylamino- and di(C1-C6-alkenyl)aminocarbonyl, in each case optionally substituted by fluorine, chlorine, hydroxyl, C1-C4-alkoxy;

C1-C4-alkylsulfonyl, optionally substituted by fluorine, chlorine, hydroxyl, C1-C4-alkoxy;

C1-C4-alkenylsulfonyl;

or aryl, arylcarbonyl, (arylthio)carbonyl, aryloxycarbonyl, arylaminocarbonyl, (arylamino)thiocarbonyl, arylsulfonyl, arylalkylaminocarbonyl, arylalkyl, arylalkenyl, arylalkylcarbonyl, aryl(alkylthio)carbonyl or arylalkoxycarbonyl, each of which is substituted by up to two radicals R6 which are independent of one another, it being possible for the alkyl radical to contain in each case 1 to 3 carbon atoms and R5 being as defined above, or 1- or 2-naphthylmethyl, 2-, 3- or 4-picolyl, 2- or 3-furylmethyl, 2- or 3-thienylmethyl, 2- or 3-pyrrolylmethyl, 2-, 3- or 4-pyridylcarbonyl, 2- or 3-furylcarbonyl, 2- or 3-thienylcarbonyl, 2- or 3-thienylacetyl, 2-, 3- oder 4-picolyloxycarbonyl, 2- or 3-furylmethyloxycarbonyl, 2- or 3-thienylmethyloxycarbonyl each of which is substituted by up to two radicals R6 which are independent of one another, and R3 and R4 are identical or different and independently of one another are hydrogen, C1-C4-alkyl, optionally substituted by fluorine, chlorine, hydroxyl, amino, mercapto, C1-C4-acyloxy, benzoyloxy, phenoxy, C1-C4-alkoxy, C1-C4-alkylamino, di(C1-C4-alkyl)amino, C1-C4-alkylthio, Cl-C4-alkylsulfonyl, C1-C4-alkylsulfinyl, carboxyl or carbamoyl;

C2-C6-alkenyl, optionally substituted by fluorine or chlorine;

C3-C6-cycloalkyl, optionally substituted by fluorine, chlorine. hydroxyl, amino,mercapto, C1-C4-acyloxy, benzoyloxy, benzyloxy, phenoxy, C1-C4-alkoxy, C1-C4-alkylamino, di(C1-C4-alkyl)amino, C1-C4-alkylthio, C1-C4-alkylsulfonyl, C1-C4-alkylsulfinyl, carboxyl or carbamoyl;

C3-C8-cycloalkenyl, optionally substituted by fluorine or chlorine;

aryl, benzyl, heteroaryl or heteroarylmethyl, each of which is substituted by up to two radicals R6 which are independent of one another, R3 and R4 can furthermore also be part of a saturated or unsaturated carbo- or heterocyclic ring which has 3 to 6 carbon atoms and which can optionally be substituted by fluorine, chlorine, hydroxyl, amino, C1-C4-acyloxy, benzoyloxy, C1-C4-alkoxy, oxo, thioxo, carboxyl or carbamoyl, and X is oxygen or sulfur.

4. A compound of the formula I or Ia as claimed in claims 1-3, wherein the abovementioned substituents have the following meanings:
n is zero, one or two, the individual substituents R1 independently of one another are fluorine, chlorine, bromine, trifluoromethyl, hydroxyl, C1-C4-alkyl, C1-C4-alkoxy, (C1-C4-alkoxy)-(C1-C2-alkoxy), C1-C4-alkylthio, nitro, amino, C1-C4-alkylamino, di(C1-C4-alkyl)amino, piperidino, morpholino, 1-pyrrolidinyl, 4-methylpiperazinyl, C1-C4-acyl, C1-C4-acyloxy, C1-C4-acylamino, cyano, carbamoyl, carboxyl, (C1-C4-alkyl)oxycarbonyl, hydroxysulfonyl or sulfamoyl or a phenyl, phenoxy, phenylthio, phenylsulfonyl, phenoxysulfonyl, benzoyl, 2-pyridyl, 3-pyridyl or 4-pyridyl radical which is substituted by up to two radicals R6 which are independent of one another, where R6 can be fluorine, chlorine, bromine, cyano, trifluoromethyl, nitro, amino, C1-C4-alkyl, C1-C4-alkoxy, (C1-C4-alkyl)oxycarbonyl, phenyl or phenoxy, R2 is hydrogen and R5 is C1-C6-alkyl, optionally substituted by C1-C4-alkoxy or C1-C4-alkylthio;

C2-C6-alkenyl, optionally substituted by oxo;

C3-C6-allenyl;

C3-C8-alkynyl, in particular 2-butynyl;

C3-C6-cycloalkyl;

C5-C6-cycloalkenyl;

(C3-C6-cycloalkyl)-(C1-C2-alkyl), in particular cyclopropylmethyl, optionally substituted by (1-C4-alkyl;

(C3-C6-cycloalkenyl)-(C1-C2-alkyl), in particular cyclohexenylmethyl;

C1-C6-alkylcarbonyl, optionally substituted by fluorine, chlorine, hydroxyl, benzyloxy, phanoxy, C1-C4-alkoxy, C1-C4-alkylamino, C1-C4-alkenylamino, di(C1-C4-alkyl)amino, 1-pyrrolidinyl, piperidino, morpholino, 4-methylpiperazin-1-yl or C1-C4-alkylthio;

C2-C6-alkenylcarbonyl;

C1-C6-alkyloxycarbonyl, optionally substituted by fluorine, chlorine, bromine, hydroxyl, C1-C4-alkoxy, C1-C4-alkylamino, di(C1-C4-alkyl)amino or C1-C4-alkyl-thio;

C2-C6-alkenyloxycarbonyl, in particular vinyloxycarbonyl, allyloxycarbonyl, isopropenyloxycarbonyl, butenyloxycarbonyl or pentenyloxycarbonyl;

C2-C6-alkynyloxycarbonyl, in particular propynyloxycarbonyl or butynyloxycarbonyl;

C1-C8-alkylthiocarbonyl;

C2-C6-alkenylthiocarbonyl, in particular allylthiocarbonyl;

C1-C6-alkylamino- and di(C1-C6-alkyl)aminocarbonyl;

pyrrolidin-1-yl, morpholino-, piperidino-, piperazinyl-, or 4-methylpiperazin-1-ylcarbonyl;

C2-C6-alkenylamino- and di(C1-C6-alkenyl)aminocarbonyl;

C1-C4-alkylsulfonyl;

C1-C4-alkenylsulfonyl;

or aryl which is substituted by up to two radicals R6 which are independent of one another, in particular phenyl, arylcarbonyl, in particular benzoyl, (arylthio)carbonyl, aryloxycarbonyl, arylaminocarbonyl, (arylamino)thiocarbonyl, arylalkylaminocarbonyl, arylsulfonyl, arylalkyl, in particular benzyl, phenylethyl, arylalkenyl, arylalkylcarbonyl, arylalkoxycarbonyl or aryl(alkylthio)carbonyl, it being possible for the alkyl radical to contain in each case 1 to 3 carbon atoms and R6 being as defined above, or 1- or 2-naphthylmethyl, 2-, 3- or 4-picolyl, 2- or 3-furylmethyl, 2- or 3-thienylmethyl, 2- or 3-pyrrolylmethyl, 2-, 3- or 4-pyridylcarbonyl, 2- or 3-furylcarbonyl, 2- or 3-thienylcarbonyl, 2- or 3-thienylacetyl, 2-, 3- or 4-picolyloxycarbonyl, 2- or 3-furylmethyloxycarbonyl, or 2- or 3-thienyl-methyloxycarbonyt, each of which is substituted by up to two radicals R6 which are independent of one another, and R3 and R4 are identical or different and independently of one another are hydrogen, C1-C4-alkyl, optionally substituted by hydroxyl, mercapto, C1-C4-alkoxy, C1-C4-alkylthio, C1-C4-alkylsulfonyl, C1-C4-alkylsulfinyl, carboxyl or carbamoyl;

C2-C6-alkenyl, aryl, benzyl, thienyl or thienylmethyl, each of which is substituted by up to two radicals R6 which are independent of one another, R6 having the meaning as defined above R3 and R4 can also be part of a saturated or unsaturated carbo- or heterocyclic ring which has 3 to 6 carbon atoms and can optionally be substituted by oxo or thioxo, and X is oxygen or sulfur.
5. A process for the preparation of compounds of the formula I as claimed in claim 1, which comprises A) for preparing compounds of the formula I where X is oxygen and the radicals R1, R2, R3, R4 and R5 are as defined in claim 1, reacting a compound of the formula II

(II) with the definitions mentioned in claim 1 applying to R1, R3 and R4, with a compound of the formula III

R-Z (III) where R has the meanings for R5 and R2 which have been mentioned in claim 1 with the exception of hydrogen, hydroxyl, C1-C6-alkoxy, aryloxy, C1-C6-acyloxy, amino, C1-C6-alkylamino, di(C1-C6-alkyl)amino, arylamino and C1-C6-acylamino, and Z is a leaving group, or B) preparing compounds of the formula I where X is sulfur and R1, R2, R3, R4 and R5 are as defined in claim 1 by reacting a compound of the formula I where X is oxygen and the definitions mentioned in claim 1 apply to R1, R2, R3, R4 and R5, with a sulfurizing reagent, or C) preparing compounds of the formula Ia where X and the radicals R1 to R5 are as defined in claim 1, by reacting a compound of the formula IV

(IV) or (IV) where the definitions mentioned in claim 1 apply to R1, R3, R4 and R5, with a compound of the formula III

R2-Z (III) where the definitions described in claim 1 for formula I and Ia apply to R2 with the exception of hydrogen, hydroxy, C1-C6-alkoxy, aryloxy, C1-C6-acyloxy, amino, C1-C6-alkylamino, Di(C1-C6-allyl)amino, arylamino, C1-C6-acylamino and Z is a leaving group, or D) preparing compounds of the formula I where X is oxygen and the radicals R1 toR5 are as defined in claim 1 by cyclizing a compound of the formula V

V

where R1 to R5 are as defined in claim 1 and Y is hydroxyl, C1-C4-alkoxy, optionally halogenated C1-C4-acyloxy, chlorine, bromine or iodine, or E) preparing compounds of the formula I where X is oxygen, R4 and R5 are hydrogen and the definitions mentioned in claim 1 apply to R1 to R3, from the quinoxalinones of the formula XI

X I

where R1 to R3 are as defined at the outset, by addition of hydrogen on the C=N
bond, or F) preparing compounds of the formula I where X is oxygen and R1 to R5 are as defined in claim 1, from compounds of the formula VI

V I

where R1, R2 and R5 are as defined in claim 1, by reacting them with chloroform or bromoform and a carbonyl compound of the formula XIII

R3-CO-R4 (XIII) where R3 and R4 are as defined in claim 1, or with .alpha.-(trihalomethyl)alkanols of the formula XIV

Hal3C-C(OH)-R3R4 (XIV) where Hal is Cl, Br or 1, in which R3 and R4 are as defined at the outset, or G) preparing compounds of the formula I where X is oxygen and R1, R2, R3, R4 andR5 are as defined in claim 1, by reacting a compound of the formula I where X isoxygen and the definitions mentioned in claim 1 apply to R1, R2, R5 and to R3 and R4, with the exception that at least one of the radicals R3 or R4 is hydrogen, with an alkylating reagent of the formula XV

R'-Z (XV) where R' has the meanings mentioned above for R3 and R4 with the exception of hydrogen and Z is a leaving group, or H) preparing compounds of the formula I where X is oxygen, R1, R2, R3 and R4 areas defined in claim 1 and R5 is C1-C8-alkyl, optionally substituted by fluorine,chlorine, bromine, iodine, hydroxyl, C1-C6-acyloxy, benzoyloxy, phenoxy, C1-C6-alkoxy, C1-C6-alkylamino, di(C1-C6-alkyl)amino, C1-C6-alkylthio, cyano, carboxyl, carbamoyl, C3-C8-alkenyl, optionally substituted by fluorine, chlorine, bromine, iodine, hydroxyl, C1-C6-acyloxy, benzoyloxy, phenoxy, Cl-C6-alkoxy, C1-C6-alkylamino, di(C1-C6-alkyl)amino, C3-C8-alkylthio, cyano, carboxyl or carbamoyl, C3-C8-alkynyl, optionally substituted by fluorine, chlorine, bromine,iodine, hydroxyl, C,1-C6-acyloxy, benzoyloxy, phenoxy, C1-C6-alkoxy, C1-C6-alkylamino, di(C1-C6-alkyl)amino, C1-C6-alkylthio, cyano, carboxyl or carbamoyl,C4-C8-cycloalkyl, optionally substituted by fluorine, chiorine, bromine, iodine,hydroxyl, C1-C6-acyloxy, benzoyloxy, phenoxy, C1-C6-alkoxy, C1-C6-alkylamino, di(C1-C6-alkyl)amino, C1-C6-alkylthio, cyano, carboxyl or carbamoyl, C5-C3-cyclo-alkenyl, optionally substituted by fluorine, chlorine, bromine, iodine, hydroxyl, C1-C6-acyloxy, benzoyloxy, phenoxy, C1-C6-alkoxy, C1-C6-alkylamino, di(C1-C6-alkyl)amino, C1-C6-alkylthio, cyano, carboxyl or carbamoyl, (C1-C6-alkoxy)-(C1-C6-alkyl), di(C1-C6-alkylamino)-(C1-C6-alkyl) or (C3-C6-cycloalkyl)alkyl, (C6-C8-cycloalkenyl)alkyl, or arylalkyl, naphthylalkyl or heteroarylalkyl, each of which is substituted by up to five radicals R6 which are independent of one another, it being possible for the alkyl radical to contain in each case 1 to 3 carbon atoms, by reductive alkylation of a compound of the formula I where R5 is hydrogen and X
is oxygen and the definitions mentioned in claim 1 apply to R1, R2, R3 and R4, with a carbonyl compound of the formula XVI, R"-C(-O)-R''' (XVI) where R" and R''' are identical or different and independently of one another are hydrogen, C1-C7-alkyl, optionally substituted by fluorine, chlorine, bromine, iodine, hydroxyl, C1-C6-acyloxy, benzoyloxy, phenoxy, C1-C6-alkoxy, C1-C6-alkylamino, di(C1-C6-alkyl)amino, C1-6-alkylthio, cyano, carboxyl or carbamoyl, C3-C7-alkenyl, optionally substituted by fluorine, chlorine, bromine, iodine, hydroxyl, C1-C6-acyloxy, benzoyloxy, phenoxy, C1-C8-alkoxy, C1-C6-alkylamino, di(C1-C6-alkyl)amino, C1-C6-alkylthio, cyano, carboxyl or carbamoyl, C3-C7-alkynyl, optionally substituted by fluorine, chlorine, bromine, iodine, hydroxyl, C1-C6-acyloxy, benzoyloxy, phenoxy, C1-C6-alkoxy, C1-C6-alkylamino, di(C1-C6-alkyl)amino, C1-C6-alkylthio, cyano, carboxyl or carbamoyl, C4-C8-cycloalkyl, optionally substituted by fluorine, chlorine, bromine, iodine, hydroxyl, C1-C6-acyloxy, benzoyloxy, phenoxy, C1-C6-alkoxy, C1-C6-alkylamino, di(C1-C6-alkyl)amino, C1-C6-alkylthio, cyano, carboxyl or carbamoyl, C5-cycloalkenyl, optionally substituted by fluorine, chlorine, bromine, iodine, hydroxyl, C1-C6-acyloxy, benzoyloxy, phenoxy, C1-C6-alkoxy, C1-C6-alkylamino, di(C1-C6-alkyl)amino, C1-C6-alkylthio, cyano, carboxyl or carbamoyl, (C1-C6-alkoxy)-(C1-C6-alkyl), [di(C1-C6-alkyl)amino]-(C1-C5-alkyl) or(C4-C6-cycloalkyl)alkyl, (C6-cycloalkenyl)alkyl, or arylalkyl, naphthylalkyl or heteroarylalkyl, each of which is substituted by up to five radicals R6 which are independent of one another, it being possible for the alkyl radical to contain in each case 0 to 2 carbon atoms, and where R" and R''' can be linked to each other to form a 4- to 8-membered ring, or 1) preparing compounds of the formula I where X is oxygen and R1, R2, R3 and R4 are as defined in claim 1 and R5 is C1-C8-alkyloxycarbonyl, C1-C8-alkylthiocarbonyl, C2-C8-alkenyloxycarbonyl, C2-C8-alkenylthiocarbonyl, C2-C8-alkynyloxycarbonyl, C1-C6-alkylaminocarbonyl, C3-C6-alkenylaminocarbonyl, di(C1-C6-alkyl)aminocarbonyl, pyrrolidin-1-yl, morpholino-, piperidino-, piperazinyl-, 4-methylpiperazin-1-ylcarbonyl, optionally substituted by fluorine, chlorine, bromine, iodine, cyano, amino, mercapto, hydroxyl, C1-C6-acyloxy, benzoyloxy, benzyloxy, phenoxy, C1-C6-alkoxy, C1-C6-alkylamino, di(C1-C6-alkyl)amino, C1-C6-alkylthio, C1-C6-alkylsulfonyl, phenylsulfonyl, oxo, thioxo, carboxyl or carbamoyl;
or aryloxycarbonyl arylthio(carbonyl), arylaminocarbonyl, heteroaryloxycarbonyl,heteroarylthiocarbonyl, heteroarylaminocarbonyl, arylalkyloxycarbonyl, (aryl-alkylthio)carbonyl, arylalkylaminocarbonyl, heteroalkyloxycarbonyl, (heteroalkylthio)carbonyl or heteroalkylaminocarbonyl, each of which is substi~uted by up to five radicals R6 which are independent of one another, it being possible for the alkyl radical to contain in each case 1 to 3 carbon atoms, by reacting a compound of the formula XVII

XVII
where the definitions mentioned in claim 1 apply to R1, R2, R3 and R4, n is 0, 1, 2 or 3, X is oxygen and U is a leaving group, with a compound of the formula XVIII

Nu-H (XVIII) where Nu is C1-C8-alkoxy, C2-C8-alkenyloxy, C2-C8-alkynyloxy, C1-C8-alkylthio, C2-C8-alkenylthio, C1-C8-alkylamino- and di(C1-C8-alkyl)amino, C2-C8-alkenylamino-and di(C1-C6-aikyl)amino, optionally substituted by fluorine, chlorine, bromine,hydroxyl, C1-C4-alkoxy, C1-C4-alkylamino, di(C1-C4-alkyl)amino, C1-C4-alkylthio,pyrrolidin-1-yl, morpholino-, piperidino-, piperazinyl- or 4-methylpiperazin-1-ylcarbonyl, optionally substituted by C1-C4-alkyl, C2-C6-alkenyl, C1-C4-acyl, oxo, thioxo, carboxyl or phenyl, or aryloxy, arylthio, arylamino, arylalkyloxy, arylalkylthio, arylalkylamino, heteroaryloxy, heteroarylthio, heteroarylamino, heteroarylalkyloxy, heteroarylalkylthio or heteroarylalkylamino, each of which is substituted by up to five radicals R6 (R6 is as defined at the outset) which areindependent of one another, it being possible for the alkyl radical to esntain in each case 1 to 3 carbon atoms.
6. The use of a compound of the formula I or Ia as claimed in one or more of claims 1-4 as a pharmaceutical.
7. A pharmaceutical comprising an effective amount of at least one compound of the formula Ia as claimed in one or more of claims 1-4.
8. A process for the preparation of a pharmaceutical as claimed in claim 7, which comprises formulating an effective amount of a compound of the formula I or Ia together with customary pharmaceutical auxiliaries to give a suitable dosage form.
9. The use of a compound of the formula I or Ia (I) (Ia) in which n is zero, one, two, three or four, the individual substituents R1 independently of one another are fluorine, chlorine, bromine, iodine, trifluoromethyi, trifluoromethoxy, hydroxyl, C1-C8-alkyl, C5-C8-cycloalkyl, C1-C6 alkoxy, (C1-C6-alkoxy) (C1-C4 alkoxy), C1-C6-alkytthio, C1-C6-alkylsulfinyl, C1-C6-alkylsulfonyl, nitro, amino, azido, C1-C6-alkylamino, di(C1-C6-alkyl)amino, piperidino, morpholino, 1-pyrrolidinyl, 4-methylpiperazinyl, thiomorpholino, imidazolyl, triazolyl, tetrazolyl, C1-C6-acyl, C1-C6-acyloxy, C1-C6-acylamino, cyano, carbarnoyl, carboxyl, (C1-C6-alkyl)oxycarbonyl, hydroxysuifonyl, sulfarnoyl or a phenyl, phenoxy, phenoxycarbonyl, phenyithio, phenylsulfinyl, phenylsulfonyl, phenoxysulfonyl, phenylsulfonyloxy, anilinosulfonyl, phenylsulfonylamino, benzoyl, 2-pyridyl, 3-pyridyl or 4-pyridyl radical which issubstituted by up to five radicals R6 which are independent of one another, where R6 can be fluorine, chlorine, bromine, iodine, cyano, trifluoromethyl, trifluoromethoxy, nitro, amino, azido, C1-C6-alkyl, C3-C8-cycloalkyl, C1-C6-alkoxy, C1-C6-alkylthio, C1-C6-alkylsulfinyl, C1-C6-alkylsulfonyl, C1-C6-alkylamino, di(C1-C6-alkyl)amino, (C1-C6-alkyl)oxycarbonyl, phenyl, phenoxy, 2-, 3- or 4-pyridyl, R2 and R5 are identical or different and independently of one another are hydrogen, hydroxyl, C1-C6-alkoxy, aryloxy, C1-C6-acyloxy, cyano, amino, C1-C6-alkylamino, di(C1-C6-alkyl)amino, arylamino, C1-C6-acylamino, C1-C8-alkyl, optionally substituted by fluorine, chlorine, bromine, iodine, cyano, amino, mercapto, hydroxyl, C1-C6-acyloxy, benzoyloxy, benzyloxy, phenoxy, C1-C6-alkoxy, C1-C6-alkylamino, di(C1-C6-alkyl)amino, C1-C8-alkylthio, C1-C8-alkylsuifonyl, phenylsulfonyl, oxo, thioxo, oarboxyl or carbamoyl;

C2-C8-alkenyl, optionally substituted by fluorine, chlorine, bromine, iodine, cyano, amino, mercapto, hydroxyl, C1-C6-acyloxy, benzoyloxy, benzyloxy, phenoxy, C1-C4-alkoxy, C1-C6-alkylamino, di(C1-C6-alkyl)amino, C1-C6-alkylthio, C1-C6-alkylsulfonyl, phenylsulfonyl, oxo, thioxo, carboxyl and carbamoyl;

C3-C8-allenyl, optionally substituted by fluorine, chlorine or hydroxyl, C1-C4-alkoxy, oxo, phenyl;
C3-C8-alkynyl, optionally substituted by fluorine, chlorine, bromine, iodine, cyano, amino, mercapto, hydroxyl, C1-C6-acyloxy, benzoyloxy, benzyloxy, phenoxy, C1-C6-alkoxy, C1-C6-alkylamino, di(C1-C6-alkyl)amino, C1-C6-alkylthio, C1-C6-alkylsulfonyl, phenylsulfonyl, oxo, thioxo, carboxyl or carbamoyl;

C3-C8-cycloalkyl, optionally substituted by fluorine, chlorine, bromine, iodine, cyano, amino, mercapto, hydroxyl, C1-C6-acyloxy, benzoyloxy, benzyloxy, phenoxy, C1-C8-alkoxy, C1-C6-alkylamino, di(C1-C6-alkyl)amino, C1-C6-alkylthio, C1-C6-alkylsulfonyl, phenylsulfonyl, oxo, thioxo, carboxyl or carbamoyl;

C3-C8-cycloalkenyl, optionally substituted by fluorine, chlorine, bromine, iodine, cyano, amino, mercapto, hydroxyl, C1-C6-acyloxy, benzoyloxy, benzyloxy, phenoxy, C1-C6-alkoxy, C1-C6-alkylamino, di(C1-6-alkyl)amino, C1-C6-alkylthio, C1-C6-alkylsulfonyl, phenylsulfonyl, oxo, thioxo, carboxyl or carbamoyl;

(C3-C8-cycloalkyl)-(C1-C4-alkyl), optionally substituted by fluorine, chlorine, bromine, iodine, cyano, amino, mercapto, hydroxyl, C1-C6-acyloxy, benzoyloxy, benzyloxy, phenoxy, C1-C6-alkoxy, C1-C6-alkylamino, di(C7-C6-alkyl)amino, C1-C5-alkylthio, (C1-C6-alkylsulfonyl, phenylsulfonyl, oxo, thioxo, carboxyl or carbamoyl;

(C3-C8-cycloalkenyl)-(C1-C4-alkyl), optionally substituted by fluorine, chlorine, bromine, iodine, cyano, amino, mercapto, hydroxyl, C1-C6-acyloxy, benzoyloxy, benzyloxy, phenoxy, C1-C6-alkoxy, C1-C6-alkylamino, di(C1-C6-alkyl)amino, C1-C6-alkylthio, (C1-C6-alkylsulfonyl, phenylsulfonyl, oxo, thioxo, carboxyl or carbamoyl;

C1-C6-alkylcarbonyl, optionally substituted by fluorine, chlorine, bromine, iodine, cyano, amino, mercapto, hydroxyl, C1-C6-acyloxy, benzoyloxy, benzyloxy, phenoxy, C1-C6-alkoxy, C1-C6-alkylamino, di(C1-C6-alkyl)amino, C1-C6-alkylthio, C1-C6-alkylsulfonyl, phenylsulfonyl, oxo, thioxo, carboxyl or carbamoyl;

C2-C8-alkenylcarbonyl, optionally substituted by fluorine, chlorine or hydroxyl,C,-C4-alkoxy, oxo, phenyl;

(C3-C8-cycloalkyl)carbonyl, optionally substituted by fluorine, chlorine or hydroxyl, C1-C4-alkoxy, oxo, phenyl;

(C5-C8-cycloalkenyl)carbonyl, optionally substituted by fluorine, chlorine or hydroxyl, C1-C4-alkoxy, oxo, phenyl;
(C3-C8-cycloalkyl)-(C1-C3-alkyl)carbonyl, optionally substituted by fluorine, chlorine or hydroxyl, C1-C4-alkoxy, oxo, phenyl;

(C5-6-cycloalkenyl)-(C1-C3-alkyl)carbonyl, optionally substituted by fluorine, chlorine or hydroxyl, C1-C4-alkoxy, oxo, phenyl;

C1-C8-alkyloxycarbonyl, optionally substituted by fluorine, chlorine, bromine, hydroxyl, C1-C4-alkoxy, C1-C4-alkylamino, di(C1-C4-alkyl)amino, C1-C4-alkylthio;
C2-C8-alkenyloxycarbonyl, optionally substituted by fluorine, chlorine,hydroxyl, C1-C4-alkoxy, oxo, phenyl;

C2-C8-alkynyloxycarbonyl, optionally substituted by fluorine, chlorine,hydroxyl, C1-C4-alkoxy, oxo, phenyl;

C2-C8-alkylthiocarbonyl, optionally substituted by fluorine, chlorine, hydroxyl,C1-C4-alkoxy, oxo, phenyl;

C2-C8-alkenylthiocarbonyl, optionally substituted by fluorine, chlorine, hydroxyl, C1-C4-alkoxy, oxo, phenyl;

C1-C8-alkylamino- and di(C1-C8-alkyl)aminocarbonyl, in each case optionally substituted by fluorine, chlorine, hydroxyl, C1-C4-alkoxy, oxo, phenyl;

pyrrolidin-1-yl, morpholino-, piperidino-, piperazinyl-, or 4-methylpiperazin-1-ylcarbonyl, in each case optionally substituted by C1-C4-alkyl, C2-C6-alkenyl,C1-C4-acyl, oxo, thioxo, carboxyl, or phenyl;

C2-C8-alkenylamino- and di(C1-C6-alkenyl)aminocarbonyl, in each case optionally substituted by fluorine, chlorine, hydroxyl, C1-C4-alkoxy, oxo, phenyl;

C1-C6-alkylsulfonyl, optionally substituted by fluorine, chlorine, hydroxyl, C1-C4-alkoxy, oxo, phenyl;

C1-C6-alkenylsulfonyi, optionally substituted by fluorine, chlorine, hydroxyl, Cl-C4-alkoxy, oxo, phenyl;
or aryl, arylcarbonyl, aryl(thiocarbonyl), (arylthio)carbonyl, (arylthio)thiocarbonyl, aryloxycarbonyl, arylaminocarbonyl, (arylamino)thio-carbonyl, arylalkylaminocarbonyl, arylsulfonyl, arylalkyl, arylalkenyl, arylalkynyl, arylalkylcarbonyl, arylalkenylcarbonyl, arylalkoxycarbonyl or aryl(alkylthio)carbonyl, each of which is substituted by up to five radicals R6 which are independent of one another, it being possible for the alkyl radical to contain in each case 1 to 5 carbon atoms, and R6 being as defined above, or heteroaryl, heteroarylalkyl, heteroarylalkenyl, heteroarylalkylcarbonyl or heteroarylalkenylcarbonyl, heteroaryloxycarbonyl, (heteroarylthio)carbonyl, heteroarylaminocarbonyl, heteroarylalkyloxycarbonyl, heteroaryl(alkylthio)carbonyl or heteroarylalkylaminocarbonyl, each of which is substituted by up to three radicals R6 which are independent of one another, it being possible for the alkyl radical to contain in each case 1 to 3 carbon atoms, R3 and R4 are identical or different and, independently of one another, are hydrogen, C1-C8-alkyl which is optionally substituted by fluorine, chlorine, hydroxyl, amino, mercapto, C1-C4-acyloxy, benzoyloxy, benzyloxy, phenoxy, C1-C4-alkoxy, C1-C4-alkylamino, di(C1-C4-alkyl)amino, C1-C4-alkylthio, C1-C4-alkylsulfonyl, C1-C4-alkylsulfinyl, carboxyl or carbamoyl;

C2-C8-alkenyl, optionally substituted by fluorine or chlorine, hydroxyl, amino, mercapto, C1-C4-acyloxy, benzoyloxy, benzyloxy, phenoxy, C1-C4-alkoxy, C1-C4-alkylamino, di(C1-C4-alkyl)amino, C1-C4-alkylthio, C1-C4-alkylsulfonyl, C1-C4-alkylsulfinyl, carboxyl or carbamoyl;

C3-C8-cycloalkyl, optionally substituted by fluorine, chlorine, hydroxyl, amino,mercapto, C1-C4-acyloxy, benzoyloxy, benzyloxy, phenoxy, C1-C4-alkoxy, C1-C4-alkylamino, di(C1-C4-alkyl)amino, C1-C4-alkylthio, C1-C4-alkylsulfonyl, C1-C4-alkylsulfinyl, carboxyl or carbamoyl;

C3-C8-cycloalkenyl, optionally substituted by fluorine or chlorine, hydroxyl, amino, mercapto, C1-C4-acyloxy, benzoyloxy, benzyloxy, phenoxy, C1-C4-alkoxy, C1-C4-alkylamino, di(C1-C4-alkyl)amino, C1-C4-alkylthio, C1-C4-alkylsulfonyl, C1-C4-alkylsylfinyl, carboxyl or carbamoyl;

aryl, arylalkyl, heteroaryl or heteroarylalkyl, each of which is substituted by up to five radicals R6 which are independent of one another, it being possible for the alkyl radical to contain 1 to 3 carbon atoms in each case, and R6 being as defined above, R3 and R4 or R3 and R5 can furthermore also be part of a saturated or unsaturated carbo- or heterocyclic ring which has 3 to 8 carbon atoms and which can optionally be substituted by fluorine, chlorine, hydroxyl, amino, C1-C6-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, C1-C6-acyloxy, benzoyloxy, C1-C6-alkoxy, oxo, thioxo, carboxyl, carbamoyl or phenyl, is oxygen, sulfur, selenium or substituted nitrogen N-R2, it being possible for R2 to have the abovementioned meanings, for the preparation of pharma-ceuticals for the treatment of diseases caused by viruses, in particular diseases caused by HIV.
CA002065985A 1991-04-15 1992-04-14 Quinoxalines, processes for their preparation, and their use Abandoned CA2065985A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE4112234 1991-04-15
DEP4112234.8 1991-04-15
DE19914142322 DE4142322A1 (en) 1991-12-20 1991-12-20 Antiviral quinoxaline deriv.
DEP4142322.4 1991-12-20

Publications (1)

Publication Number Publication Date
CA2065985A1 true CA2065985A1 (en) 1992-10-16

Family

ID=25902841

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002065985A Abandoned CA2065985A1 (en) 1991-04-15 1992-04-14 Quinoxalines, processes for their preparation, and their use

Country Status (19)

Country Link
EP (1) EP0509398B1 (en)
JP (1) JP2718595B2 (en)
KR (1) KR100245138B1 (en)
AT (1) ATE205837T1 (en)
AU (1) AU654178B2 (en)
CA (1) CA2065985A1 (en)
CZ (1) CZ293825B6 (en)
DE (1) DE59209965D1 (en)
DK (1) DK0509398T3 (en)
ES (1) ES2164639T3 (en)
HK (1) HK1011971A1 (en)
HU (1) HU224439B1 (en)
IE (1) IE921187A1 (en)
IL (1) IL101583A (en)
MX (1) MX9201760A (en)
NZ (1) NZ242346A (en)
PT (1) PT509398E (en)
TW (1) TW207533B (en)
ZA (1) ZA922722B (en)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ251610A (en) * 1992-04-23 1996-02-27 Merrell Dow Pharma 4-imidomethyl-1-(2-phenyl-2-oxoethyl)piperidine derivatives and pharmaceutical compositions
TW304945B (en) * 1992-06-27 1997-05-11 Hoechst Ag
TW274550B (en) * 1992-09-26 1996-04-21 Hoechst Ag
DE4335438A1 (en) * 1993-10-18 1995-04-20 Bayer Ag 4-cyanophenylimino heterocycles
DE4342024A1 (en) * 1993-12-09 1995-06-14 Hoechst Ag Combination preparations containing a quinoxaline and a nucleoside
DE4344452A1 (en) * 1993-12-24 1995-06-29 Hoechst Ag Aza-4-iminoquinolines, process for their preparation and their use
DE4437406A1 (en) * 1994-10-19 1996-04-25 Hoechst Ag Quinoxalines, process for their preparation and their use
DE19506742A1 (en) * 1995-02-27 1996-08-29 Bayer Ag Use of quinoxalines in combination with protease inhibitors as medicaments for the treatment of AIDS and / or HIV infections
DE19613591A1 (en) * 1996-04-04 1997-10-09 Hoechst Ag Substituted quinoline derivatives, process for their preparation and their use
DE19703131A1 (en) * 1997-01-29 1998-07-30 Bayer Ag Use of quinoxaline in a combination of three with protease inhibitors and reverse transcriptase inhibitors as medicaments for the treatment of AIDS and / or HIV infections
US6288075B1 (en) 1998-02-26 2001-09-11 Rhone-Poulenc Rorer S.A. Thiazolo[5,4,3-ij]quinolines, preparation and medicines containing the same
FR2760237B1 (en) * 1997-02-28 1999-04-16 Rhone Poulenc Rorer Sa THIAZOLOBENZOHETEROCYCLES, THEIR PREPARATION AND THE MEDICINES CONTAINING THEM
ES2297943T3 (en) 1998-12-23 2008-05-01 Aventis Pharma Limited DIHIDRO-BENZO (1,4) OXACINES AND TETRAHYDROQUINOXALINS.
DE10134721A1 (en) * 2001-07-17 2003-02-06 Bayer Ag tetrahydroquinoxalines
WO2005018531A2 (en) * 2003-08-26 2005-03-03 'chemical Diversity Research Institute', Ltd. Pharmaceutical compositions, azo-heterocyclic compounds and method for the production and use thereof
US7351709B2 (en) 2004-06-09 2008-04-01 Wyeth Estrogen receptor ligands
JP5054996B2 (en) * 2006-03-14 2012-10-24 参天製薬株式会社 Novel 1,2,3,4-tetrahydroquinoxaline derivative having glucocorticoid receptor binding activity
US8551991B2 (en) 2006-03-14 2013-10-08 Santen Pharmaceutical Co., Ltd. 1,2,3,4-tetrahydroquinoxaline derivative having glucocorticoid receptor binding activity
US8193187B2 (en) 2007-05-29 2012-06-05 Santen Pharmaceutical Co., Ltd. 1,2,3,4-tetrahydroquinoxaline compound with a phenyl group substituent having a sulfonic acid ester structure or a sulfonic acid amide structure introduced therein and having glucocorticoid receptor-binding activity
CN103242238B (en) * 2013-05-10 2016-04-20 常州齐晖药业有限公司 A kind of preparation method of fenbendazole
JP6851825B2 (en) 2013-07-15 2021-03-31 ヘルムホルツ ツェントゥルム ミュンヘン ドイチェス フォルシュングスツェントゥルム フューア ゲズントハイト ウント ウムヴェルト (ゲーエムベーハー) Spiroquinoxaline derivative as an inhibitor of non-apoptotic controlled cell death
TW201536760A (en) * 2013-08-09 2015-10-01 參天製藥股份有限公司 Manufacturing method for 3,3-dimethyl-3,4-dihydro-1H-quinoxaline-2-one derivate and intermediate for the manufacturing method
WO2016075137A1 (en) 2014-11-10 2016-05-19 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Spiropyrazine derivatives as inhibitors of non-apoptotic regulated cell-death

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE706623A (en) * 1967-11-16 1968-04-01
US4032639A (en) * 1976-03-22 1977-06-28 American Home Products Corporation 2,3,4,4A-Tetrahydro-1H-pyrazino[1,2-a,]quinoxalin-5(6H)-ones and derivatives thereof for relieving hypertension
EP0190105A3 (en) * 1985-01-31 1988-10-26 Ciba-Geigy Ag Herbicidal agent
US4940708A (en) * 1986-10-30 1990-07-10 Pfizer Inc. 4-arylsulfonyl-3,4-dihydro-2(1H)-quinoxalinone-1-alkanoic acids, esters, and salts
US5318946A (en) * 1991-11-27 1994-06-07 American Cyanamid Company 2-(heteroaryloxyphenoxy)alkylsulfonates useful as herbicidal agents

Also Published As

Publication number Publication date
DK0509398T3 (en) 2002-01-14
ZA922722B (en) 1992-11-25
JPH05148243A (en) 1993-06-15
EP0509398B1 (en) 2001-09-19
KR100245138B1 (en) 2000-03-02
DE59209965D1 (en) 2002-10-17
KR920019761A (en) 1992-11-19
HU224439B1 (en) 2005-09-28
IL101583A0 (en) 1992-12-30
HK1011971A1 (en) 1999-07-23
NZ242346A (en) 1994-12-22
TW207533B (en) 1993-06-11
EP0509398A1 (en) 1992-10-21
CZ293825B6 (en) 2004-08-18
PT509398E (en) 2002-02-28
IL101583A (en) 2000-07-16
MX9201760A (en) 1992-10-01
IE921187A1 (en) 1992-10-21
HU9201288D0 (en) 1992-07-28
AU1485392A (en) 1992-10-22
ATE205837T1 (en) 2001-10-15
HUT61004A (en) 1992-11-30
CZ113692A3 (en) 1993-01-13
JP2718595B2 (en) 1998-02-25
ES2164639T3 (en) 2002-03-01
AU654178B2 (en) 1994-10-27

Similar Documents

Publication Publication Date Title
CA2065985A1 (en) Quinoxalines, processes for their preparation, and their use
CA2953132C (en) Heteroaryl compounds useful as inhibitors of sumo activating enzyme
CN111039942B (en) Nitrogen-containing heterocyclic compound, and preparation method, pharmaceutical composition and application thereof
AU2002313410B2 (en) Hepatitis C virus polymerase inhibitors with a heterobicyclic structure
JPH06211855A (en) Azaquinoxaline compound, its production, and its use
JP3110765B2 (en) Pyrid [2,3-d] pyrimidine derivatives and pharmaceutical compositions thereof
JP2021524457A (en) Condensed pyrimidine derivative as an A2A / A2B inhibitor
JPH04211662A (en) Spirocyclic antipsychotic
US6369057B1 (en) Quinoxalines, processes for their preparation and their use
TW200409637A (en) Compounds
JP2001508395A (en) New cycloalkyl-substituted imidazole
AU2005288080A1 (en) Carbostyril compound
CN111163766A (en) AHR inhibitors and uses thereof
IE83508B1 (en) Quinoxalines, processes for their preparation, and their use
CN101679392B (en) Quinolone compound and pharmaceutical composition
WO2023274251A1 (en) Polycyclic compound for inhibiting rna helicase dhx33, and application of compound
EP0077983B1 (en) Triazine derivatives, processes for preparation thereof and pharmaceutical compositions comprising the same
US9416143B2 (en) Griseofulvin derivatives
NZ270088A (en) Antiviral medicaments containing a quinoxaline and a nucleoside derivative
AU710238B2 (en) Substituted quinoline derivatives, a process for their preparation, and their use
AU670435B2 (en) 4-iminoquinolines, processes for their preparation, and their use
US7951838B2 (en) Substituted spirocyclic chromanamine compounds as Beta-Secretase modulators and methods of use

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued